Methamphetamine/GHB/Hallucinogens/Oxycodone

Methods: We recruited 58 MA-dependent young adult females from a compulsory isolation drug rehabilitation center in Sichuan Province and randomly divided them into an MBRP group (n = 29) and a control group (n = 29) according to their degree of psychological craving. The MBRP group received 2 hours of MBRP training twice a week for 4 weeks, alongside routine treatment at the drug rehabilitation center. Meanwhile, the control group solely received routine treatment at the drug rehabilitation center without any additional interventions. The assessment was conducted before and immediately after the intervention, with the Compulsive Drug Use Scale (OCDUS) used to assess craving and the Five-Factor Mindfulness Scale (FFMQ) used to assess trait mindfulness. Also, a “mental feedback monitoring balance” instrument was used to assess concentration and relaxation during some training sessions. This randomized trial was conducted to evaluate the effectiveness of decreasing psychological craving and increasing trait mindfulness.

Results: At baseline, there were no significant differences in total or dimension scores for FFMQ or OCDUS between the two groups (all P > 0.05). After the intervention, the repeated measures ANOVA showed a significant time main effect on changes in observing, non-judging, and non-reacting scores (all P < 0.05), and a significant interaction effect between time and group on both FFMQ total score and OCDUS score (P < 0.01 or P < 0.05). Mental feedback monitoring indicated significant improvement in concentration and relaxation after breath meditation exercises (P < 0.05 or P < 0.001). Additionally, the MBRP group showed improved relaxation during the body scan exercise (P < 0.01).

Conclusion: MBRP training can improve the trait mindfulness of MA addicts and reduce psychological cravings effectively.

The full article can be accessed via the source link below:

Source: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1339517/full

Vaping among younger adults and binge drinking among mid-life adults also maintained historically high levels, NIH-supported study shows

August 29, 2024

 

Past-year use of cannabis and hallucinogens stayed at historically high levels in 2023 among adults aged 19 to 30 and 35 to 50, according to the latest findings from the Monitoring the Future survey. In contrast, past-year use of cigarettes remained at historically low levels in both adult groups. Past-month and daily alcohol use continued a decade-long decline among those 19 to 30 years old, with binge drinking reaching all-time lows. However, among 35- to 50-year-olds, the prevalence of binge drinking in 2023 increased from five and 10 years ago. The Monitoring the Future study is conducted by scientists at the University of Michigan’s Institute for Social Research, Ann Arbor, and is funded by the National Institutes of Health.

Reports of vaping nicotine or vaping cannabis in the past year among adults 19 to 30 rose over five years, and both trends remained at record highs in 2023. Among adults 35 to 50, the prevalences of nicotine vaping and of cannabis vaping stayed steady from the year before, with long-term (five and 10 year) trends not yet observable in this age group as this question was added to the survey for this age group in 2019.

For the first time in 2023, 19- to 30-year-old female respondents reported a higher prevalence of past-year cannabis use than male respondents in the same age group, reflecting a reversal of the gap between sexes. Conversely, male respondents 35 to 50 years old maintained a higher prevalence of past-year cannabis use than female respondents of the same age group, consistent with what’s been observed for the past decade.

“We have seen that people at different stages of adulthood are trending toward use of drugs like cannabis and psychedelics and away from tobacco cigarettes,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA). “These findings underscore the urgent need for rigorous research on the potential risks and benefits of cannabis and hallucinogens – especially as new products continue to emerge.”

Since 1975, the Monitoring the Future study has annually surveyed substance use behaviors and attitudes among a nationally representative sample of teens. A longitudinal panel study component of Monitoring the Future conducts follow-up surveys on a subset of these participants (now totaling approximately 20,000 people per year), collecting data from individuals every other year from ages 19 to 30 and every five years after the participants turn 30 to track their drug use through adulthood. Participants self-report their drug use behaviors across various time periods, including lifetime, past year (12 months), past month (30 days), and other use frequencies depending on the substance type. Data for the 2023 panel study were collected via online and paper surveys from April 2023 through October 2023.

Full data summaries and data tables showing the trends below, including breakdowns by substance, are available in the report. Key findings include:

Cannabis use in the past year and past month remained at historically high levels for both adult age groups in 2023. Among adults 19 to 30 years old, approximately 42% reported cannabis use in the past year, 29% in the past month, and 10% daily use (use on 20 or more occasions in the past 30 days). Among adults 35 to 50, reports of use reached 29%, 19%, and 8%, respectively. While these 2023 estimates are not statistically different from those of 2022, they do reflect five- and 10-year increases for both age groups.

Cannabis vaping in the past year and past month was reported by 22% and 14% of adults 19 to 30, respectively, and by 9% and 6% of adults 35 to 50 in 2023. For the younger group, these numbers represent all-time study highs and an increase from five years ago.

Nicotine vaping among adults 19 to 30 maintained historic highs in 2023. Reports of past-year and past-month vaping of nicotine reached 25% and 19%, respectively. These percentages represent an increase from five years ago, but not from one year ago. For adults 35 to 50, the prevalence of vaping nicotine remained steady from the year before (2022), with 7% and 5% reporting past-year and past-month use.

Hallucinogen use in the past year continued a five-year steep incline for both adult groups, reaching 9% for adults 19 to 30 and 4% for adults 35 to 50 in 2023. Types of hallucinogens reported by participants included LSD, mescaline, peyote, shrooms or psilocybin, and PCP.

Alcohol remains the most used substance reported among adults in the study. Past-year alcohol use among adults 19 to 30 has showed a slight upward trend over the past five years, with 84% reporting use in 2023. However, past month drinking (65%), daily drinking (4%), and binge drinking (27%) all remained at study lows in 2023 among adults 19 to 30. These numbers have decreased from 10 years ago. Past-month drinking and binge drinking (having five or more drinks in a row in the past two week period) decreased significantly from the year before for this age group (down from 68% for past month and 31% for binge drinking reported in 2022).

Around 84% of adults 35 to 50 reported past-year alcohol use in 2023, which has not significantly changed from the year before or the past five or 10 years. Past-month alcohol use and binge drinking have slightly increased over the past 10 years for this age group; in 2023, past-month alcohol use was at 69% and binge drinking was at 27%. Daily drinking has decreased in this group over the past five years and was at its lowest level ever recorded in 2023 (8%).

Additional data: In 2023, past-month cigarette smoking, past-year nonmedical use of prescription drugs, and past-year use of opioid medications (surveyed as “narcotics other than heroin”) maintained five- and 10-year declines for both adult groups. Among adults 19 to 30 years old, past-year use of stimulants (surveyed as “amphetamines”) has decreased for the past decade, whereas for adults 35 to 50, past-year stimulant use has been modestly increasing over 10 years. Additional data include drug use reported by college/non-college young adults and among various demographic subgroups, including sex and gender and race and ethnicity.

The 2023 survey year was the first time a cohort from the Monitoring the Future study reached 65 years of age; therefore, trends for the 55- to 65-year-old age group are not yet available.

“The data from 2023 did not show us many significant changes from the year before, but the power of surveys such as Monitoring the Future is to see the ebb and flow of various substance use trends over the longer term,” said Megan Patrick, Ph.D., of the University of Michigan and principal investigator of the Monitoring the Future panel study. “As more and more of our original cohorts – first recruited as teens – now enter later adulthood, we will be able to examine the patterns and effects of drug use throughout the life course. In the coming years, this study will provide crucial data on substance use trends and health consequences among older populations, when people may be entering retirement and other new chapters of their lives.”

View more information on data collection methods for the Monitoring the Future panel study and how the survey adjusts for the effects of potential exclusions in the report. Results from the related 2023 Monitoring the Future study of substance use behaviors and related attitudes among teens in the United States were released in December 2023, and 2024 results are upcoming in December 2024.

 

Source:  https://nida.nih.gov/news-events/news-releases

How can modern psychedelic research and traditional approaches integrate to address substance use disorders and mental health challenges?

A recent study published in the Journal of Studies on Alcohol and Drugs discusses the history and current state of psychedelic research for the treatment of substance abuse disorders (SUDs).

Psychedelics

Psychedelics are consciousness-altering drugs, some of which include lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), psilocybin, and mescaline. Methylenedioxymethamphetamine (MDMA) and ketamine are also considered psychedelics; however, these drugs have different mechanisms of action.

Although psychedelics have been exploited for centuries to induce altered states of consciousness, their use, as opposed to their abuse, has largely been unexplored in modern medicine. In fact, several studies have indicated the potential utility of psychedelics for individuals who have mental illness due to traumatic experiences, false beliefs, and unhealthy behavioral patterns, such as posttraumatic stress disorder (PTSD) and depression.

The recent coronavirus disease 2019 (COVID-19) pandemic led to global changes in the use of methamphetamine, alcohol, and cannabis, as well as a significant increase in opioid overdoses in the United States. Thus, another promising application of psychedelics is their potential use for treating SUDs.

However, restrictive policies, poor funding, lack of equitable and diverse recruitment and access, as well as the multiplicity of small-scale psychedelic research programs have prevented researchers from effectively investigating the effects of psychedelics in the treatment of SUDs.

Overview

Over the past seven decades, researchers have become increasingly interested in examining the potential use of psychedelics in traditional medicine. Despite federal policies banning recreational drug use, researchers have elucidated some of the biological effects of psychedelics on the central nervous system (CNS) and their potential role in the treatment of SUDs. Nevertheless, there remains a lack of well-controlled multi-center trials and systematic reviews in this area.

As researchers continue to examine the pharmacological potential of these drugs, it is crucial to address their addiction and abuse potential, the legalization of recreational drugs, and the attempts of pharmaceutical companies to introduce high-selling psychedelics as therapies for mental illness.

History and current use of psychedelics

Psychedelics like ayahuasca, Peyote, and psilocybin-containing mushrooms have been used throughout history by traditional healers and indigenous communities for both spiritual and health purposes. By recognizing these contributions, researchers can benefit from the potential benefits of traditional usage patterns while investigating the use of these drugs for treating SUDs and other mental health disorders.

For example, a hybridized SUD therapy program in Peru utilizes ayahuasca to treat alcohol and drug use. At one year following treatment, reduced depression and anxiety, higher quality of life, and reduced severity of addiction have been reported.

One notable contribution is the acknowledgment that key experiences of treatment participants might provide more insight than the search for putative “active ingredients” of interventions as complex as psychedelic-assisted treatment.”

Purging in psychedelic treatment

Psychedelic use, specifically ayahuasca use, is closely linked to vomiting as a means of purging the body. This is reported to have spiritual, Amazonian, and clinical benefits.

Conclusions

The optimal approach to psychedelic-assisted treatment involves mutual respect for and recognition of the value of both traditional and modern applications. Thus, mixed-methods research is crucial, as traditional approaches may help identify a better therapeutic agent or program than traditional approaches to identifying and isolating active ingredients.

However, it is essential to evaluate and quantify the success rates of traditional approaches to psychedelic use, as well as elucidate the biological mechanisms that may contribute to their therapeutic effects. Researchers must recognize and credit traditional history and practices throughout these efforts to protect these cultures from being exploited, ignored, and suppressed by pharmaceutical industries.

The rush to patent processes in psychedelic treatments of addiction and other psychiatric conditions reflects the enormous greed of private commercial entities to benefit financially from vulnerable patients in need of effective therapies.

Thus, regulatory control of psychedelic therapies is vital to establish rigorous research standards that can lead to the generation of sufficient evidence in this area. Without this type of overview, private corporate interests may seek to exploit governmental support for crucial research needed to address these mental health issues.

Source:  https://www.news-medical.net/news/20240828/Psychedelics-A-new-hope-for-substance-abuse-treatment.aspx

This is the Executive Summary of the DEA’s 2024 National Drug Threat Assessment 

Fentanyl is the deadliest drug threat the United States has ever faced, killing nearly 38,000 Americans in the first six months of 2023 alone. Fentanyl and other synthetic drugs, like methamphetamine, are responsible for nearly all of the fatal drug overdoses and poisonings in our country. In pill form, fentanyl is made to resemble a genuine prescription drug tablet, with potentially fatal outcomes for users who take a pill from someone other than a doctor or pharmacist. Users of other illegal drugs risk taking already dangerous drugs like cocaine, heroin, or methamphetamine laced or replaced with powder fentanyl. Synthetic drugs have transformed not only the drug landscape in the United States, with deadly consequences to public health and safety; synthetic drugs have also transformed the criminal landscape in the United States, as the drug cartels who make these drugs reap huge profits from their sale.
Mexican cartels profit by producing synthetic drugs, such as fentanyl (a synthetic opioid) and methamphetamine (a synthetic stimulant), that are not subject to the same production challenges as traditional plant-based drugs like cocaine and heroin – such as weather, crop cycles, or government eradication efforts. Synthetic drugs pose an increasing threat to U.S. communities because they can be made anywhere, at any time, given the required chemicals and equipment and basic know-how. Health officials, regulators, and law enforcement are constantly challenged to quickly identify and act against the fentanyl threat, and the threat of new synthetic drugs appearing on the market. The deadly reach of the Mexican Sinaloa and Jalisco cartels into U.S. communities is extended by the wholesale-level traffickers and street dealers bringing the cartels’ drugs to market, sometimes creating their own deadly drug mixtures, and exploiting social media and messaging applications to advertise and sell to customers.
The Sinaloa Cartel and the Cartel Jalisco Nueva Generación (also known as CJNG or the Jalisco Cartel) are the main criminal organizations in Mexico, and the most dangerous. They control clandestine drug production sites and transportation routes inside Mexico and smuggling corridors into the United States and maintain large network “hubs” in U.S. cities along the Southwest Border and other key locations across the United States. The Sinaloa and Jalisco cartels are called “transnational criminal organizations” because they are not just drug manufacturers and traffickers; they are organized crime groups, involved in arms trafficking, money laundering, migrant smuggling, sex trafficking, bribery, extortion, and a host of other crimes – and have a global reach extending into strategic transportation zones and profitable drug markets in Europe, Africa, Asia, and Oceania.

Source: https://www.dea.gov/sites/default/files/2024-05/NDTA_2024.pdf May 2024

The United States is knee-deep in what some experts call the opioid epidemic’s “fourth wave,” which is not only placing drug users at greater risk but is also complicating efforts to address the nation’s drug problem.

These waves, according to a report from Millennium Health, were the crisis in prescription opioid use, followed by a significant jump in heroin use, then an increase in the use of synthetic opioids like fentanyl.
The latest wave involves using multiple substances at the same time, combining fentanyl mainly with either methamphetamine or cocaine, the report found. “And I’ve yet to see a peak,” said one of the co-authors, Eric Dawson, vice president of clinical affairs at Millennium, a specialty laboratory that provides drug-testing services to monitor use of prescription medications and illicit drugs.
The report, which takes a deep dive into the nation’s drug trends and breaks usage patterns down by region, is based on 4.1 million urine samples collected from January 2013 to December 2023 from people receiving some kind of drug-addiction care.
Its findings offer staggering statistics and insights. Its major finding is how common polysubstance use has become. According to the report, an overwhelming majority of fentanyl-positive urine samples — nearly 93% — contained additional substances. “That is huge,” said Nora Volkow, director of the National Institute on Drug Abuse at the National Institutes of Health.
The most concerning, Volkow and other addiction experts said, is the dramatic increase in the combination of methamphetamine and fentanyl use. Meth, a highly addictive drug often in powder form that poses several serious cardiovascular and psychiatric risks, was found in 60% of fentanyl-positive tests last year. That is an 875% increase since 2015.
“I never, ever would have thought this,” Volkow said.
Among the report’s other key findings:

  • The nationwide spike in methse alongside fentanyl marks a change in drug use patterns.
  • Polydrug use trends complicate overdose treatments. For instance, naloxone, an opioid-overdose reversal medication, is widely available, but there isn’t an FDA-approved medication for stimulant overdose.
  • Both heroin and prescribed-opioid use alongside fentanyl have dipped. Heroin detected in fentanyl-positive tests dropped by 75% since peaking in 2016. Prescription opioids were found at historic low rates in fentanyl-positive tests in 2023, down 89% since 2013.

But Jarratt Pytell, an addiction medicine specialist and assistant professor at the University of Colorado’s School of Medicine, warned these declines shouldn’t be interpreted as a silver lining.
A lower level of heroin use “just says that fentanyl is everywhere,” Pytell said, “and that we have officially been pushed by our drug supply to the most dangerous opioids that we have available right now.”
“Whenever a drug network is destabilizing and the product changes, it puts the people who use the drugs at the greatest risk,” he said. “That same bag or pill that they have been buying for the last several months now is coming from a different place, a different supplier, and is possibly a different potency.”
In the illicit drug industry, suppliers are the controllers. It may not be that people are seeking out methamphetamine and fentanyl but rather that they’re what drug suppliers have found to be the easiest and most lucrative product to sell.
“I think drug cartels are kind of realizing that it’s a lot easier to have a 500-square-foot lab than it is to have 500 acres of whatever it takes to grow cocaine,” Pytell said.
Dawson said the report’s drug use data, unlike that of some other studies, is based on sample analysis with a quick turnaround — a day or two.
Sometimes researchers face a months-long wait to receive death reports from coroners. Under those circumstances, you are often “staring at today but relying on data sources that are a year or more in the past,” said Dawson.
Self-reported surveys of drug users, another method often used to track drug use, also have long lag times and “often miss people who are active for substance use disorders,” said Jonathan Caulkins, a professor at Carnegie Mellon University. Urine tests “are based on a biology standard” and are good at detecting when someone has been using two or more drugs, he said.
But using data from urine samples also comes with limitations. For starters, the tests don’t reveal users’ intent.
“You don’t know whether or not there was one bag of powder that had both fentanyl and meth in it, or whether there were two bags of powder, one with fentanyl in it and one with meth and they took both,” Caulkins said. It can also be unclear, he said, if people intentionally combined the two drugs for an extra high or if they thought they were using only one, not knowing it contained the other.
Volkow said she is interested in learning more about the demographics of polysubstance drug users. “Is this pattern the same for men and women, and is this pattern the same for middle-age or younger people? Because again, having a better understanding of the characteristics allows you to tailor and personalize interventions.”
All the while, the nation’s crisis continues. According to the Centers for Disease Control and Prevention, more than 107,000 people died in the U.S. in 2021 from drug overdoses, most because of fentanyl.
Caulkins said he’s hesitant to view drug use patterns as waves because that would imply people are transitioning from one to the next.
“Are we looking at people whose first substance use disorder was an opioid use disorder, who have now gotten to the point where they’re polydrug users?” he said. Or, are people now starting substance use disorders with methamphetamine and fentanyl, he asked.
One point was clear, Dawson said: “We’re just losing too many lives.”

 

Source: https://lexingtonky.news/2024/02/24/opioid-epidemic-is-in-a-fourth-wave-with-multiple-substances-being-used-at-the-same-time-and-fentanyl-is-the-most-common/

Illicit fentanyl, the driving force behind the U.S. overdose epidemic, is increasingly being used in conjunction with methamphetamine, a new report shows.

The laboratory Millennium Health said 60% of patients whose urine samples contained fentanyl last year also tested positive for methamphetamine. Cocaine was detected in 22% of the fentanyl-positive samples.

Millennium officials said the report represents the impact of the “fourth wave” of the nation’s overdose epidemic, which began over a decade ago with the misuse of prescription opioids, then came a heroin crisis and more recently an increase in the use of illicit fentanyl. The study found that people battling addiction are increasingly using illicit fentanyl along with other substances, including stimulants such as methamphetamine and cocaine.

The report suggests heroin and prescription opioids are being abused less often than they were a decade ago. Of the urine samples containing fentanyl analyzed in the report, 17% also contained heroin and 7% showed the presence of prescription opioids.

The Millennium report is based on analyses of urine samples collected from more than 4.1 million patients in 50 states from Jan. 1, 2013, to Dec. 15, 2023. The samples were collected in doctors’ offices and clinics that see patients for pain, addiction and behavioral health treatment.

Overall, 93% of fentanyl samples tested positive for at least one other substance, a concerning finding, said Dr. Nora Volkow, director of the National Institute on Drug Abuse.

“I did not expect that number to be so high,” she said.

Overdose deaths climb

Drug overdose deaths in the United States surged past 100,000 in 2021 and increased again in 2022. Provisional data from the Centers for Disease Control and Prevention showed overdose deaths through September 2023 increased about 2% compared with the year before.

Other reports show that stimulants, mostly methamphetamine, are increasingly involved in fentanyl overdoses. In 2021, stimulants were detected in about 1 in 3 fentanyl overdose deaths, compared with just 1 in 100 in 2010.

The finding of methamphetamine in so many samples is especially concerning, said Eric Dawson, vice president of clinical affairs Millennium Health.

“Methamphetamine is more potent, more pure and probably cheaper than it’s ever been at any time in this country,” Dawson said. “The methamphetamine product that is flooding all of our communities is as dangerous as it’s ever been.”

Methamphetamine has no rescue drugs, treatments

As methamphetamine use appears to play a larger role in the addiction crisis, the medical community does not have the same tools to counter its misuse.

Naloxone and similar overdose reversal medications counteract opioid overdoses by blocking opioid receptors in the brain to quickly reverse the effects of an overdose. Narcan, a nasal spray version of naloxone, can be purchased and is kept in stock by public health departments, schools, police and fire departments and federal agencies nationwide. Chain retailers such as CVS, Walgreens, Rite Aid and Walmart began selling Narcan over the counter without a prescription.

But there is no medication approved by the Food and Drug Administration for overdoses involving stimulants such as methamphetamine.

Opioid substitute medications such as methadone and buprenorphine are used to reduce cravings and ease withdrawal symptoms from opioids. There are no equivalent medications, however, for people who are dependent on methamphetamine or other stimulants, Dawson said.

That deficit is glaring, Dawson said: “We need effective treatments for stimulant-use disorder.”

Meth samples more common in the West

The Millennium report also found that drug use differed by region, and methamphetamine samples were detected more frequently in the western U.S.

Methamphetamine was detected in more than 70% of fentanyl-positive urine samples in the Pacific and Mountain West states. Meth showed up least often in fentanyl-positive samples in the mid- and south-Atlantic states, the report said.

Cocaine appeared to be more prevalent in the eastern U.S. More than 54% of fentanyl-positive samples in New England also had cocaine. By comparison, fewer than 1 in 10 of the samples showed cocaine in the mountain region of the West, the report said.

Other findings from the report:

∎ The presence of cocaine samples in fentanyl-positive specimens surged 318% from 2013 to 2023.

∎ The presence of heroin in fentanyl-positive specimens dropped by 75% after a peak in 2016.

∎ The presence of prescription opioids in fentanyl-positive specimens dropped to an all-time low in 2023, which researchers cite as evidence that the U.S. addiction crisis has shifted from pain medications.

Nationwide, the addiction epidemic has evolved to a phase in which people are often using multiple substances, not just fentanyl, Volkow said. This polysubstance abuse complicates matters for public health authorities seeking to slow the nation’s overdose deaths.

Volkow said reports such as Millennium Health’s are important because they give researchers a snapshot of the nation’s evolving drug use and provide more timely data than death investigations from overdoses can offer.

 

Source: https://eu.usatoday.com/story/news/health/2024/02/21/methamphetamine-plays-increasing-role-in-addiction-crisis/72661430007/

Abstract and Figures

In 2017 Iceland received word-wide attention for having dramatically reversed the course of teenage substance use. From 1998 to 2018, the percentage of 15-16-year-old Icelandic youth who were drunk in the past 30 days declined from 42% to 5%; daily cigarette smoking dropped from 23% to 3%; and having used cannabis one or more times fell from 17% to 5%. The core elements of the model are: 1) long-term commitment by local communities; 2) emphasis on environmental rather than individual change; 3) perception of adolescents as social attributes. This presentation describes how the Iceland prevention model is built upon collaboration between policy makers, researchers, parent organizations, and youth practitioners. These groups have created a system whereby youth receive the necessary guidance and support to live fun and productive lives without reliance on psychoactive substances. The Model is being replicated in 35 municipalities within 17 countries around the globe. The Icelandic Model: Evidence Based Primary Prevention – 20 Years of Successful Primary Prevention Work was featured for the past two years at the Special Session of the United Nations General Assembly on the World Drug Problem.

Source: https://www.researchgate.net/publication/330347576_Perspective_Iceland_Succeeds_at_Preventing_Teenage_Substance_Use February 2019

The United States is knee-deep in what some experts call the opioid epidemic’s “fourth wave,” which is not only placing drug users at greater risk but is also complicating efforts to address the nation’s drug problem.

These waves, according to a report from Millennium Health, began with the crisis in prescription opioid use, followed by a significant jump in heroin use, then an increase in the use of synthetic opioids like fentanyl.

The latest wave involves using multiple substances at the same time, combining fentanyl mainly with either methamphetamine or cocaine, the report found.

“And I’ve yet to see a peak,” said one of the co-authors, Eric Dawson, vice president of clinical affairs at Millennium Health, a specialty laboratory that provides drug testing services to monitor use of prescription medications and illicit drugs.

The report, which takes a deep dive into the nation’s drug trends and breaks usage patterns down by region, is based on 4.1 million urine samples collected from January 2013 to December 2023 from people receiving some kind of drug addiction care.

Its findings offer staggering statistics and insights. Its major finding: How common polysubstance use has become. According to the report, an overwhelming majority of fentanyl-positive urine samples — nearly 93% — contained additional substances.

“And that is huge,” said Nora Volkow, director of the National Institute on Drug Abuse at the National Institutes of Health.

The most concerning, she and other addiction experts said, is the dramatic increase in the combination of meth and fentanyl use. Methamphetamine, a highly addictive drug often in powder form that poses several serious cardiovascular and psychiatric risks, was found in 60% of fentanyl-positive tests last year. That is an 875% increase since 2015.

“I never, ever would have thought this,” Volkow said.

Among the report’s other key findings:

  • The nationwide spike in methamphetamine use alongside fentanyl marks a change in drug use patterns.
  • Polydrug use trends complicate overdose treatments. For instance, though naloxone, an opioid-overdose reversal medication, is widely available, there isn’t an FDA-approved medication for stimulant overdose.
  • Both heroin and prescribed opioid use alongside fentanyl have dipped. Heroin detected in fentanyl-positive tests dropped by 75% since peaking in 2016. Prescription opioids were found at historic low rates in fentanyl-positive tests in 2023, down 89% since 2013.

But Jarratt Pytell, an addiction medicine specialist and assistant professor at the University of Colorado’s School of Medicine, warned these declines shouldn’t be interpreted as a silver lining.

A lower level of heroin use “just says that fentanyl is everywhere,” Pytell said, “and that we have officially been pushed by our drug supply to the most dangerous opioids that we have available right now.”

“Whenever a drug network is destabilizing and the product changes, it puts the people who use the drugs at the greatest risk,” he said. “That same bag or pill that they have been buying for the last several months now is coming from a different place, a different supplier, and is possibly a different potency.”

In the illicit drug industry, suppliers are the controllers. It may not be that people are seeking out methamphetamine and fentanyl but rather that they’re what drug suppliers have found to be the easiest and most lucrative product to sell.

“I think drug cartels are kind of realizing that it’s a lot easier to have a 500-square-foot lab than it is to have 500 acres of whatever it takes to grow cocaine,” Pytell said.

Dawson said the report’s drug use data, unlike that of some other studies, is based on sample analysis with a quick turnaround — a day or two.

Sometimes researchers face a months-long wait to receive death reports from coroners. Under those circumstances, you are often “staring at today but relying on data sources that are a year or more in the past,” said Dawson.

Self-reported surveys of drug users, another method often used to track drug use, also have long lag times and “often miss people who are active for substance use disorders,” said Jonathan Caulkins, a professor at Carnegie Mellon University’s Heinz College. Urine tests “are based on a biology standard” and are good at detecting when someone has been using two or more drugs, he said.

But using data from urine samples also comes with limitations.

For starters, the tests don’t reveal users’ intent.

“You don’t know whether or not there was one bag of powder that had both fentanyl and meth in it, or whether there were two bags of powder, one with fentanyl in it and one with meth and they took both,” Caulkins said. It can also be unclear, he said, if people intentionally combined the two drugs for an extra high or if they thought they were using only one, not knowing it contained the other.

Volkow said she is interested in learning more about the demographics of polysubstance drug users: “Is this pattern the same for men and women, and is this pattern the same for middle-age or younger people? Because again, having a better understanding of the characteristics allows you to tailor and personalize interventions.”

All the while, the nation’s crisis continues. According to the Centers for Disease Control and Prevention, more than 107,000 people died in the U.S. in 2021 from drug overdoses, most because of fentanyl.

Caulkins said he’s hesitant to view drug use patterns as waves because that would imply people are transitioning from one to the next.

“Are we looking at people whose first substance use disorder was an opioid use disorder, who have now gotten to the point where they’re polydrug users?” he said. Or, are people now starting substance use disorders with methamphetamine and fentanyl, he asked.

One point was clear, Dawson said: “We’re just losing too many lives.”

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

Source:  https://dailymontanan.com/2024/03/17/fourth-wave-of-opioid-epidemic-crashes-ashore-propelled-by-fentanyl-and-meth/

Methamphetamine, a well-known psychostimulant drugs of abuse is in a resurgence in people using opioids and others. While many treatment options exist for patients with opioid use disorders, alcohol use disorders, and even tobacco smokers, there are far fewer options for people trying to stop using methamphetamines. No known medical treatments exist for overdose, dependence, craving, relapse, or to reverse all of the effects of methamphetamine binges and dependence. Experts studying substance use disorders recognize that their effects from misuse, especially the misuse of methamphetamine, can linger even after periods of abstinence.

Patients treated for methamphetamine binges, or dependence, for example, often suffer from cognitive impairments, including psychosis. Some of the persistent problems may reflect underlying brain change or even damage. If overlooked, cognitive problems can limit the effectiveness of treatment. They can also create a dangerous hopelessness or relapse cycle. That’s one reason why it’s so important to understand how substances like methamphetamine may alter the brain’s structure.

How Long Do Methamphetamine Brain Changes Last?

Methamphetamine addiction is a growing epidemic worldwide, following on the heels of the opioid crisis. Chronic methamphetamine use has been shown to lead to neurotoxicity in both humans and animals.  Magnetic resonance imaging (MRI) studies in methamphetamine users have shown enlarged striatal volumes, and positron emission tomography (PET) studies have shown decreased brain glucose metabolism (BGluM) in the striatum of abstinent methamphetamine users.

Some features of the methamphetamine toxicity profile are puzzling as well as difficult to treat. In prior work, it’s been noted how psychosis can follow methamphetamine use and last into abstinence. Varying levels of methamphetamine use can induce psychosis, depending in part on an individual’s background, and it can develop quickly or after 20 years of use. This psychosis can be quite similar to Schizophrenia – in some cases, violent behaviors have been connected to methamphetamine psychosis as well.

A study of Japanese prisoners found that a subgroup of methamphetamine users experienced chronic psychosis. Lingering cognitive problems may cause other health complications, difficulty thinking or concentrating at work, and increasingly risky behavior, in addition to higher relapse rates. Furthermore, later-in-life stress can also revive psychotic symptoms. More research on methamphetamine and cognitive problems can help treatment providers understand these hidden tripwires for patients.

One study, by Thanos et. al., looked at brain changes in rats after long-term methamphetamine use. Researchers split rats into 3 groups and gave them methamphetamine daily for 4 months. They dissolved methamphetamine in a saline solution and gave one rat group high methamphetamine doses, one rat group low methamphetamine doses, and the remaining rat group saline. Subsequent testing showed significant changes in the rats’ brains, stemming from higher doses. They also detected changes in brain glucose metabolism across different areas of the brain. These changes affect sleep cycles, face sensory processing, navigation, and memory. Researchers additionally found increases in striatal volume, referring to a part of the brain with a key role in decisions and reward management.

These increases resemble the results of other research, an important part of the study. Cognitive problems in humans taking methamphetamine can exist before substance use. But Thanos et. al. observe that a combination of research on methamphetamine use and this part of the brain, involving humans, monkeys, and rats, all finds similar increases. Unfortunately, this combination indicates that some methamphetamine-induced problems in the brain are prolonged and significant.

Thanos et. al. also start the rats’ substance use in adolescence. They point out that studies of human use in adolescence and adulthood find similar brain problems, adding to the likelihood of long-term damage. Thanos has continued this work with NIDA Director Volkow, looking at damage produced in the brain by methamphetamine. These most current results from their group, corroborate clinical experiences and reports of toxicity and encourage us to further examine the mechanisms behind MA-induced neurotoxicity.

 Why Is This Important?

This kind of study is important because treatment and recovery providers need to understand the full spectrum of issues their patients face. Once the acute problems are resolved, many challenges may remain. Even in abstinence, brain problems after methamphetamine use may become substantial hurdles for patients in recovery.

Psychological and neuropsychological testing may help the clinical team understand what has been lost and what might be done to help. Thanos et. al. also suggest that methamphetamine use may trigger a direct brain injury that we suggested was similar to a concussion or traumatic brain injury. Thanos suggests that methamphetamine targets the dopamine rich pleasure system, undermines it and the residual brain inflammation is both the proof and the cause of the post-drug changes to the health of our dopamine systems. Determining long-term methamphetamine brain changes can be even more useful for setting goals and interventions designed to help patients. Some of the strategies currently used to treat traumatic brain injuries may be helpful, as may use of exercise, dance, and transcranial magnetic stimulation. Post drug abstinence psychoses may not be as reversible by medications used for naturally-occurring psychoses.

Many patients, for example, show subtle changes without clear signs of cognitive difficulties. Testing may reveal real problems. Others present with fears and anxiety or disordered thinking that may have there roots in changes to their brains. And untangling cause and effect can help us better understand when pre-existing cognitive problems, and not substance use, are the main culprits. As with many substance use disorders, we have to remember that a holistic approach based on individual needs is the best way to help.

With methamphetamine this is even more important as medication assisted therapies do not exist. Time of abstinence, rehabilitation with healthy thinking, eating, sleeping, and diet are easier to prescribe or advise than find. Time of abstinence is of the essence as it appears that methamphetamine induces a drug use disorder with binges, relapses and cravings but also with loss of brain function and evidence of something that looks like a traumatic brain injury. Treating it like a neurological injury in addition to traditional addiction treatment, may be an idea worth looking at too.

Source:https://www.addictionpolicy.org/blog/tag/research-you-can-use/examining-brain-health-could-help-fight-methamphetamine-use-disorder    1st  August 2019

Tragically, the last few months of music festivals repeatedly resembled scenes from a hospital emergency ward, witnessing this season’s highest number of drug related hospitalisations and the deaths of predominately young adults ranging from 19 to 25 years-old.
In the aftermath of these heart wrenching events, harm reduction advocates have taken to media on mass advocating for pill testing as the next risk minimisation strategy that could potentially save lives.
Often, supporters are quick to highlight that pill testing is “not a silver bullet”, just one measure among a plethora of strategies. But the metaphor is a false equivocation. Rather, pill testing is more like Russian Roulette.
Similar to Russian Roulette, taking psychotropic illicit drugs is a deadly, unpredictable high stakes ‘game’. It’s the reason they’re illegal. There is no ‘safe’ way to play.
But arguments and groups supporting pill testing construct this false perception, regardless of how strenuously advocates claim otherwise. Organisations such as STA-SAFE, Unharm, Harm Reduction Australia, the ‘Safer Summer’ campaign all exploit the context of harm and safety within an illicit drug taking culture.
To continue the metaphor of Russian Roulette, it’s rather like insisting on testing a ‘bullet’ for velocity or the gun for cleanliness and handing both back. It’s pointless. The bullet might not kill at first, but the odds increase exponentially after each attempt.

No Standard Dose Available and the Limitations of Pill Testing
In reality, no testing of the hundreds of new psychoactive substances flooding nations every year can make a dose safe.

As Drug Watch International succinctly puts it, “Most people have been conned into using the word ‘overdose’ regarding illicit drugs. No such thing. Why? Because it clearly implies there is a ‘safe’ dose which can be taken – and everyone knows that’s a lie. The same goes for the words, ‘use’ and ‘abuse’. Those terms can only be applied to prescribed pharmaceuticals because they have a prescribed safe dose. I have asked each jurisdiction in Australia if the legal amount of alcohol when driving, up to 0.49, is considered safe for driving. All said no – they would not state that.”
These substances remain prohibited because they are not manufactured to a pharmaceutical standard and are poisonous, unpredictable toxins that make it impossible to test which dose either in isolation or in a myriad of combinations proves fatal.
The limitations of pill testing4 have been discussed by Dr John Lewis (University of Technology Sydney) and prominent toxicologist Dr John Ramsey, emphasising that it is:
• Complex process
• Costly and time consuming
• Detects mainly major components of a sample that may not be the active substance
For example, even a relatively small amount of ingredients such as Carfentanil are lethal.
Speaking after Canberra’s pill trial in 2017, forensic toxicologist, Andrew Leibie, warned that pill testing trial is no “magic bullet” for preventing drug deaths but also expressed deep concern surrounding the freedom for scientific debate because public sector employees feared repercussions.

Leading harm reduction activist, Dr David Caldicott, in a 2015 interview admitted that the quality and type of pill testing would affect pill taking behaviour at festivals. When told that users potentially wouldn’t get their drugs back and the lengthy 45-minute process involved, “‘I think there’ll be a lot of people who will say forget it completely.’ His reasoning being that a lot of young people don’t have the money to spare a pill and it would slow down the momentum of the party.”

Could this be the motivation behind current trial of pill testing at Goovin’ the Moo where volunteering attendees where given the choice between testing the entire pill – effectively destroying it – or scraping the contents and handing back the remainder, despite the fact that the latter approach brings even less accuracy. This is another example of drug users, not evidence informing policy procedure.
The irony of course is that many of the advocates for pill testing would object to sugary drinks, foods and caffeinated energy drinks in school cafeterias on the basis these hinder the normal development of healthy children but do not object to the infinitely direr situation facing kids at music festivals.

Purity vs Contaminated – Another Misleading Contrast
The fallacious arguments surrounding safe dosage remain the same irrespective of whether the substance is tested as seemingly pure. Take MDMA that goes by various street names Molly and Ecstasy. It is the most popular recreational drug in Australia and was responsible for many of the deaths at music festivals.
In 1995, 15-year old, Anna Woods, died after several hours from consuming a single pill of pure MDMA at a Rave Party. Pill testing would not have changed this outcome. Anna’s case also highlights the idiosyncratic nature of drug taking in that while her three friends ingested the same tablets, Anna was the only one to have a reaction. Russian Roulette is again the most appropriate metaphor.
The Coroner’s report on Anna Wood’s death stated, “It is not unlikely that a tragedy such as this will occur again in N.S.W. In an effort to reduce the chance of that happening, I propose to recommend that the N.S.W. Health Department publishes a pamphlet, which will have the twofold effect of educating those who use the drug as to its dangers, and also educating the community as to the appropriate care of the individual who becomes ill following ingestion of the drug.”
Nearly twenty-five years later the fatalities involving MDMA keep mounting. In the only Australian study of 82 drug related deaths between 2001 to 2005, MDMA featured predominately. The fluctuating potency of this drug is further established as it is not only fifteen-year-old girls but grown men dying.

“The majority of decedents were male (83%), with a median age of 26 years. Deaths were predominantly due to drug toxicity (82%), with MDMA the sole drug causing death in 23% of cases, and combined drug toxicity in 59% of cases. The remaining deaths (18%) were primarily due to pathological events/disease or injury, with MDMA a significant contributing condition.”
The indiscriminate nature of MDMA was also witnessed with the latest fatalities at music festivals. For example, very different amounts of MDMA accounted for the five young people that died across New South Wales.
“In one case, a single MDMA pill had proved lethal while another young man who ingested six to nine pills over the course of the day had an MDMA purity of 77 per cent… (That is) a very high rate of purity,” Dr Dwyer said.”
Comparable stories are found all over the world including the UK case of Stephanie Jade Shevlin that is eerily similar to Anna Woods.
Drug dealers aware of the naïvely misleading narrative of pure and impure illicit drugs have been caught bringing pill testing kits to concerts in a bid to convince potential buyers of quality and hike up prices.

High Risk-Taking Culture

The prevailing culture at music festivals is one of blissful abandon and haste. It is a no longer fringe groups at the edges of society but the mainstream choice for generations of children and young adults fully embracing the legacy of, “tune in, turn on and drop out”.
Yet despite the prevailing culture, harm reductionists insist that pill testing will better inform partygoers of drug contents and provide the necessary platform for ‘further conversations about the drug dangers.’ (All of which of course can be achieved outside a venue.)
But this is conjecture and another attempt at experimental based policy.
As cited earlier, Dr Caldicott admitted, anything that stops the party momentum experience is likely rejected. This is because when dealing with high-risk behaviour removing too many risks takes away the thrill of reward.

In an age that has more educated men and women than ever before, it’s not the lack of information that is driving this level of experimentation but the growing indifference to it.
In the aftermath of the death of 25-year-old pharmacist, Sylvia Choi (2015), it was discovered that security staff at the Stereosonic festival were consuming and dealing drugs.
Further, the report often cited purporting to show a growing body of research for drug users wanting pill testing actually confirms that those with college degrees were less likely than those with high school qualifications to test their pills.
This seems to be a trend in Australia also with one judge fed up with groups of “well-off pill poppers” and “privileged” young professionals, including nurses and bankers – filling the court.
Another article describes the attitude of drug taking among festival goers (including University students) as not so much concerned about what is on offer but demand for cheap designer drugs.
The author notes, “A few deaths don’t deter experimentation, and if you’re going to experiment, you need to be sure you don’t die.”
But the determination for experimentation with different forms of self-destructive drugs is making staying alive increasingly less likely, as the levels of polydrug use is also on the rise.
According to Global Drug Survey, “Over 90% of people seeking Emergency Medical Treatment each year after MDMA have used other drugs (often cocaine or ketamine) and/or alcohol and more frequent use of MDMA is associated with the higher rates of combined MDMA use with other stimulant drugs and ketamine.”

Australia’s enquiry into MDMA supports this finding, “Nevertheless, the fact that half of the toxicology reports noted the detection of methamphetamine in the blood is consistent with the polydrug use patterns of living MDMA users.”

Pill Testing Overseas Failing to Stop Drug Demand and Supply

The push continues for Australia to adopt front of house or front-line pill testing at music festivals as in Europe and the UK. But not everyone is convinced of its resounding success.
Last year, UK’s largest festival organiser reversed its previous support for drug testing facilities. Managing director, Melvyn Benn, stating, “Front of house testing sounds perfect but has the ability to mislead I fear.”
Mr Benn details those fears, “Determining to a punter that a drug is in the ‘normal boundaries of what a drug should be’ takes no account of how many he or she will take, whether the person will mix it with other drugs or alcohol and nor does it give you any indicator of the receptiveness of a person’s body to that drug.”
In 2001, The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) produced its scientific report, On-Site Pill-Testing Interventions In The European Union.
Incomplete evaluation procedures have hindered the availability for empirical evidence on the effectiveness of pill testing. “The conclusions one can draw from that fact remain ambiguous.”
Perhaps the most disturbing feature of the report is the admission that decreasing black market activity isn’t within the scope of pill testing goals. “Overall, to alter black markets is ‘not a primary goal’ or ‘no goal at all’ for most pill-testing projects.” Within that same report drug users are classed as ‘consumers’ with an entitlement to know what their pills contain.
The report goes on to list the range of services offered alongside pill testing at venues. These include everything from: brain machines, internet consultations, needle exchange, presenting on-site results of pill-testings, chill-out zones, offering massage, giving out fruits, giving out free drinking water and giving out condoms.
And in another twist of just how far the common sense boundaries are stretched, for number of participating nations, tax payer funded pill testing is also offered at illegal rave venues.

Given the overwhelming lack of evidence that pill testing indeed saves lives, Australian toxicologist, Andrew Liebie’s claim is not easily dismissed, “the per capita death rate from new designer drugs was higher in Europe – where pill testing was available in some countries – than in Australia.”
The antipathy to drug taking was also witnessed by the Ambulance Commander at the latest pill testing trial, again in Canberra, Groovin’ the Moo.

No War on Drugs Just a Submission to Harm Reduction Promotion
The narrative for pill testing will at some stage mention the failed “war on drugs” and by association hard line but failing law enforcement measures either explicitly or implicitly such as in the statement below.
“Regardless of the desirability of treating it as a criminal issue rather than a health one, policing at festivals has limited impact on drug consumption, as research presented at the Global Cities After Dark conference last year suggests: 69.6 per cent of survey respondents said they would use drugs if police were present.”
But what this article completely fails to grasp is that police presence makes little impact because the law is rarely or, at best, laxly enforced and a climate of de facto decriminalisation has been the norm for decades. This was the situation with Portugal before finally decriminalising drugs for personal use in 2001.
Journalists for The Weekend Australian attempting to report events at a recent dance party stated sniffer dogs did nothing to stop the “rampart” stream of drugs. They described a scene of disarray; discarded condoms with traces of coffee grounds within toilets (believed to mask the smell of drugs), bodies strewn on the ground littered with drug paraphernalia, others were rushed to waiting ambulances, while one attendant told them “I got away with it” and another admitting popping two pills a night was “average”. Had they been allowed to stay longer maybe more party goers would be openly stating what many know, drugs supply and demand are at all-time highs irrespective of police presence.

Journalists instead were treated as criminal trespassers, threatened by security and ordered to leave under police escort.
The basis of Australia’s National Drug Strategy includes harm minimisation efforts as part of an overall strategy that also supports reductions in drug supply and demand.
The inadvertent admission that pill testing is not about curbing drug demand comes from another harm reduction stalwart, Alex Wodak, “It’s a supposition that this (pill testing) might increase drug use, but if it does increase drug use but decrease the number of deaths, surely that’s what we should be focusing on.”
In fact, Dr Wodak confirms that pill testing would incentivise drug dealers to provide a better product. “There was no commercial pressure on drug dealers to ensure their products were safe. But if we had testing and 10% of drug dealer A’s supply was getting rejected at the drug testing counter, then word would get around.”
A similar focus on consequences rather than causes is expressed by Dr David Caldicott, “I don’t give a s**t about the morality or philosophy of drug use. All I care about is people staying alive.”
In other words, take the pill, just don’t die…this time. What the long-term affects are to those drug users that survive hospitalisation, the impact on development, mental health, employment loss, families, the growing cost to taxpayers and the crushing weight on emergency services, hospitals and physicians let alone the constant appetite and entrenchment for more drugs will have to wait. Just don’t die.
The ongoing dilution of law enforcement is also seen by various experts all but demanding that police and sniffer dogs be removed entirely from music festivals. No doubt to be replaced with on-site massages, electrolyte drinks, brain machinery, chill out zones, fruit and more free condoms.
Prof Alison Ritter from the University of NSW and Fiona Measham from the University of Durham both agree that intensive policing combined with on-site dealing “could significantly increase drug related harm.” How intensive could police efforts be with such blatant on-site dealing was not explained.

The Unrelenting Push for Drug Legalisation
The real end game behind the dubious safety and harm messaging is drug legalisation. Pill testing, minus the caveat of being called a ‘trial’, would unlikely find full approval without a corresponding change in the law.
The limitations of pill testing and the legal ramifications in giving back a tested pill that proved lethal would become a public liability minefield.
This is clearly seen from the article in the Daily Telegraph, Pill Test Death Waiver Revealed, Jan 5, “The testing capabilities are so limited that revellers would be required to sign a death waiver, which includes a warning that tests cannot accurately determine drug purity levels or give any indication of safety.”
Later the article reports, “Mr Vumbaca said he had been given extensive legal advice to include the warnings on the waiver because of the limitations of testing information … we are not a laboratory and we have one piece of equipment … the test gives you an indication of purity, but you can’t tell the exact amount.”
The waiver would release everyone in testing from, “any liability for personal injury or death suffered … in any way from the services.”
Scattered within the pages of countless articles on pill testing released over the last few months, this admission of pill testing tied in within a broader agenda of drug legalisation is repeatedly made but easily missed among the hype.
Gary Barns from the Australian Lawyers Alliance said the latest deaths could be avoided or risk of death could be minimised with a “law change”.
Sydney Criminal Lawyers are more explicit, “And it seems clear that if adults were able to purchase quality controlled MDMA over the counter in plain packaging with the contents marked on the side, it would be far safer than buying from some backyard manufacturer with no oversight or guarantees.”
And disappointingly, even former AFP and DPP speaking on Four Corners state drug legalisation as a necessary public conversation.
It seems that these same advocates for policy and law change are willing to give a platform for the rights of those determined to self-destruct but not the rest of the law abiding community and their common good.

Pill testing – The Climate Change of Drugs
If comparing pill testing as a ‘silver bullet’ was an inaccurate metaphor, then the comparison to climate change shows the extent of not only erroneous but deliberate obfuscation. “This issue of pill-testing is climate change for drugs,” says Dr David Caldicott.
And yet the dark environment which produces the pills and wreaks so much unnecessary destruction to countless thousands of people all over the world is never fully understood or exposed to those that would blissfully take one small pill for a few hours of entertainment.
But talk of boycotting products that pollute the atmosphere, meat that is packaged from abused animals, clothing produced from exploited workers, or products genetically modified, most likely those same illicit pill takers would passionately relinquish and possibly even risk their personal safety to protest these injustices.
Yet, these are dwarfed by illicit drugs. The most barbaric network of human, economic and environmental exploitation.
Some of the social miseries are well known, including international crime syndicates and narco-terrorism. While others such as environmental damage due to deforestation, chemical waste and the recent drug toxicity detected in Adelaide waterways are often overlooked in an age of socially conscientious consumerism.
But the list of downward consequences is always local and personal, with illicit drugs linked to preventable death, disease and poverty. In cases of domestic violence, alcohol and drugs contributed to 49 per cent of women assaulted in the preceding 12 months.

Those who suffer the most are those who can least afford the consequences; the poor, young, vulnerable, indigenous and rural communities as revealed in the Australian Criminal Intelligence Commission report.
Faced with such overwhelming statistics pro-drug lobbyists use inevitability mantras such as, “they’re doing it anyway” to sway public opinion toward legalisation; but fail to apply the same arguments to other societal abuses such as paedophilia, obesity, gambling, domestic violence, alcohol or tobacco.
It is time to stop the dishonest rhetoric of harm reductionist activists and the deliberate intellectual disconnect that has greatly influenced the Australian government drug strategy and peak medical bodies toward policies emphasising reducing drug harms (injecting rooms, needle distribution, methadone and now pill testing) while minimising the need to reduce demand and supply.
Eleni Arapoglou
– Writer and Researcher, Drug Advisory Council of Australia (DACA)

Source: PillTestingDACA_PoliticianBrief05-02-19.pdf (drugfree.org.au) February 2019

Three decades ago, I would have been over the moon to see marijuana legalized. It would have saved me a lot of effort spent trying to avoid detection, constantly looking for places to hide a joint. I smoked throughout my teens and early 20s. During this period, upon landing in a new city, my first order of business was to score a quarter-ounce. The thought of a concert or a vacation without weed was simply too bleak.

These days it’s hard to find anybody critical of marijuana.

The drug enjoys broad acceptance by most Americans — 63 percent favoured ending cannabis prohibition in a recent Quinnipiac poll — and legislators on both sides of the aisle are becoming more likely to endorse than condemn it. After years of loosening restrictions on the state level, there are signs that the federal government could follow suit: In April, Senate Minority Leader Charles E. Schumer (D-N.Y.) became the first leader of either party to support decriminalizing marijuana at the federal level, and President Trump (his attorney general notwithstanding) promised a Republican senator from Colorado that he would protect states that have legalized pot.

And why not? The drug is widely thought to be either benign or beneficial. Even many of those apathetic toward its potential health benefits are ecstatic about its commercial appeal, whether for personal profit or state tax revenue. Legalization in many cases, and for many reasons, can be a good thing. I’m sympathetic.

But I am also a neuroscientist, and I can see that the story is being oversimplified. The debate around legalization — which often focuses on the history of racist drug laws and their selective enforcement — is astoundingly naive about how the widespread use of pot will affect communities and individuals, particularly teenagers. In our rush to throw open the gate, we might want to pause to consider how well the political movement matches up with the science, which is producing inconveniently alarming studies about what pot does to the adolescent brain.

Marijuana for sale at a Colorado dispensary.    (Matthew Staver/Bloomberg Creative Photos)

I took a back-door route to the science of marijuana, starting with a personal investigation of the plant’s effects. When I was growing up in South Florida in the 1980s, pot was readily available, and my appreciation quickly formed the basis for an avid habit. Weed seemed an antidote to my adolescent angst and ennui, without the sloppiness of alcohol or the jaw-grinding intensity of stimulants.

Of the many things I loved about getting high, the one I loved best was that it commuted the voice in my head — usually peevish or bored — to one full of curiosity and delight. Marijuana transformed the mundane into something dramatic: family outings, school, work or just sitting on the couch became endlessly entertaining when I was stoned.

Like any mind-altering substance, marijuana produces its effects by changing the rate of what is already going on in the brain. In this case, the active ingredient delta-9-THC substitutes for your own natural endocannabinoids and mimics their effects. It activates the same chemical processes the brain employs to modulate thoughts, emotions and experiences. These specific neurotransmitters, used in a targeted and judicious way, help us sort the relentless stream of inputs and flag the ones that should stand out from the torrent of neural activity coding stray thoughts, urges and experience. By flooding the entire brain, as opposed to select synapses, marijuana can make everything, including the most boring activities, take on a sparkling transcendence.

Why object to this enhancement? As one new father told me, imbibing made caring for his toddler much more engrossing and thus made him, he thought, a better parent. Unfortunately, there are two important caveats from a neurobiological perspective.

As watering a flooded field is moot, widespread cannabinoid activity, by highlighting everything, conveys nothing. And amid the flood induced by regular marijuana use, the brain dampens its intrinsic machinery to compensate for excessive stimulation. Chronic exposure ultimately impairs our ability to imbue value or importance to experiences that truly warrant it.

In adults, such neuro-adjustment may hamper or derail a successful and otherwise fulfilling life, though these capacities will probably recover with abstinence. But the consequences of this desensitization are more profound, perhaps even permanent, for adolescent brains. Adolescence is a critical period of development, when brain cells are primed to undergo significant organizational changes: Some neural connections are proliferating and strengthening, while others are pared away.

Although studies have not found that legalizing or decriminalizing marijuana leads to increased use among adolescents, perhaps this is because it is already so popular. More teenagers now smoke marijuana than smoke products with nicotine; between 30 and 40 percent of high school seniors report smoking pot in the past year, about 20 percent got high in the past month, and about 6 percent admit to using virtually every day. The potential consequences are unlikely to be rare or trivial.

The decade or so between puberty and brain maturation is a critical period of enhanced sensitivity to internal and external stimuli. Noticing and appreciating new ideas and experiences helps teens develop a sense of personal identity that will influence vocational, romantic and other decisions — and guide their life’s trajectory. Though a boring life is undoubtedly more tolerable when high, with repeated use of marijuana, natural stimuli, like those associated with goals or relationships, are unlikely to be as compelling.

It’s not surprising, then, that heavy-smoking teens show evidence of reduced activity in brain circuits critical for  flagging newsworthy experiences, are 60 percent less likely to graduate from high school, and are at substantially increased risk for heroin addiction and alcoholism. They show alterations in cortical structures associated with impulsivity and negative moods; they’re seven times more likely to attempt suicide.

Recent data is even more alarming: The offspring of partying adolescents, specifically those who used THC, may be at increased risk for mental illness and addiction as a result of changes to the epigenome — even if those children are years away from being conceived. The epigenome is a record of molecular imprints of potent experiences, including cannabis exposure, that lead to persistent changes in gene expression and behavior, even across generations. Though the critical studies are only now beginning, many neuroscientists prophesize a social version of Rachel Carson’s “Silent Spring,” in which we learn we’ve burdened our heirs only generations hence.

Might the relationship between marijuana exposure and changes in brain and behavior be coincidence, as tobacco companies asserted about the link between cancer and smoking, or does THC cause these effects? Unfortunately, we can’t assign people to smoking and nonsmoking groups in experiments, but efforts are underway to follow a large sample of children across the course of adolescent development to study the effects of drug exposure, along with a host of other factors, on brain structure and function, so future studies will probably be able to answer this question.

In the same way someone who habitually increases the volume in their headphones reduces their sensitivity to birdsong, I followed the “gateway” pattern from pot and alcohol to harder drugs, leaping into the undertow that eventually swept away much of what mattered in my life. I began and ended each day with the bong on my nightstand as I floundered in school, at work and in my relationships. It took years of abstinence, probably mirroring the duration and intensity of my exposure, but my motivation for adventure seems largely restored. I’ve been sober since 1986 and went on to become a teacher and scholar. The single-mindedness I once directed toward getting high came in handy as I worked on my dissertation. I suspect, though, that my pharmacologic adventures left their mark.

Now, as a scientist, I’m unimpressed with many of the widely used arguments for the legalization of marijuana. “It’s natural!” So is arsenic. “It’s beneficial!” The best-documented medicinal effects of marijuana are achieved without the chemical compound that gets users high. “It’s not addictive!”  This is false, because the brain adapts to marijuana as it does to all abused drugs, and these neural adjustments lead to tolerance, dependence and craving — the hallmarks of addiction.

It’s true that a lack of benefit, or even a risk for addiction, hasn’t stopped other drugs like alcohol or nicotine from being legal, used and abused. The long U.S. history of legislative hypocrisy and selective enforcement surrounding mind-altering substances is plain to see. The Marihuana Tax Act of 1937, the first legislation designed to regulate pot, was passed amid anti-Mexican sentiment (as well as efforts to restrict cultivation of hemp, which threatened timber production); it had nothing do with scientific evidence of harm. That’s true of most drug legislation in this country. Were it not the case, LSD would be less regulated than alcohol, since the health, economic and social costs of the latter far outweigh those of the former. (Most neuroscientists don’t believe that LSD is addictive; its potential benefits are being studied at Johns Hopkins and New York University, among other places.)

Still, I’m not against legalization. I simply object to the astounding lack of scepticism about pot in our current debate. Whether or not to legalize weed is the wrong question. The right one is: How will growing use of delta-9-THC affect individuals and communities?

Though the evidence is far from complete, wishful thinking and widespread enthusiasm are no substitutes for careful consideration. Instead of rushing to enact new laws that are as nonsensical as the ones they replace, let’s sort out the costs and benefits, using current scientific knowledge, while supporting the research needed to clarify the neural and social consequences of frequent use of THC. Perhaps then we’ll avoid practices that inure future generations to what’s really important.

                                       By Judith Grisel,    May 25, 2018

Source:  https://www.washingtonpost.com/ posteverything/wp/2015/04/30/yes-pot-should-be-legal-but-it-shouldnt-be-sold-for-a-profit/   

Abstract

Background

Ecological research suggests that increased access to cannabis may facilitate reductions in opioid use and harms, and medical cannabis patients describe the substitution of opioids with cannabis for pain management. However, there is a lack of research using individual-level data to explore this question. We aimed to investigate the longitudinal association between frequency of cannabis use and illicit opioid use among people who use drugs (PWUD) experiencing chronic pain.

Methods and findings

This study included data from people in 2 prospective cohorts of PWUD in Vancouver, Canada, who reported major or persistent pain from June 1, 2014, to December 1, 2017 (n = 1,152). We used descriptive statistics to examine reasons for cannabis use and a multivariable generalized linear mixed-effects model to estimate the relationship between daily (once or more per day) cannabis use and daily illicit opioid use. There were 424 (36.8%) women in the study, and the median age at baseline was 49.3 years (IQR 42.3–54.9). In total, 455 (40%) reported daily illicit opioid use, and 410 (36%) reported daily cannabis use during at least one 6-month follow-up period. The most commonly reported therapeutic reasons for cannabis use were pain (36%), sleep (35%), stress (31%), and nausea (30%). After adjusting for demographic characteristics, substance use, and health-related factors, daily cannabis use was associated with significantly lower odds of daily illicit opioid use (adjusted odds ratio 0.50, 95% CI 0.34–0.74, p < 0.001). Limitations of the study included self-reported measures of substance use and chronic pain, and a lack of data for cannabis preparations, dosages, and modes of administration.

Conclusions

We observed an independent negative association between frequent cannabis use and frequent illicit opioid use among PWUD with chronic pain. These findings provide longitudinal observational evidence that cannabis may serve as an adjunct to or substitute for illicit opioid use among PWUD with chronic pain.

Author summary

Why was this study done?

  • High numbers of people who use (illicit) drugs (PWUD) experience chronic pain, and previous research shows that illicit use of opioids (e.g., heroin use, non-prescribed use of painkillers) is a common pain management strategy in this population.
  • Previous research has suggested that some patients might substitute opioids (i.e., prescription painkillers) with cannabis (i.e., marijuana) to treat pain.
  • Research into cannabis as a potential substitute for illicit opioids among PWUD is needed given the high risk of opioid overdose in this population.
  • We conducted this study to understand if cannabis use is related to illicit opioid use among PWUD who report living with chronic pain in Vancouver, Canada, where cannabis is abundant and the rate of opioid overdose is at an all-time high.

What did the researchers do and find?

  • Using data from 2 large studies of PWUD in Vancouver, Canada, we analyzed information from 1,152 PWUD who were interviewed at least once and reported chronic pain at some point between June 2014 and December 2017.
  • We used statistical modelling to estimate the odds of daily opioid use for (1) daily and (2) occasional users of cannabis relative to non-users of cannabis, holding other factors (e.g., sex, race, age, use of other drugs, pain severity) equal.
  • For participants who reported cannabis use, we also analyzed their responses to a question about why they were using cannabis (e.g., for intoxication, for pain relief)
  • We found that people who used cannabis every day had about 50% lower odds of using illicit opioids every day compared to cannabis non-users. People who reported occasional use of cannabis were not more or less likely than non-users to use illicit opioids on a daily basis. Daily cannabis users were more likely than occasional cannabis users to report a number of therapeutic uses of cannabis including for pain, nausea, and sleep.

What do these findings mean?

  • Although more experimental research (e.g., randomized controlled trial of cannabis coupled with low-dose opioids to treat chronic pain among PWUD) is needed, these findings suggest that some PWUD with pain might be using cannabis as a strategy to alleviate pain and/or reduce opioid use.

Introduction

Opioid-related morbidity and mortality continue to rise across Canada and the United States. In many regions, including Vancouver, Canada—where drug overdoses were declared a public health emergency in 2016—the emergence of synthetic opioids (e.g., fentanyl) in illicit drug markets has sparked an unprecedented surge in death. The overdose crisis is also the culmination of shifting opioid usage trends (i.e., from initiating opioids via heroin to initiating with pharmaceutical opioids) that can be traced back, in part, to the over-prescription of pharmaceutical opioids for chronic non-cancer pain.

Despite this trend of liberal opioid prescribing, certain marginalized populations experiencing high rates of pain, including people who use drugs (PWUD), lack access to adequate pain management through the healthcare system. Under- or untreated pain in this population can promote higher-risk substance use, as patients may seek illicit opioids (i.e., unregulated heroin or counterfeit/diverted pharmaceutical opioids) to manage pain. In Vancouver, this practice poses a particularly high risk of accidental overdose, as estimates show that almost 90% of drugs sold as heroin are contaminated with synthetic opioids, such as fentanyl. Another less-examined pain self-management strategy among PWUD is the use of cannabis. Unlike illicit opioids and illicit stimulants, the cannabis supply (unregulated or regulated) has not been contaminated with fentanyl, and cannabis is not known to pose a direct risk of fatal overdose. As a result, cannabis has been embraced by some, including emerging community-based harm reduction initiatives in Vancouver, as a possible substitute for opioids in the non-medical management of pain and opioid withdrawal. Further, clinical evidence supports the use of cannabis or cannabinoid-based medications for the treatment of certain types of chronic non-cancer pain (e.g., neuropathic pain).

As more jurisdictions across North America introduce legal frameworks for medical or non-medical cannabis use, ecological studies have provided evidence to suggest that states providing access to legal cannabis experience population-level reductions in opioid use, opioid dependence, and fatal overdose. However, these state-level trends do not necessarily represent changes within individuals, highlighting a critical need to conduct individual-level research to better understand whether cannabis use is associated with reduced use of opioids and risk of opioid-related harms, particularly among individuals with pain. Of particular interest is a possible opioid-sparing effect of cannabis, whereby a smaller dose of opioids provides equivalent analgesia to a larger dose when paired with cannabis. Although this effect has been identified in pre-clinical studies, much of the current research in humans is limited to patient reports of reductions in the use of prescription drugs (including opioids) as a result of cannabis use. However, a recent study among patients on long-term prescription opioid therapy produced evidence to counter the narrative that cannabis use leads to meaningful reductions in opioid prescriptions or dose. These divergent findings confirm an ongoing need to understand this complex issue. To date, there is a lack of research from real-world settings exploring the opioid-sparing potential of cannabis among high-risk individuals who may be engaging in frequent illicit opioid use to manage pain. We therefore sought to examine whether frequency of cannabis use was related to frequency of illicit opioid use among PWUD who report living with chronic pain in Vancouver, Canada, the setting of an ongoing opioid overdose crisis.

Methods

Study sample

Data for this study were derived from 2 ongoing open prospective cohort studies of PWUD in Vancouver, Canada. The Vancouver Injection Drug Users Study (VIDUS) consists of HIV-negative people who use injection drugs. The AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS) consists of people living with HIV who use drugs. The current study, nested within these cohorts, was designed as part of a larger doctoral research project (SL) examining cannabis use and access among PWUD in the context of changing cannabis policy and the ongoing opioid overdose crisis. The analysis plan for this study is provided in S1 Text. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies (S1 Checklist).

Recruitment for the cohort studies has been ongoing since 1996 (VIDUS) and 2005 (ACCESS) through extensive street outreach in various areas across Vancouver’s downtown core, including the Downtown Eastside (DTES), a low-income neighbourhood with an open illicit drug market and widespread marginalization and criminalization. To be eligible for VIDUS, participants must report injecting drugs in the previous 30 days at enrolment. To be eligible for ACCESS, participants must report using an illicit drug (other than or in addition to cannabis, which was a controlled substance under Canadian law until October 17, 2018) in the previous 30 days at enrolment. For both cohorts, HIV serostatus is confirmed through serology. Other eligibility requirements include being aged 18 years or older, residing in the Metro Vancouver Regional District, and providing written informed consent. Aside from HIV-disease-specific assessments, all study instruments and follow-up procedures are harmonized between the 2 studies to facilitate combined data analysis and interpretation.

At study enrolment, participants complete an interviewer-administered baseline questionnaire. Every 6 months thereafter, participants are eligible to complete a follow-up questionnaire. The questionnaires elicit information on socio-demographic characteristics, lifetime (baseline) and past-6-month (baseline, follow-up) patterns of substance use, risk behaviours, healthcare utilization, social and structural exposures, and other health-related factors. Nurses collect blood samples for HIV testing (VIDUS) or HIV clinical monitoring (ACCESS) and hepatitis C virus serology, providing referrals to appropriate healthcare services as needed. Participants are provided a Can$40 honorarium for their participation at each study visit.

Ethics statement

Ethics approval for this study was granted by the University of British Columbia/Providence Health Care Research Ethics Board (VIDUS: H14-01396; ACCESS: H05-50233). Written informed consent was obtained from all study participants.

Measures

To examine the use of illicit opioids and cannabis for possible ad hoc management of pain among PWUD, we restricted the study sample to individuals experiencing major or persistent pain. Beginning in follow-up period 17 (i.e., June 2014), the following question was added to the study questionnaire: “In the last 6 months, have you had any major or persistent pain (other than minor headaches, sprains, etc.)?” We included all observations from participants beginning at the first follow-up interview in which they reported chronic pain. For example, a participant who responded “no” to the pain question at follow-up 17 and “yes” at follow-up 18 would be included beginning at follow-up 18. For the purpose of these analyses, this first follow-up period with a pain report is considered the “baseline” interview.

The outcome of interest was frequent use of illicit opioids, defined as reporting daily (once or more per day) non-medical use of heroin or pharmaceutical opioids (diverted, counterfeit, or not-as-prescribed use) by injection or non-injection (i.e., smoking, snorting, or oral administration) in the previous 6 months. This outcome was captured through 4 different multipart questions based on class of opioid (i.e., heroin and pharmaceutical opioids) and mode of administration (i.e., injection and non-injection). For example, at each 6-month period, injection heroin use was assessed through the question: “In the last 6 months, when you were using, which of the following injecting drugs did you use, and how often did you use them?” Respondents were provided a list of commonly injected drugs, including heroin, and were asked to estimate their average frequency of injection in the past 6 months according to the following classifications: <1/month, 1–3/month, 1/week, 2–3/week, ≥1/day. An identical question for non-injection drugs assessed the frequency of non-injection heroin use. Pharmaceutical opioid injection was assessed through the question “In the past 6 months, have you injected any of the following prescription opioids? If so, how often did you inject them?” Participants were provided a list of pharmaceutical opioids with corresponding pictures for ease of identification. The question was repeated for non-injection use of pharmaceutical opioids, and the frequency categories were identical to those listed above. Using frequency categorizations from these 4 questions, participants who endorsed past-6-month daily injection or non-injection of heroin or pharmaceutical opioids were coded as “1” for the outcome (i.e., daily illicit opioid use) for that follow-up period. The main independent variable was cannabis use, captured through the question “In the last 6 months, have you used marijuana (either medical or non-medical) for any reason (e.g., to treat a medical condition or for a non-medical reason, like getting high)?” Those who responded “yes” were also asked to estimate their average past-6-month frequency of use according to the frequency categories described above. Frequency was further categorized as “daily” (i.e., ≥1/day), “occasional” (i.e., <1/month, 1–3/month, 1/week, 2–3/week), and “none” (no cannabis use; reference category). Sections of the questionnaire used for sample restriction and main variable building are provided in S2 Text.

We also considered several socio-demographic, substance use, and health-related factors with the potential to confound the association between cannabis use and illicit opioid use. Secondary socio-demographic variables included in this analysis were sex (male versus female), race (white versus other), age (in years), employment (yes versus no), incarceration (yes versus no), homelessness (yes versus no), and residence in the DTES neighbourhood (yes versus no). We considered the following substance use patterns: daily crack or cocaine use (yes versus no), daily methamphetamine use (yes versus no), and daily alcohol consumption (yes versus no). Health-related factors that were hypothesized to bias the association between cannabis and opioid use were enrolment in opioid agonist treatment (i.e., methadone or buprenorphine/naloxone; yes versus no), HIV serostatus (HIV-positive versus HIV-negative), prescription for pain (including prescription opioids; yes versus no), and average past-week pain level (mild–moderate, severe, or none). The pain variable was self-reported using a pain scale ranging from 0 (no pain) to 10 (worse possible pain). We used 3 as the cut-point for mild–moderate pain and 7 as the cut-point for moderate–severe pain. Although there is no universal standard for pain categorization, these cut-points are common and have been validated in other pain populations. Due to low cell count for mild pain (scores 1–3), we collapsed this variable with moderate pain (4–6) to create the mild–moderate category. With the exception of sex and race, all variables are time-updated and refer to behaviours and exposures in the 6-month period preceding the interview. All variables except HIV status were derived through self-report. As data for the present study were derived from 2 large cohort studies with broader objectives of monitoring changing health and substance use patterns in the community, the study participants and interviewers were blinded to the objective of this particular study.

Statistical analysis

We explored differences in characteristics at baseline according to daily cannabis use status (versus occasional/none) using chi-squared tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. Then, we estimated bivariable associations between each independent variable and the outcome, daily illicit opioid use, using generalized linear mixed-effects models (GLMMs) with a logit-link function to account for repeated measures within individuals over time. Next, we built a multivariable GLMM to estimate the adjusted association between frequency of cannabis use and illicit opioid use. We used the least absolute shrinkage and selection operator (LASSO) approach to determine which variables to include in the multivariable model. This method uses a tuning parameter to penalize the model based on the absolute value of the magnitude of coefficients (i.e., L1 regularization), shrinking some coefficients down to 0 (i.e., indicating their removal from the multivariable GLMM). Four-fold cross-validation was used to determine the optimal value of the tuning parameter. GLMMs were estimated using complete cases (98.6%–100% of observations for bivariable estimates; 99.0% of observations for multivariable estimates).

In the most recent follow-up period (June 1, 2017, to December 1, 2017), participants who reported any cannabis use in the previous 6-month period were eligible for the follow-up question: “Why did you use it?” Respondents could select multiple options from a list of answers or offer an alternative reason under “Other”. These data were analyzed descriptively, and differences between at least daily and less than daily cannabis users were analyzed using a chi-squared test, or Fisher’s test for small cell counts.

All analyses were performed in RStudio (version 1.1.456; R Foundation for Statistical Computing, Vienna, Austria). All p-values are 2-sided.

Results

Between June 1, 2014, and December 1, 2017, 1,489 participants completed at least 1 study visit and were considered potentially eligible for these analyses. Of them, 13 participants were removed due to missing data on the fixed variable for race (n = 9), no response to the pain question (n = 1), or multiple interviews during a single follow-up period (n = 3). Of the remaining 1,476 participants, 1,152 (78.0%) reported major or persistent pain during at least one 6-month follow-up period and were included in this analysis. We considered all observations from these individuals beginning from the first report of chronic pain, yielding 5,350 study observations, equal to 2,676.5 person-years of observation. There were 424 (36.8%) female participants in the analytic sample, and the median age at the earliest analytic interview was 49.3 years (IQR 42.3–54.9).

Over the study period, a total of 410 (35.6%) respondents reported daily and 557 (48.4%) reported occasional cannabis use throughout at least 1 of the 6-month follow-up periods; 455 (39.5%) reported daily illicit opioid use throughout at least 1 of the 6-month follow-up periods. At baseline (i.e., the first interview in which chronic pain was reported), 583 (50.6%) participants were using cannabis either occasionally (n = 322; 28.0%) or daily (n = 261; 22.7%), and 269 (23.4%) were using illicit opioids daily. At baseline, 693 (60.2%) participants self-reported a lifetime chronic pain diagnosis including bone, mechanical, or compressive pain (n = 347; 50.1%); inflammatory pain (n = 338; 48.8%); neuropathic pain (n = 129; 18.6%); muscle pain (n = 54; 7.8%); headaches/migraines (n = 41; 5.9%); and other pain (n = 53; 7.6%).

Table 1 provides a summary of baseline characteristics of the sample stratified by daily cannabis use status (yes versus no). Daily cannabis use at baseline was significantly more common among men (odds ratio [OR] 1.76, 95% 95% CI 1.30–2.38, p < 0.001) and significantly less common among those who used illicit opioids daily (OR 0.54, 95% CI 0.37–0.77, p < 0.001).

Discussion

In this longitudinal study examining patterns of past-6-month frequency of cannabis and illicit opioid use, we found that the odds of daily illicit opioid use were lower (by about half) among those who reported daily cannabis use compared to those who reported no cannabis use. However, we observed no significant association between occasional cannabis use and daily opioid use, suggesting that there may be an intentional therapeutic element associated with frequent cannabis use. This is supported by cross-sectional data from the sample in which certain reasons for cannabis use were observed to differ according to cannabis use frequency. Specifically, daily users reported more therapeutic motivations for cannabis use (including to address pain, stress, nausea, mental health, or symptoms of HIV or antiretroviral therapy, or to improve sleep) than occasional users, and non-medical motivations—although common among all users—were not more likely to be reported by daily users. Together, our findings suggest that PWUD experiencing pain might be using cannabis as an ad hoc (i.e., improvised, self-directed) strategy to reduce the frequency of opioid use.

A recent study analyzed longitudinal data from a large US national health survey and found that cannabis use increases, rather than decreases, the risk of future non-medical prescription opioid use in the general population, providing important evidence to challenge the hypothesis that increasing access to cannabis facilitates reductions in opioid use. The findings of our study reveal a contrasting relationship between cannabis use and frequency of opioid use, possibly due to inherent differences in the sampled populations and their motivations for using cannabis. Within the current study population, poly-substance use is the norm; HIV and related comorbidities are common; and pain management through prescribed opioids is often denied, increasing the likelihood of non-medical opioid use for a medical condition. Furthermore, our study is largely focused on this relationship in the context of pain (i.e., by examining individuals with self-reported pain and accounting for intensity of pain). Our findings align more closely with those of a recent study conducted among HIV-positive patients living with chronic pain, in which the authors found that patients who reported past-month cannabis use were significantly less likely to be taking prescribed opioids. While this finding could have resulted from prescription denial associated with the use of cannabis (or any illicit drug), we show that daily cannabis users in this setting were slightly more likely to have been prescribed a pain medication at baseline, and adjusting for this factor in a longitudinal multivariable model did not negate the significant negative association of frequent cannabis use with frequent illicit opioid use.

The idea of cannabis as an adjunct to, or substitute for, opioids in the management of chronic pain has recently earned more serious consideration among some clinicians and scientists. A growing number of studies involving patients who use cannabis to manage pain demonstrate reductions in the use of prescription analgesics alongside favourable pain management outcomes. For example, Boehnke et al. found that chronic pain patients reported a 64% mean reduction in the use of prescription opioids after initiating cannabis, alongside a 45% mean increase in self-reported quality of life. Degenhardt et al. found that, in a cohort of Australian patients on prescribed opioids for chronic pain, those using cannabis for pain relief (6% of patients at baseline) reported better analgesia from adjunctive cannabis use (70% average pain reduction) than opioid use alone (50% average reduction). However, more recent high-quality research has presented findings to question this narrative. For example, in the 4-year follow-up analysis of the above Australian cohort of pain patients, no significant temporal associations were observed between cannabis use (occasional or frequent) and a number of outcomes including prescribed opioid dose, pain severity, opioid discontinuation, and pain interference. Thus, several other explanations for our current results, aside from an opioid-sparing effect, are worthy of consideration.

We chose to include individuals with chronic pain regardless of their opioid use status to avoid exclusion of individuals who may have already ceased illicit opioid use at baseline, as these individuals may reflect an important subsample of those already engaged in cannabis substitution. On the other hand, there may be important characteristics, unrelated to pain, among regular cannabis users in this study that predispose them to engage in less frequent or no illicit opioid use at the outset. We attempted to measure and control for these factors, but we cannot rule out the possibility of a spurious connection. For example, individuals in this cohort who are consuming cannabis daily for therapeutic purposes may simply possess greater self-efficacy to manage health problems and control their opioid use. However, it is notable that our finding is in line with a previous study demonstrating that cannabis use correlates with lower frequency of illicit opioid use among a sample of people who inject drugs in California, all of whom used illicit opioids. Our study builds on this work by addressing chronic pain, obtaining detailed information on motivations for cannabis use, and examining longitudinal patterns.

We observed that daily cannabis users endorsed intentional use of cannabis for a range of therapeutic purposes that may influence pain and pain interference. After pain, insomnia (43%) and stress (42%) were the second and third most commonly reported motivations for therapeutic cannabis use among daily cannabis users. The inability to fall asleep and the inability stay asleep are common symptoms of pain-causing conditions, and experiencing these symptoms increases the likelihood of opioid misuse among chronic pain patients. The relationship between sleep deprivation and pain is thought to be bidirectional, suggesting that improved sleep management may improve pain outcomes. Similarly, psychological stress (particularly in developmental years) is a well-established predictor of chronic pain and is also likely to result from chronic pain. Thus, another possible explanation for our finding is that cannabis use substitutes for certain higher-risk substance use practices in addressing these pain-associated issues without necessarily addressing the pain itself.

Notably, our findings are consistent with emerging knowledge of the form and function of the human endocannabinoid and opioid receptor systems. The endogenous cannabinoid system, consisting of receptors (cannabinoid type 1 [CB1] and type 2 [CB2]) and modulators (the endocannabinoids anandamide and 2-arachidonoylglycerol), is involved in key pain processing pathways. The co-localization of endocannabinoid and μ-opioid receptors in brain and spinal regions involved in antinociception, and the modification of one system’s nociceptive response via modulation of the other, has raised the possibility that the phytocannabinoid tetrahydrocannabinol (THC) might interact synergistically with opioids to improve pain management. A recent systematic review and meta-analysis found strong evidence of an opioid-sparing effect for cannabis in animal pain models, but little evidence from 9 studies in humans. However, the authors of the meta-analysis identified several important limitations potentially preventing these studies in humans from detecting an effect, including low sample sizes, single doses, sub-therapeutic opioid doses, and lack of placebo. Since then, Cooper and colleagues have published the results of a double-blind, placebo-controlled, within-subject study among humans in which they found that pain threshold and tolerance were improved significantly when a non-analgesic dose of an opioid was co-administered with a non-analgesic dose of cannabis. Suggestive of a synergistic effect, these findings provide evidence for cannabis’s potential to lower the opioid dose needed to achieve pain relief.

Finally, there is pre-clinical and pilot clinical research to suggest that cannabinoids, particularly cannabidiol (CBD), may play a role in reducing heroin cue-induced anxiety and cravings and symptoms of withdrawal. Although preliminary, this research supports the idea that cannabis may also be used to stabilize individuals undergoing opioid withdrawal, as an adjunct to prescribed opioids to manage opioid use disorder, or as a harm reduction strategy. Although this evidence extends beyond chronic pain patients, it warrants consideration here given the shared history of illicit substance use amongst the study sample. It is not clear what role harm reduction or treatment motivations may have played in the current study since daily and occasional users did not differ significantly in reporting cannabis use as a strategy to reduce or treat other substance use. The phenomenon of using cannabis as a tool to reduce frequency of opioid injection has been highlighted through qualitative work in other settings, but further research is needed to determine whether this pattern is widespread enough to produce an observable effect. Clinical trials that can randomize participants to a cannabis intervention will be critical for establishing the effectiveness of cannabis both for pain management and as an adjunctive therapy for the management of opioid use disorder. Such trials would begin to shed light on whether the current finding could be causal, what the underlying mechanisms might be, and how to optimize cannabis-based interventions in clinical or community settings.

There are several important limitations to this study that should be taken into consideration. First, the cohorts are not random samples of PWUD, limiting the ability to generalize these findings to the entire community or to other settings. The older median age of the sample should especially be taken into consideration when interpreting these findings against those from other settings. Second, as discussed above, we cannot rule out the possibility of residual confounding. Third, aside from HIV serostatus, we relied on self-report for all variables, including substance use patterns. Previous work shows PWUD self-report to be reliable and valid against biochemical verification, and we have no reason to suspect that responses about the outcome would differ by cannabis use status, especially since this study was nested within a much larger cohort study on general substance use and health patterns within the community. Major or persistent pain, which qualified respondents for inclusion in this study, was also self-reported. Our definition for chronic pain is likely to be more sensitive than other assessments of chronic pain (e.g., clinical diagnoses or assessments that capture length of time with pain). Although more than half (60%) of the sample reported ever having been diagnosed with a pain condition, it is possible that some of the included respondents would not have met criteria for a formal chronic pain diagnosis. Finally, we did not collect information on the type of cannabis, mode of administration, cannabinoid content (e.g., percent THC:percent CBD), or dose during the study period. Future research will need to address these gaps to provide a more detailed picture of the instrumental use of cannabis for pain and other health concerns among PWUD.

Conclusions

In conclusion, we found evidence to suggest that frequent use of cannabis may serve as an adjunct to or substitute for illicit opioid use among PWUD with chronic pain in Vancouver. The findings of this study have implications for healthcare and harm reduction service providers. In chronic pain patients with complex socio-structural and substance use backgrounds, cannabis may be used as a means of treating health problems or reducing substance-related harm. In the context of the current opioid crisis and the recent rollout of a national regulatory framework for cannabis use in Canada, frequent use of cannabis among PWUD with pain may play an important role in preventing or substituting frequent illicit opioid use. PWUD describe a wide range of motivations for cannabis use, some of which may have stronger implications in the treatment of pain and opioid use disorder. Patient–physician discussions of these motivations may aid in the development of a treatment plan that minimizes the likelihood of high-risk pain management strategies, yet there remains a clear need for further training and guidance specific to medical cannabis use for pain management.

Source: Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis – PubMed (nih.gov) November 2019

Opioid pain relievers are most often prescribed following surgery or to treat cancer pain — situations less common to young people.

However, there are situations or ailments for which opioids may be recommended for your child. These include accidental injury, after oral surgery to remove wisdom teeth, sickle cell disease and other pediatric chronic pain conditions.

Should a health care provider recommend or prescribe an opioid for your child, there are important questions to ask, risks to be aware of and safety precautions to take.

What are some common opioid pain relievers?

  • Hydrocodone (Zohydro)
  • Hydrocodone + Acetaminophen (Vicodin)
  • Oxycodone (Oxycontin, Roxicodone)
  • Oxycodone + Acetaminophen (Percocet)
  • Codeine, Tylenol with Codeine
  • Morphine
  • Fentanyl
  • Tramadol

There are also non-opioid pain relievers (gabapentin, for example) with potential for misuse and abuse, but much lower than that of opioids.

Why is the misuse of opioids so dangerous?

Opioid pain relievers are powerful drugs — very similar to heroin in their chemical makeup and habit-forming by their very nature. This is why the U.S. Centers for Disease Control and Prevention (CDC) strongly recommends against the prescribing of opioids for long-term treatment of chronic pain. Even for treatment of short-term pain, opioid pain relievers should only be prescribed and taken sparingly.

The risk of addiction grows when the patient is a teen or young adult because their brains are still developing and biologically predisposed to experimentation. Suppose your teen or young adult is prescribed an opioid. In that case, you or another caregiver should control the medication, dispense it only as prescribed and monitor closely for signs of misuse or growing dependence.

In addition to the danger of dependence, misuse of opioids can cause dramatic increases in blood pressure and heart rate, organ damage, difficulty breathing, seizures and even death.

What questions should you ask if an opioid is recommended?

Is a prescription opioid necessary?

Ask about alternatives. An over-the-counter (OTC) pain reliever like acetaminophen (e.g., Tylenol) in combination with a non-steroidal anti-inflammatory drug (NSAID) might be just as effective. You can ask about exploring treatments like physical therapy, acupuncture, biofeedback or massage for chronic pain.

What is the quantity and duration of the prescription?

How many pills are being prescribed, and over what period of time?  Is it necessary to prescribe this quantity of pills?

What are the risks of misuse?

The prescriber should be able to answer this question for any drug being prescribed.

Should my child be screened to determine their risk of substance use disorder (SUD) before being prescribed this medication?

If not, why not? Common risk factors include co-occurring mental health disorders such as depression or ADHD, as well as a family history of addiction or a recent trauma such as a death in the family or a divorce.

What if an opioid has been prescribed?

Safeguard medication at home

Don’t just leave it in a medicine cabinet where anyone — family or visitors — can access it, and dispose of any unused medication. For proper disposal, look for a local “takeback” event. If none exist, mix the medication with coffee grounds or other unpleasant garbage and throw it out.

Supervise the dispensing of medication

Keep a count of pills to be sure they are being taken as prescribed, and clearly document when the prescription was filled and when a refill will be needed. Be suspicious of any missing medication.

Communicate the risks of misuse

Make sure your child understands the risks associated with prescription pain relievers, and be very clear that their medication, as with any prescription, is not to be shared with others.

Monitor your child’s levels of pain

Communicate regularly with your child about the level of pain they’re feeling, making sure it’s diminishing with time. Stay alert for any signs that your child is growing dependent on the medication.

What are some signs of misuse or dependence?

If your child is asking for pain medication more frequently than prescribed, or they’re insistent on refilling the prescription, this is a cause for concern. Consult the prescriber to help determine whether pain is going beyond its expected range.

Adverse effects of opioids — which could be a sign of misuse — include drowsiness, nausea, constipation, slowed breathing and slurred speech.

Signs of withdrawal — which would occur if your child has become dependent on an opioid and then stopped taking it — include anxiety, irritability, loss of appetite, craving for the drug, runny nose, sweating, vomiting and diarrhea.

If you’re concerned that your child may be dependent, consult the prescriber, who may in turn consult with a pain specialist. They should consider having a substance use counselor complete an assessment that reviews the extent of your child’s drug and alcohol use, their mental and physical health as well as personal, medical and family history.

Source: When Opioid Pain Relievers Are Prescribed For Your Child: What You Should Know – Partnership to End Addiction (drugfree.org)  March 2019

Polysubstance use—when more than one drug is used or misused over a defined period of time—can occur from either the intentional use of opioids with other drugs or by accident, such as if street drugs are contaminated with synthetic opioids. In the first half of 2018, nearly 63% of opioid overdose deaths in the United States also involved cocaine, methamphetamine, or benzodiazepines, signaling the need to address polysubstance use as part of a comprehensive response to the opioid epidemic. Fentanyl, a highly potent synthetic opioid, has been identified as a driver of overdose deaths involving other opioids, benzodiazepines, alcohol, methamphetamine, and cocaine.

Two classes of drugs are frequently co-used with opioids: depressants and stimulants. Although there are medical uses for some drugs in these classes, they also all have high potential for misuse. Mixing opioids—which are depressants—with other depressants or stimulants, either intentionally or unknowingly, has contributed to the rising number of opioid overdose deaths, which have more than doubled since 2010. Efforts to reduce opioid overdose deaths should incorporate strategies to prevent, mitigate, and treat the use of multiple substances. 

Depressants

Depressants act on the central nervous system to induce relaxation, reduce anxiety, and increase drowsiness. Opioid use concurrent with the use of another sedating drug compounds the respiratory depressant effect of each drug, creating a higher risk for overdose and fatal overdose than when either drug is used alone.

Benzodiazepines

Benzodiazepines are prescribed for medical use as sedatives but are commonly misused for nonmedical purposes and in combination with prescription and illicit opioids. In 2018, just over 9,000 U.S. deaths involved both opioids and benzodiazepines, more than twice the number of 2008 deaths due to such co-use. Moreover, in 2018, nearly half (47.2%) of benzodiazepine overdose deaths involved synthetic opioids (e.g., fentanyl). Fatal overdoses involving both prescription opioids and benzodiazepines nearly tripled from 2004 to 2011.

Alcohol

In 2017, 15% of opioid overdose deaths involved alcohol. From 2012 to 2014, more than 2 million people who misused prescription opioids were also binge drinkers of alcohol (defined as more than five drinks for a man or more than four drinks for a woman within a two-hour period); compared with nondrinkers, binge drinkers were associated with being twice as likely to misuse prescription opioids. Evidence indicates that about 23% of people with an opioid use disorder have a concurrent alcohol use disorder.

Stimulants

Stimulants increase arousal and activity in the brain. In 2017, opioids were involved in more than half of stimulant-involved overdose deaths—about 15,000 total. The co-use of stimulants with synthetic opioids such as fentanyl either intentionally or through drug contamination has increased the number of stimulant-involved overdose deaths. The opposing impacts of increased arousal from stimulants and sedation from opioids on the body can make the outcomes of co-use less predictable and raise the risk of overdose.

Methamphetamine

About 12% of opioid overdose deaths from January to June 2018 involved methamphetamine, an illicit drug. In 2017, opioids were involved in 50% of methamphetamine-involved deaths, and recent data suggests synthetic opioids are driving increases in methamphetamine-involved deaths. One study found that 65% of those seeking opioid treatment had reported a history of methamphetamine use, with more than three-quarters of them indicating that they had used methamphetamines and opioids mostly at the same time or on the same day.

Cocaine

Of the nearly 15,000 cocaine overdose deaths in 2018, nearly 11,000 also involved opioids; this number accounts for about 23% of the total opioid overdose deaths that year. In fact, since 2010 the number of deaths caused by a combination of opioids and cocaine has increased more than fivefold. People who primarily use cocaine but sometimes co-use opioids are at high risk for overdose because of the increasing presence and potency of fentanyl in the drug supply and a lower tolerance for opioids than someone who regularly uses them.

What should be done?

It is critical that state policies addressing the rise in polysubstance use and its link to increased risk of overdose span across prevention, harm reduction, and treatment strategies. To effectively accomplish this, states should:

  • Enact policies that increase provider use of prescription drug monitoring programs (PDMPs) to reduce the co-prescription of opioids and benzodiazepines. PDMPs, state-based electronic databases that contain information on controlled substance prescriptions, allow prescribers and pharmacists to monitor patients’ prescription drug use and can promote safer prescribing practices that help prevent overdoses. High rates of benzodiazepine prescribing are correlated with the drug’s involvement in opioid overdose deaths.
  • Expand naloxone distribution to reach people who use stimulants. Naloxone reverses the respiratory depression effects of opioids to safeguard against a fatal overdose and remains effective when people use opioids in combination with other drugs. Considering that opioids are frequently implicated in cocaine and methamphetamine overdose deaths, people who primarily use stimulants are recognized as an at-risk population for opioid overdose. Laws that allow for increased community distribution of naloxone can help safeguard against polysubstance use overdoses.
  • Amend drug paraphernalia laws to allow possession of fentanyl test strips. Fentanyl test strips can detect the presence of fentanyl in a person’s drug supply when dipped into a solution of a small amount of the drug in water. People who use drugs have indicated that if a test strip found fentanyl in their supply, they would take measures to prevent an overdose, such as injecting at a slower pace or using less of the drug at a time. Fentanyl test strips are mainly used by people who inject opioids but can also be helpful for those who use stimulants and fear fentanyl contamination by preventing unintentional co-use that could lead to a fatal overdose. Amending drug paraphernalia laws to allow the possession of drug-checking devices, including fentanyl test strips, would permit agencies and organizations to distribute test strips to people who use drugs and help to prevent fentanyl-related overdose deaths.
  • Prohibit the discharge of patients from publicly funded opioid use disorder (OUD) treatment programs for their continued substance use. Treatment programs often discharge patients from treatment involuntarily because of their continued illicit drug use (a practice commonly called administrative discharge). This practice poses a particular risk for patients being treated for OUD with methadone or buprenorphine who are at high risk for overdose if discharged without medication. Although co-use of other drugs, such as stimulants, with medications for OUD can interfere with treatment, it remains safer for patients to continue medication treatment because of their high risk for overdose from using illicit opioids. People with OUD who use benzodiazepines are particularly at higher risk for overdose when not on medication treatment. Federal guidelines recommend avoiding administrative discharge and instead suggest that treatment programs re-evaluate a patient’s needed level of care if the current treatment plan proves ineffective.

Conclusion

As the increase in opioid use evolves into an increase in polysubstance use, understanding how different substances interact may inform strategies that help prevent overdose. Though some individuals knowingly combine or co-use opioids with stimulants or other depressants, an additional and growing concern is the adulteration of other drug supplies with fentanyl. Strengthening policy efforts across the continuum of prevention, harm reduction, and treatment to address the risks of polysubstance use can slow the rates of drug overdose deaths in the United States.

Source: https://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2020/10/opioid-overdose-crisis-compounded-by-polysubstance-use October 2020

The proportion of inmates in jails with a moderate to severe stimulant use disorder—including addiction to methamphetamine—has surged in recent years, a study presented at the recent American Society of Addiction Medicine annual meeting suggests.

The study of inmates in two jails in rural North Carolina found over seven times more inmates with a substance use disorder met criteria for addiction to stimulants, including methamphetamine, in 2016 compared with 2008.

“These findings confirm anecdotal reports we were hearing from county sheriffs and correctional officers that they had noticed a considerable increase in meth-related crimes and meth lab seizures in rural areas,” said lead researcher Dr. Steven Proctor, Senior Research Professor and Associate Director of the Institutional Center for Scientific Research at Albizu University in Miami, Florida. “We don’t know whether a change in crime prevention strategy is driving law enforcement to prioritize meth-related crimes, leading to more arrests of people with stimulant use disorders, or whether increased use of meth is leading to an increase in meth-related crimes.”

Proctor said that although prevalence estimates of substance use disorders are provided annually for the non-institutionalized U.S. general population through nationally representative surveys, such methods are absent for correctional populations.

The study included data from 176 inmates in 2008 and 149 inmates in 2016. Proctor found alcohol was the most prevalent substance use disorder diagnosis in 2008, followed by cannabis and cocaine. Substance use disorders related to opioids and stimulants were relatively infrequent in 2008.

In sharp contrast, the substance use disorder category involving stimulants was the most prevalent diagnosis in 2016, followed by alcohol and opioids. The proportion of inmates with a moderate-severe opioid use disorder in 2016 was twice that of the prevalence of dependence in 2008.

The prevalence of cannabis use disorder remained relatively constant, but there was a dramatic drop in alcohol and cocaine use in 2008 and 2016.

Proctor noted these findings cannot be applied to the population at large. “It is difficult to track patterns of illicit meth use in the general population over the same period, because until 2015 the National Survey on Drug Use and Health only included questions about prescription stimulants, and didn’t ask about illicit meth use,” he said. “Further research is needed to determine whether these findings are applicable to non-correctional populations.”

Source: Featured News: Number of Inmates With Meth Addiction Jumps in Rural Jails – Partnership to End Addiction (drugfree.org) May 2018

A life-threatening heart infection afflicts a growing number of people who inject opioids or meth. Costly surgery can fix it, but the addiction often goes unaddressed.

Dr. Thomas Pollard, a cardiothoracic surgeon in Knoxville, Tenn., and his team working to replace heart valves that had been damaged from endocarditis, an infection the patient developed from injecting drugs. Shawn Poynter for The New York Times

OAK RIDGE, Tenn. — Jerika Whitefield’s memories of the infection that almost killed her are muddled, except for a few. Her young children peering at her in the hospital bed. Her stepfather wrapping her limp arms around the baby. Her whispered appeal to a skeptical nurse: “Please don’t let me die. I promise, I won’t ever do it again.”

Ms. Whitefield, 28, had developed endocarditis, an infection of the heart valves caused by bacteria that entered her blood when she injected methamphetamine one morning in 2016. Doctors saved her life with open-heart surgery, but before operating, they gave her a jolting warning: If she continued shooting up and got reinfected, they would not operate again.

With meth resurgent and the opioid crisis showing no sign of abating, a growing number of people are getting endocarditis from injecting the drugs — sometimes repeatedly if they continue shooting up. Many are uninsured, and the care they need is expensive, intensive and often lasts months. All of this has doctors grappling with an ethically fraught question: Is a heart ever not worth fixing?

“We’ve literally had some continue using drugs while in the hospital,” said Dr. Thomas Pollard, a veteran cardiothoracic surgeon in Knoxville, Tenn. “That’s like trying to do a liver transplant on someone who’s drinking a fifth of vodka on the stretcher.”

The problem has consumed Dr. Pollard, a calm Texan who got his Tennessee medical license in 1996, just after the widely abused opioid painkiller OxyContin hit the market. He has seen an explosion of endocarditis cases, particularly among poor, young drug users whose hearts can usually be salvaged, but whose addiction goes unaddressed by a medical system that rarely takes responsibility for treating it.

Certain cases haunt him. A little over a year ago, he replaced a heart valve in a 25-year-old man who had injected drugs, only to see him return a few months later. Now two valves, including the new one, were badly infected, and his urine tested positive for illicit drugs. Dr. Pollard declined to operate a second time, and the patient died at a hospice.

“It was one of the hardest things I’ve ever had to do,” he said.

The Treatment Gap

As cases have multiplied around the country, doctors who used to only occasionally encounter endocarditis in patients who injected drugs are hungry for guidance. A recent study found that at two Boston hospitals, only 7 percent of endocarditis patients who were IV drug users survived for a decade without reinfection or other complications, compared with 41 percent of patients who were not IV drug users. Those hospitals are among a small but growing group trying to be more proactive.

Dr. Pollard has been lobbying hospital systems in Knoxville to provide addiction treatment for willing endocarditis patients, at least on a trial basis, after their surgery. If the hospitals offered it, he reasons, doctors would have more justification for turning away patients who refused and in the long run, hospitals would save money.

Addiction has long afflicted rural east Tennessee, where the rolling hills and mountains are woven with small towns suffering from poverty and poor health. Prescribing rates for opioids are still strikingly high, and the overdose death rate in Roane County, where Ms. Whitefield lives, is three times the national average. Jobs go unfilled here because, employers say, applicants often cannot pass a drug test.

Across Tennessee, some 163,000 poor adults remain uninsured after state lawmakers refused to expand Medicaid under the Affordable Care Act. For them, and even for many covered by Medicaid, as Ms. Whitefield is, evidence-based opioid addiction treatment remains meager. More common are cash-only clinics, or abstinence-based programs that bank on willpower instead of the addiction medications that have proved more effective.

Treatment for endocarditis usually involves up to six weeks of intravenous antibiotics, often in the hospital because doctors are wary of sending addicted patients home with IV lines for fear they would use them to inject illicit drugs. Many, like Ms. Whitefield, also need intricate surgery to repair or replace damaged heart valves. The cost can easily top $150,000, Dr. Pollard said.

Advice from specialty groups, like the American Association for Thoracic Surgery and the American College of Cardiology, about when to operate remains vague. For now, “it’s just a lot of anecdote — surgeons talking to each other, trying to determine when we should and when we shouldn’t,” said Dr. Carlo Martinez, who is one of Dr. Pollard’s partners and who operated on Ms. Whitefield at Methodist Medical Center of Oak Ridge.

Their practice, owned by Covenant Health, will almost always operate on someone with a first-time case of endocarditis from injecting drugs, Dr. Pollard said. But repeat infections, when the damage can be more extensive and harder to fix, make it a tougher call. Dr. Mark Browne, Covenant’s senior vice president and chief medical officer, said, “Each patient is evaluated individually and decisions regarding the appropriate course of care are determined by their attending physician.”

In the nearly two years since she got sick, Ms. Whitefield has felt physically diminished and been prone to illness. She also feels harshly judged by a medical system that saved her life but often treats her with suspicion and disdain.

Over the same stretch of time, Dr. Pollard has grown increasingly disillusioned with hospitals that consider addiction treatment beyond their purview, and haunted by the likelihood that many of his drug-addicted patients will die young whether they get heart surgery or not. He set up a task force in 2016 to address the problem but has faced obstacles, especially concerning cost and, he believes, a societal reluctance to spend money on people who abuse drugs.

“Everybody has sympathy for babies and children,” he said. “No one wants to help the adult drug addict because the thought is they did this to themselves.”

Dr. Pollard has been consumed by the problem of endocarditis among drug users whose addiction goes unaddressed. “We’ve literally had some continue using drugs while in the hospital,” he said. Joe Buglewicz for The New York Times

____

Ms. Whitefield, a talkative young woman with brooding eyes, goes by the nickname Shae. She started on opioid painkillers as a teenager suffering from endometriosis, a disorder of the uterine tissue, and interstitial cystitis, a painful bladder condition. She got the opioids from doctors for years, and eventually from friends.

She and her high school boyfriend, Chris Bunch, had three children by the time she was 26. She trained to become a licensed practical nurse but dropped out of the program when her oldest son, Jayden, got seriously ill as a baby. The family lives in a tiny town that Mr. Bunch, now Ms. Whitefield’s husband, described as “country, country, country.”

In 2015, after their daughter, Kyzia, was born, Ms. Whitefield sank into postpartum depression. She was obsessively worried about shielding Kyzia from sexual abuse and other traumas she had experienced as a child. She started injecting crushed opioid pills and occasionally meth, savoring the needle’s sting — she had an old habit of cutting herself to provide relief from emotional pain — at least as much as the high.

After sharing a needle with one of her brothers that day in June 2016, Ms. Whitefield started shivering and sweating. A fever soon followed, and she lay for almost a week on the couch, thinking she had a kidney infection. She was delirious by the time Jayden, then 8, woke her stepfather one morning and told him to call 911.

She arrived at Methodist Medical Center of Oak Ridge with full-blown sepsis, floating in and out of consciousness. Her organs had started to shut down.

At home, she had stared at a picture on the wall of her grandmother faintly smiling, a source of reassurance, for days. When the first nurse leaned over her in the emergency room, she thought she smelled her grandmother’s perfume.

Her stepfather, Brian Mignogna, remembers being stunned when a doctor who initially assessed her said that if it were up to him, he would not go to great lengths to save her.

“He said once someone’s been shooting up, you go through all this money and surgery and they go right back to shooting up again, so it’s not worth it,” Mr. Mignogna recalled. “I was just dumbfounded.”

Dr. Martinez was the on-call heart surgeon a few days later, though, and felt strongly about taking Ms. Whitefield’s case. Her children and stepfather had been constants at her bedside, and unlike some patients he had seen, she had readily admitted to her drug use. He believed her when she said she had not been injecting for long and wanted to stop.

“She was a young mother and her family was involved; her father was there,” he said. “To me, it seemed she had that social support that patients need once they recover from this.”

Ms. Whitefield also had health coverage through Medicaid, the government insurance program for the poor, because she has young children. It paid for her care, whereas if she were uninsured, the hospital would have had to cover the cost.

Antibiotics cleared the infection that initially led her to the hospital, but she ended up needing surgery two months later. Her mitral valve was so damaged that she had begun showing signs of heart failure. Dr. Martinez was compassionate, but he stressed that the surgery would be “a one-time deal,” Mr. Mignogna recalled.

“The way he put it was, ‘You relapse and end up with another infection, we won’t treat you again,’” Mr. Mignogna said.

Dr. Martinez repaired Ms. Whitehead’s mitral valve in a three-hour operation. It involved sawing open her breastbone, connecting her to a bypass machine to keep blood flowing through her body, and then stopping her heart and fixing the valve. He reinforced it with a small plastic ring before restarting her heart and closing her up.

She had written a note to each of her children — wise Jayden, kind Elijah, strong-willed Kyzia — in case she never woke up. Two weeks later, she was well enough to go home. She soon began seeing a counselor at a clinic unaffiliated with the hospital system and taking buprenorphine, a medication that diminishes opioid cravings and has been found to reduce the risk of relapse and fatal overdose.

Ms. Whitefield has had occasional cravings since the surgery but says she has not used drugs again, traumatized by the memory of her ordeal.

“I know next time God might not save me,” she said quietly. “They will not treat me for a second time if I have track marks or anything like that.”

As she recuperated, Ms. Whitefield started thinking about returning to school, aspiring to become a drug and alcohol counselor or real estate agent, or both.

She has also started serving as an advocate of sorts for others in her community who get endocarditis or other infections from injecting, driving them to the emergency room or sharing every detail of the protocol that saved her. She smarts at the thought of providing only “comfort care” — antibiotics but no surgery — even if a patient refuses addiction treatment.

“When do you stop wanting to save a life?” she asked. “If you have that ability, who’s to say you shouldn’t use it? I see it from their standpoint — not wanting to repeat the same game. But it’s hard, you know? This isn’t an easy disease to break away from.”

____

Dr. Pollard, a quietly driven high school valedictorian, used to have no empathy for drug-addicted patients.

“I was like everyone else: ‘They do it to themselves, they deserve what they get,’” he said. “But then when you see their children, and hear about friends my kids went to school with who have died, it’s closer to home.”

When he became president of the Knoxville Academy of Medicine in 2015, he came up with the idea of the city’s hospital systems teaming up to offer addiction treatment to endocarditis patients. He had the perfect platform to push for it, he thought.

So the following year, he set up a task force that included people from each hospital system — his own, Covenant Health; the University of Tennessee Medical Center; and Tennova Healthcare — as well as from two drug treatment centers and some community groups.

At a task force meeting last August, about a year after Ms. Whitefield’s surgery, Dr. Pollard clicked through a PowerPoint presentation full of data a research nurse had compiled. From 2014 through 2016, the three hospital systems in Knoxville had provided valve surgery to 117 patients diagnosed with endocarditis from injecting drugs. Ten had received a second surgery after becoming reinfected; of those, two had received a third.

Just over half the patients were uninsured, and only 1 percent had private coverage. From the data, it was impossible to know if anyone had been reinfected but turned away by doctors. But at least 21 people — 18 percent — had died since their heart surgery, typically from sepsis or respiratory failure, which Dr. Pollard said indicated reinfection.

The group discussed Dr. Pollard’s proposal for Cornerstone of Recovery, an addiction treatment center here, to admit a handful of endocarditis patients as soon as they were cleared for discharge. Cornerstone would provide several months of inpatient treatment and up to a year’s worth of Vivitrol, a monthly $1,000 shot that blocks cravings and helps prevent relapse.

Buprenorphine, the medication Ms. Whitefield takes, is less expensive. But Cornerstone does not provide it because it is an opioid itself and “is trading one for the other,” said Webster Bailey, its executive director of marketing. Many addiction experts have called that view “grossly inaccurate.” They say it is weaker than drugs like oxycodone and heroin, activating the brain’s opioid receptors enough to ease cravings but not enough to provide a high in people who are already dependent on opioids.

Patients would sign an agreement stating that if they returned to abusing drugs after addiction treatment, they might not be considered a candidate for future heart surgery. The total cost per patient: perhaps $55,000, which Dr. Pollard hopes that government and private funding would help cover if the program expanded.

“This should be part of the treatment, just like antibiotics are,” he told the group.

A surgeon from Tennova dryly pointed out: “Not everybody in that group is going to say, ‘This is for me, I’m going to do it.’”

Still, the group decided Dr. Pollard should take the next step, pitching the pilot plan to each system’s top executives.

“We are competing systems, but this is a common enemy that unites us all,” he said afterward. “We need a united policy.”

Source: https://www.nytimes.com/2018/04/29/health/drugs-opioids-addiction-heart-endocarditis.html April 2018

Legalization advocates and the weed industry can support necessary reforms while being honest about the risks of marijuana use, the study’s author says.

A large percentage of marijuana users around the world report signs of dependence, even as cannabis appears to be one of the safest and most commonly used drugs overall, according to the results of a survey released on Wednesday.

The findings are contained in the 2018 Global Drug Survey, a detailed questionnaire that compiled responses from more than 130,00 people in over 40 countries in the past year. One section of the survey used the “Severity of Dependence Scale,” or SDS, a popular tool that asks respondents five questions regarding impaired control over drug use and anxieties related to consumption and quitting.

Around 50,000 of the survey respondents reported having used marijuana in the last 12 months. Only alcohol and tobacco use were more common.

Of all cannabis users, 20.2 percent showed substantial signs of dependence, measured by affirmative answers to at least four of the five SDS questions. Crystal methamphetamine was the drug most closely associated with dependence, with nearly 25 percent of users scoring four or higher on the SDS.

A positive SDS score is not the same as a clinical diagnosis of dependence, Adam Winstock, a British addiction psychiatrist and founder of the Global Drug Survey, told HuffPost. But it does suggest that many marijuana users have considerable misgivings about their habits.

“You’ve got 20 percent of the people who are significantly worried about the impact of their use on their life,” said Winstock. “It’s a measure of subjective worry and concern, but those questions tap into things like how much you use, how often, your sense of control and your desire to stop.”

The responses to individual SDS questions offer a window into some of those feelings of dependence.

Cannabis was the substance most frequently associated with anxiety over the prospect of quitting, for example. Although nearly 74 percent of users said the idea of stopping “never or almost never” made them anxious, 19.7 percent said it “sometimes” did, with the rest reporting that it “often” or “always” did.

A total of 21.4 percent of marijuana users said it would be “quite difficult” for them to stop using, with 6.4 percent responding that it would be either “very difficult” or “impossible.” Around 72 percent said quitting would not be difficult.

Nearly 30 percent of cannabis users reported that their cannabis use was at least occasionally “out of control,” with 22.6 percent of respondents saying it was only “sometimes” an issue, 5.3 percent saying it was “often” an issue and 1.6 percent saying it was “always or nearly always” an issue.

The survey also sought to measure the overall safety of substances by asking respondents if they’d sought emergency medical treatment after using various drugs. Just 0.5 percent of all cannabis users reported seeking treatment after use, the second-lowest rate of any substance. Magic mushrooms appeared to be the safest recreational drug for the second year in a row, with just 0.2 percent of users saying they’d pursued medical intervention.

The cannabis dependence results were particularly surprising to Winstock, who said he would’ve expected to see around 10 to 15 percent of marijuana users report signs of dependence.

“You’re legalizing a drug that a fair number of people who use it have worries about themselves,” Winstock said. “The question is what do you do about that?”

The Global Drug Survey may hold some answers. Since 2014, the independent research company has partnered with medical experts and media groups to conduct an annual survey with the goal of making drug use safer through increased access to education and treatment resources.

Around 300,000 marijuana users have partaken in Global Drug Surveys over the years, said Winstock. Those respondents have consistently shown high levels of support for establishing government guidelines around safe marijuana use. Among cannabis users who have expressed a desire to use less frequently or quit entirely, many have said they’d like assistance in doing so. But very few end up seeking help.

Taken together, the surveys suggest elected officials and the marijuana industry should be engaging in a more honest discussion about the risks associated with cannabis use so they can better address issues that may arise as laws are liberalized, said Winstock.

That advice may be particularly salient in the U.S., where a number of states are considering legalizing recreational marijuana in the face of growing public opposition to prohibition. Eight states, as well as Washington, D.C., have already legalized weed.

“Clearly arresting someone and giving them a criminal record for smoking a joint is a futile and pointless exercise and … nothing I’m suggesting is me saying cannabis is a bad drug and the government made a mistake,” said Winstock.

“What I’m saying is that at the point they regulated cannabis, they should have mandated a whole bunch of things that allowed it to be easier for people to reflect on their cannabis use and how it impacted on them and how to control their use,” he went on. “There should have been mandated health warnings and advice and an index of harm for different products.”

Among the 3,400 U.S. marijuana users surveyed this year, just under 25 percent expressed a desire to use less ― compared to 29.3 percent of users globally. Just over 25 percent reported getting high more than 300 days out of the past year, though that may not be reflective of broader marijuana trends, because the survey didn’t randomly sample users nationwide.

Sixteen percent of the American marijuana users who said they wanted to cut back also responded that they’d like help doing so. Nearly 50 percent of all U.S. users said they’d attempted to quit at some point, with 67 percent of those saying they’d tried in the previous year.

Winstock says it makes sense to increase access to harm reduction tools in order to reach those who say they want help with their dependence on cannabis. But broad support for this sort of comprehensive approach requires people on all sides to confront the fact that marijuana, like pretty much any drug, can lead to dependence with some frequency.

Instead, the legalization debate has played out in a far more polarized fashion, with advocates often pushing back against decades of government anti-weed hysteria by claiming cannabis is a harmless drug, especially when compared to alcohol or tobacco.

In light of the cataclysmic failures of the nation’s war on drugs, there is plenty of reason to be tempted by that portrayal.

“It could just be that so many people are saying we’ve raised billions in taxes, saved thousands of hours of police time, saved loads of innocent young lives from having their careers ruined and being banged up in prison,” said Winstock. “Those are such huge wins that I could see people going, ‘That’s enough.’”

But just because the status quo has been so bad for so long and marijuana is less harmful than alcohol or tobacco ― legal drugs that kill more people each year than all illicit drugs combined ― doesn’t mean the push to legalize cannabis can’t learn from past mistakes.

For Winstock, it’s not too late for legal weed states and leaders in the marijuana industry to place more focus on public health.

“Stop for a moment and think about how you cannot become the tobacco industry or the alcohol industry,” said Winstock. “Be the best you can be, don’t just make the biggest profit. Be the most responsible industry you can, and that means be honest.”

Source: Marijuana Users Report High Rates Of Dependence In Global Drug Survey | HuffPost UK Health (huffingtonpost.co.uk) May 2018

They were the mind-altering drugs of the Sixties, but now lysergic acid diethylamide (better known as LSD), magic mushrooms and a range of other banned psychedelic drugs are making a comeback.

Not on the party scene, but as the focus of researchers who believe they could treat a variety of mental health problems, including depression.

British researchers are at the forefront of this renaissance of hallucinogenics. But, as Good Health can reveal, a key organisation funding their work is a pressure group with a parallel agenda.

In addition to supporting research into the potential therapeutic benefits of banned drugs, the Beckley Foundation — created by Amanda Feilding, a wealthy countess who’s spent a lifetime advocating the benefits of LSD — is working ‘to erode the pervasive taboo surrounding . . . recreational drug use’.
It would be wrong to dismiss the ‘Cannabis Countess’ (who’s previously advocated legalising the drug) as simply a colourful character.

For here we reveal the extent of her influence in this controversial area, both in funding the research and also actively participating ‘in the inception, design, and writing up’ of no fewer than 37 studies — despite the fact that she has no scientific qualifications.

In 2012, there were just 58 papers exploring the effects and possible medical benefits of LSD, psilocybin (the active ingredient in magic mushrooms) and ayahuasca, a mind-altering plant used in rituals by Amazon tribes. In the past year alone, there have been at least 135.

In the vanguard are researchers at Imperial College London. Known as the Psychedelic Research Group, they’re exploring the potential of banned drugs for treating conditions including depression and even for dealing with grief.

One of the key figures is David Nutt, the psychiatrist and professor of neuropsychopharmacology at Imperial who, in 2009, had to resign as the government’s chief drugs adviser after he said that LSD, ecstasy and cannabis were less harmful than alcohol.

Since then, Professor Nutt has collaborated with the Beckley Foundation and its founder Feilding — the two are co-directors of what is described by the foundation as the Beckley Imperial Research Programme. Despite lacking scientific qualifications, Feilding is co-author of 24 papers published by researchers at Imperial College London and is one of the 32‑member team of the Psychedelic Research Group, as is Professor Nutt.

Feilding’s involvement may raise a serious question about her foundation’s twin agendas.

On its website, it seeks donations to ‘support psychedelic research’, but also ‘drug policy reform’. Feilding herself insists that the war on drugs has failed and has campaigned tirelessly for reform.

In Jamaica, where Feilding has a house, the foundation played a role in the government’s decision to decriminalise cannabis.

At a conference in 2015, Feilding expressed the hope that ‘the United Kingdom will learn some lessons from Jamaica’s progress, and will at least begin by recognising the rights of those in need of access to cannabis for medicinal and religious purposes’.

But more disturbing, perhaps, is her support for ‘microdosing’, where small amounts of psychedelics are taken supposedly to achieve greater creativity; worryingly, some are reportedly using it to treat depression and anxiety.

At a psychedelics conference in the U.S. last year, Feilding spoke of her use of LSD when younger to ‘hit that sweet spot, where vitality and creativity are enhanced’, a practice she compared to ‘what people are now doing with microdosing’.

She added that microdosing ‘may indeed be the way we break down barriers, and make the psychedelic experience more accessible to people at large’.

Another member of the Beckley Imperial Research Programme with links to the countercultural aspects of psychedelic drugs is Dr Robin Carhart-Harris, a frequent co-author on papers with Feilding.

In 2016, he addressed a London conference of The Psychedelic Society, which ‘advocates the careful use of psychedelics as a tool for personal and spiritual development’ (such drugs, it says, are banned solely ‘on the basis of unsubstantiated health risks and tabloid hysteria’).

This isn’t the first time scientists have experimented with mind-altering drugs for mental health conditions. Between 1954 and 1965 psychiatrists at British hospitals used LSD to treat patients. This ended in 1966, when it was banned amid fears it caused delusions and suicidal thoughts.

But according to Professor Nutt, clinical use and studies before the ban showed that patients with disorders such as depression had ‘sometimes benefited considerably’ from the ability of ‘the classical psychedelic drugs . . . to “loosen” otherwise fixed, maladaptive patterns of cognition and behaviour, particularly when given in a supportive, therapeutic setting’.

He believes such drugs ‘may have a place in the treatment of neurotic disorders, particularly depressive disorder, anxiety disorders, addictions and in the psychological challenges associated with death’.

But for psychedelic treatment to become a reality, what’s needed are large-scale scientific trials. Now, thanks to the support of the Beckley Foundation, that’s about to happen.

Imperial’s Psychedelic Research Group has been recruiting patients with long-term depression for a major trial comparing the effects of a six-week course of the antidepressant escitalopram with a single dose of psilocybin. Dr Carhart-Harris, Professor Nutt and Feilding are the leading members of the research team.

Imperial wouldn’t say if funding is forthcoming from the Beckley Foundation for this study. But in a response to a Freedom of Information request we sent, it revealed that since 2009 it has received ‘a total of £108,519’ from the Foundation for ‘research projects’.

Public funding has also been provided for psychedelic research. In 2012, the Medical Research Council (MRC) gave Professor Nutt £500,000 for research into psilocybin to treat major depression.

The next year they gave him £250,000 for a study on psilocybin and schizophrenia. And the National Institute for Health Research, the research arm of the NHS, told us it funded ‘a small proportion’ of Professor Nutt’s salary.

The new trial follows on from a series of studies by Professor Nutt and colleagues at other UK institutions since 2010 involving psilocybin for depression.

Some involved healthy volunteers. But then, in 2016, a team from Imperial, University College London, Barts Health NHS Trust, King’s College and the Maudsley Hospital conducted the first trial with patients.

Involving just 12 people, it was designed to investigate the safety and feasibility of psilocybin for major long-term depression.

As The Lancet Psychiatry reported, eight of the patients were ‘depression-free’ one week after treatment; five were still clear after three months. But all experienced ‘transient anxiety’ and nine also reported ‘transient confusion or thought disorder’.

Last December, Compass Pathways, a new UK company whose expert advisers include Dr Carhart-Harris and Professor Sir Alasdair Breckenridge, former chair of the drug watchdog the Medicines and Healthcare products Regulatory Agency, announced a programme of clinical trials of psilocybin.

In the past few years, the Psychedelic Research Group has also looked at the potential use of drugs such as LSD.

But are yet more drugs, not least mind-altering psychedelic ones, really the solution for conditions such as depression?

In fact, the recommended treatment is psychological therapy. But as the British Medical Association found this year, thousands of patients with serious mental health problems were waiting up to two years for treatments such as cognitive behavioural therapy.

Too often ‘the only thing on offer to patients with depression is medication, which often has significant unwanted side-effects and does not help everyone’, says Anne Cooke, editor of the British Psychological Society report, Understanding Psychosis And Schizophrenia.

As for the use of psychedelics to treat mental health problems, Ms Cooke, a consultant clinical psychologist at Canterbury Christ Church University, adds: ‘My understanding is they could be used as an adjunct to psychological therapy, to try to help the person enter a frame of mind where they can make best use of the therapy.

‘But the same can sometimes be achieved by other means, such as relaxation methods. And, as we know, these drugs can also have adverse effects, so it’s important to exercise caution.’

Peter Kinderman, a professor of clinical psychology at the University of Liverpool and a member of the Council for Evidence-based Psychiatry, agrees drugs such as psilocybin ‘might help’ encourage ‘flexible thinking’.

He’s even advising a European research project looking at psilocybin for depression.

But he says it’s ‘important we’re very cautious with drugs such as psilocybin and LSD’ and says he’s ‘pretty sceptical’ generally about drug treatments for mental health: ‘I really worry that a lot of people in the mental health system have been prescribed too large quantities of too many drugs for too long.’

Amanda Feilding declined to comment.

I’m all for keeping an open mind about how drugs can be used. Even drugs that were once considered dangerous can, in certain circumstances, have benefits.

Thalidomide, banned after it was found to cause birth deformities, has made a comeback as an effective treatment for certain types of lung cancer, for example.

But I have profound reservations about this sudden interest in illegal drugs and fear it will erode our drug laws further. 

As a doctor who has worked in drug addiction, this makes me profoundly uneasy. Time and again I have seen the destruction these drugs can cause.

Yes, of course, substances such as alcohol are also very dangerous. But that’s not a reason to decriminalise other drugs, too.

It’s perfectly possible that illegal recreational drugs could have a medical use; a major analysis suggested LSD can help in alcoholism. But there are many other drugs that help and which don’t have the potential for abuse or psychiatric complications.

What makes me suspicious is that the resurgence of interest in recreational drugs for mental health conditions hasn’t sprung out of new research or a new discovery about how the brain works.

Why focus on recreational drugs and not on developing new antidepressants, for example? It seems more of a fishing expedition to find results that support a certain view, rather than being led by a solid, scientific reason to research these drugs. We’ve seen a similar thing with cannabis. There’s no doubt it can help some with conditions such as epilepsy. Which is why scientists are trying to identify the specific component responsible and turning it into a medication that can be prescribed to help patients.

That’s what usually happens in medicine. For instance, the key ingredient in aspirin is acetylsalicylic acid, which was originally derived from the leaves of the willow tree.

But when someone has a headache, we don’t give them a bit of tree to chew on. We’ve identified the chemical responsible for the useful property and produced it in a tablet, where the dose and purity can be consistent. But rather than identify the components, campaigners insist we should simply legalise cannabis for medicinal use.

To me, this is just a back-door attempt to make recreational use legal, too.

I’m not convinced LSD even has any benefits. I’ve never met someone who’s used it and said to myself: ‘Well, that’s solved all your problems.’ Rather, too often I’ve come across regular users, typically in their 60s or 70s, and thought how odd they were. I’ve also met many who have spent significant periods in hospital as a result of drug use.

Making illegal drugs medically acceptable is the first step in making them socially acceptable. If decriminalisation is what you really want, at least be honest about it. Don’t try to use medicine to push a social agenda.

The blue-blooded brains behind it – with NO science qualifications! 

One of the driving forces behind the research into psychedelic drugs is Amanda Feilding, the 75-year‑old Countess of Wemyss and March.

She stood unsuccessfully for Parliament on the platform that trepanation — drilling a hole in the head — should be available on the NHS to allow people to experience a higher state of consciousness.

In a speech she gave to a conference on psychedelic drugs last October, Feilding said she ‘learned the value’ of regular doses of LSD back in the Sixties. She was able to ‘live and work on LSD, and in my opinion to see much further and deeper . . .I grew to love this state’.

But it would be a mistake to dismiss Feilding as just eccentric.

She is a leading figure in the explosion of research into the ‘medicinal use’ of psychedelic drugs and a founder and co-director (with Professor David Nutt) of the Beckley Imperial Research Programme at Imperial College London, as well as working with other UK and international universities.

On the website of the Beckley Foundation, which she set up in 1996 as the Foundation to Further Consciousness, she is described as ‘the “hidden hand” behind the renaissance of psychedelic science’.

Since 2010, the foundation, which is based at Beckley Park — her spectacular stately home in Oxfordshire — has funded, or otherwise been involved in, the research for almost 60 papers published in scientific journals investigating the properties and therapeutic potential of illicit mind-altering drugs including LSD, ecstasy and psilocybin (the active ingredient in magic mushrooms).

‘None of it would have been possible without Amanda and the Beckley Foundation,’ Dr Robin Carhart-Harris, the head of Imperial’s Psychedelic Research Group, told a newspaper in 2015.

Good Health has learned that at least five British universities have accepted money from the foundation. Imperial College London has received £108,519 since 2009, while the University of Exeter received £11,488 for a study on cannabidiol (a component of cannabis).

The Institute of Psychiatry at King’s College London was given £4,000, also for cannabis studies, and Cardiff University says the foundation has agreed to give it £50,000 to investigate ecstasy for post-traumatic stress disorder.

University College London (UCL) says it has ‘no record of any philanthropic donations from the Beckley Foundation or Amanda Feilding’. But between 2012 and 2015 Feilding collaborated with Val Curran, a professor of psychopharmacology at UCL.

One 2012 paper on cannabis, on which Professor Curran and Feilding are co-authors, clearly states the study was part-funded by the Beckley Foundation. Another paper published in 2013 and co-authored by Feilding looking at ‘the harms and benefits’ of psychoactive drugs acknowledges as ‘a potential conflict of interest . . . the study was funded by the Beckley Foundation which seeks to change global drug policy’.

The Beckley Foundation has a lot of money at its disposal. Accounts filed with the Office of the Scottish Charity Regulator show that between 2013 and 2017 it had an income of £2.26 million.

Since 2009 the foundation has supported the Beckley Imperial Research Programme which aims ‘to develop a comprehensive account of how substances such as LSD, psilocybin [and] MDMA [ecstasy] affect the brain to alter consciousness, and how they produce their potentially therapeutic effects’.

Feilding’s involvement doesn’t stop at funding. Despite confirming to Good Health that she has ‘no formal qualifications’, she is credited as a co-author on 37 academic papers published in journals ranging from The Lancet Psychiatry to the Journal of Psychopharmacology (24 of these papers, exploring the potential clinical uses of drugs including psilocybin, LSD and ecstasy, have been published in collaboration with Imperial researchers, including Professor Nutt and Dr Carhart-Harris).

On almost all of these 37 papers on which Feilding is a co-author, her foundation is acknowledged as having funded the research. Yet on almost none is her dual role recognised as a potential conflict of interest.

A spokesperson for the Beckley Foundation said that Feilding had ‘actively participated in the inception, design, and writing up’ of all the papers where she was a co-author. All had been peer-reviewed, ‘which means that the scientific community at large is confident that these results speak for themselves, regardless of the author’s viewpoint or political position’.

But criticism of this unusual arrangement was voiced in January 2017 in a paper in the journal Therapeutic Advances in Psychopharmacology, which queried the merits of a paper on psilocybin published by the Beckley Foundation-funded Imperial College team in the British Journal of Psychiatry in March 2012.

It said: ‘Since detailed information on conflicts of interest has not been provided scepticism may arise as to the role of such foundations [i.e. Beckley] in study design and execution, potentially biasing the results.’

Feilding’s influence extends to the upper reaches of the scientific community. Members of the Beckley Foundation’s scientific advisory board include Sir Colin Blakemore, former chief executive of the Medical Research Council (MRC), which controls much of the public funding for medical research and which, since Sir Colin’s tenure ended, has funded Professor Nutt’s work with psilocybin to the tune of £750,000.

In its annual report for 2017, the Beckley Foundation celebrated the MRC’s backing as ‘the first time UK government funds have been allocated to a classic psychedelic study since before prohibition’.

Sir Colin has been a member of the board since 2001, including during his leadership of the MRC (from 2003 to 2007).

While still head of the MRC, Sir Colin was a co-author with Professor Nutt on a paper in The Lancet that challenged the classification of illegal drugs. ‘Some of the ideas developed in this paper,’ they wrote, ‘arose out of discussion at workshops organised by the Beckley Foundation.’

An MRC spokesperson told us: ‘Neither Colin nor the MRC saw his involvement with the Beckley Foundation as a conflict with his position at the MRC.’

Meanwhile, a spokesperson for the Beckley Foundation said it was ‘an inaccurate shortcut’ to suggest Feilding wanted banned drugs such as LSD legalised for recreational use. Rather, she believed ‘such drugs should be investigated thoroughly, both in terms of their safety and their therapeutic potential, and that their legal scheduling should be based on facts rather than ungrounded beliefs’.

Imperial College London, Amanda Feilding, Professor Nutt and Dr Carhart-Harris did not respond to requests for their comments.

Source: How you have paid to help legalise lethal party drugs | Daily Mail Online May 2018

Increases seen in deaths from other drugs, including methamphetamine and cocaine.

Colorado drug deaths almost certainly were the worst in the state’s history last year, as the opioid epidemic morphed into a broader overdose crisis.

Deaths from methamphetamine exploded. What had been seen as a hopeful downturn in deaths from opioid painkillers reversed. Deaths from heroin and cocaine remained well above where they were just two years ago.

All together, drug overdoses probably killed more people last year than car crashes, according to preliminary numbers. And those numbers are more likely to increase than decrease as the state collects the remaining figures and finalizes the data in the coming weeks.

“Yes, it’s getting worse, and it continues to grow,” said Rob Valuck, the director of the Colorado Consortium for Prescription Drug Prevention. “It’s a long problem. I’m of the mind that it’s going to be anywhere from five to 10 years until we see this thing turn.”

The reason for that: Even as the state moves aggressively to crack down on the proliferation of opioids, the overdose epidemic is changing in ways that are harder for policy-makers to target, according to the latest data and a new report from the Colorado Health Institute.

The preliminary figures show that 959 people died in Colorado last year from drug poisoning, a figure that includes both intentional and unintentional overdoses. In 2016, 912 people died. In 2000, for comparison, drug poisonings claimed fewer than 400 lives.

Opioid deaths at an all-time high

Opioid overdose deaths in Colorado hit a new high in 2017. While the death rate* for painkillers, which include legal prescription drugs and drugs manufactured illegally, have climbed steadily since 1999, the rate for heroin and methamphetamine deaths has spiked since 2010. For the first time since 2007, there were more overdose deaths from meth than heroin in 2017.

The preliminary age-adjusted rate of deaths from drug overdoses, which accounts for population growth, was 16.7 deaths for every 100,000 people in 2017 — its highest in at least two decades. The largest number of deaths in 2017 occurred in the Denver metro area and in El Paso County, according to the preliminary figures. Areas of southern Colorado had some of the highest rates of drug overdose deaths, though.

Opioid painkillers continue to lead the way. In 2017, the drugs — whether obtained legally with a prescription or illegally — claimed a documented 357 lives, a record for Colorado, according to the preliminary figures. Two years of declining death numbers turned out not to be a trend but “just a blip,” Valuck said.

Their real toll was also likely higher because the state lists dozens of other deaths as being from “unspecified” drugs. A study published last year, for instance, estimated that Colorado’s death rate from opioid painkillers would have been almost 25 percent higher in 2014 had the drugs involved in those deaths been identified.

But the state’s overdose epidemic is no longer confined to opioid painkillers, according to the new Colorado Health Institute report.

The report documents a rise in cocaine deaths in recent years — from 60 in 2015 to 101 in 2016, falling only slightly to a preliminary 93 last year. Fatal methamphetamine overdoses increased dramatically — 139 in 2015, 196 in 2016 and a preliminary 280 in 2017. And heroin deaths have also risen sharply — 160 in 2015, 228 in 2016 and a preliminary 213 in 2017.

Jaclyn Zubrzycki, the report’s lead author, said those increases could partly be a result of the opioid epidemic. As hospitals and doctors’ offices crack down on their prescribing, those addicted to opioids may be forced into looking for drugs on the black market — and taking whatever they can find there.

“I think it’s tied to the opioid epidemic and the prescription epidemic, but it’s also an independent growth,” Zubrzycki said.

Colorado’s trends are not unique nationally. Preliminary numbers released by the federal Centers for Disease Control and Prevention showed that drug overdose death rates increased in 36 states and the District of Columbia during the 12-month period ended July 1.

And, for Valuck, this all just shows how much work Colorado and other states have to do in fighting the epidemic.

An opioid death isn’t instantaneous, he said. It’s the conclusion of an often years-long addiction that begins with a doctor’s prescription. So, the first step in stopping overdoses, he said, is to reduce the flow of opioids out of pharmacies — both to prevent people from becoming addicted to their own medicine and to limit the number of leftover opioids floating around that commonly fuel additional cases of addiction.

Colorado hospitals have made progress in reducing opioid prescribing, Valuck said. But their prescription levels are still 87 percent of what they used to be.

“The faucet is being shut off at a slower rate than we would like,” he said.

But even if new cases of addiction can be stopped, that still leaves thousands of people in need of treatment who are vulnerable to overdosing on any of an expanding list of drugs. But, Valuck said, treatment services lag in rural areas, while urban areas also have challenges reaching everyone who needs help.

“If you look at the numbers,” he said, “everywhere in Colorado has a problem.”

Source: More Coloradans died last year from drug overdoses than any year in the state’s history. That shows how the opioid epidemic is changing. – The Denver Post April 2018

America’s largest drug companies saturated the country with 76 billion oxycodone and hydrocodone pain pills from 2006 through 2012 as the nation’s deadliest drug epidemic spun out of control, according to previously undisclosed company data released as part of the largest civil action in U.S. history.

The information comes from a database maintained by the Drug Enforcement Administration that tracks the path of every single pain pill sold in the United States — from manufacturers and distributors to pharmacies in every town and city. The data provides an unprecedented look at the surge of legal pain pills that fueled the prescription opioid epidemic, which has resulted in nearly 100,000 deaths from 2006 through 2012.

Just six companies distributed 75 percent of the pills during this period: McKesson Corp., Walgreens, Cardinal Health, AmerisourceBergen, CVS and Walmart, according to an analysis of the database by WAPO. Three companies manufactured 88 percent of the opioids: SpecGx, a subsidiary of Mallinckrodt; ­Actavis Pharma; and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals.

[Top takeaways from The Post’s analysis of the DEA database]

Purdue Pharma, which the plaintiffs allege sparked the epidemic in the 1990s with its introduction of OxyContin, its version of oxycodone, was ranked fourth among manufacturers with about 3 percent of the market.

The volume of the pills handled by the companies skyrocketed as the epidemic surged, increasing about 51 percent from 8.4 billion in 2006 to 12.6 billion in 2012. By contrast, doses of morphine, a well-known treatment for severe pain, averaged slightly more than 500 million a year during the period.

Those 10 companies along with about a dozen others are now being sued in federal court in Cleveland by nearly 2,000 cities, towns and counties alleging that they conspired to flood the nation with opioids. The companies, in turn, have blamed the epidemic on overprescribing by doctors and pharmacies and on customers who abused the drugs. The companies say they were working to supply the needs of patients with legitimate prescriptions desperate for pain relief.

The database reveals what each company knew about the number of pills it was shipping and dispensing and precisely when they were aware of those volumes, year by year, town by town. In case after case, the companies allowed the drugs to reach the streets of communities large and small, despite persistent red flags that those pills were being sold in apparent violation of federal law and diverted to the black market, according to the lawsuits.

Plaintiffs have long accused drug manufacturers and wholesalers of fueling the opioid epidemic by producing and distributing billions of pain pills while making billions of dollars. The companies have paid more than $1 billion in fines to the Justice Department and Food and Drug Administration over opioid-related issues, and hundreds of millions more to settle state lawsuits.  But the previous cases addressed only a portion of the problem, never allowing the public to see the size and scope of the behavior underlying the epidemic. Monetary settlements by the companies were accompanied by agreements that kept such information hidden.

The drug companies, along with the DEA and the Justice Department, have fought furiously against the public release of the database, the Automation of Reports and Consolidated Order System, known as ARCOS. The companies argued that the release of the “transactional data” could give competitors an unfair advantage in the marketplace. The Justice Department argued that the release of the information could compromise ongoing DEA investigations. Until now, the litigation has proceeded in unusual secrecy. Many filings and exhibits in the case have been sealed under a judicial protective order. The secrecy finally lifted after The Post and HD Media, which publishes the Charleston Gazette-Mail in West Virginia, waged a year-long legal battle for access to documents and data from the case.

On Monday evening, U.S. District Judge Dan Polster removed the protective order for part of the ARCOS database. Lawyers for the local governments suing the companies hailed the release of the data. “The data provides statistical insights that help pinpoint the origins and spread of the opioid epidemic — an epidemic that thousands of communities across the country argue was both sparked and inflamed by opioid manufacturers, distributors, and pharmacies,” said Paul T. Farrell Jr. of West Virginia, co-lead counsel for the plaintiffs.

In statements emailed to The Post on Tuesday, the drug distributors stressed that the ARCOS data would not exist unless they had accurately reported shipments and questioned why the government had not done more to address the crisis. “For decades, DEA has had exclusive access to this data, which can identify the total volumes of controlled substances being ordered, pharmacy-by-pharmacy, across the country,” McKesson spokeswoman Kristin Chasen said. A DEA spokeswoman declined to comment Tuesday “due to ongoing litigation.”

Cardinal Health said that it has learned from its experience, increasing training and doing a better job to “spot, stop and report suspicious orders,” company spokeswoman Brandi Martin wrote.

AmerisourceBergen derided the release of the ARCOS data, saying it “offers a very misleading picture” of the problem. The company said its internal “controls played an important role in enabling us to, as best we could, walk the tight rope of creating appropriate access to FDA approved medications while combating prescription drug diversion.”

While Walgreens still dispenses opioids, the company said it has not distributed prescription-controlled substances to its stores since 2014. “Walgreens has been an industry leader in combatting this crisis in the communities where our pharmacists live and work, ” said Phil Caruso, a Walgreens spokesman.

Mike DeAngelis, a spokesman for CVS, said the plaintiffs’ allegations about the company have no merit and CVS is aggressively defending against them. Walmart, Purdue and Endo declined to comment about the ARCOS database.  A Mallinckrodt spokesman said in a statement that the company produced opioids only within a government-controlled quota and sold only to DEA-approved distributors.Actavis Pharma was acquired by Teva Pharmaceutical Industries in 2016, and a spokeswoman there said  the company “cannot speak to any systems in place beforehand.”

A virtual road map  –  The Post has been trying to gain access to the ARCOS database since 2016, when the news organization filed a Freedom of Information Act request with the DEA. The agency denied the request, saying some of the data was available on its website. But that data did not contain the transactional information the companies are required to report to the DEA every time they sell a controlled substance such as oxycodone and hydrocodone.

 

The drug companies and pharmacies themselves provided the sales data to the DEA. Company officials have testified before Congress that they bear no responsibility for the nation’s opioid epidemic. The numbers of pills the companies sold during the seven-year time frame are staggering, far exceeding what has been previously disclosed in limited court filings and news stories. Three companies distributed nearly half of the pills: McKesson with 14.1 billion, Walgreens with 12.6 billion and Cardinal Health with 10.7 billion. The leading manufacturer was Mallinckrodt’s SpecGx with nearly 28.9 billion pills, or nearly 38 percent of the market.

The states that received the highest concentrations of pills per person per year were: West Virginia with 66.5, Kentucky with 63.3, South Carolina with 58, Tennessee with 57.7 and Nevada with 54.7. West Virginia also had the highest opioid death rate during this period. Rural areas were hit particularly hard: Norton, Va., with 306 pills per person; Martinsville, Va., with 242;  Mingo County, W.Va., with 203; and Perry County, Ky., with 175.   In that time, the companies distributed enough pills to supply every adult and child in the country with 36 each year.

The database is a virtual road map to the nation’s opioid epidemic that began with prescription pills, spawned increased heroin use and resulted in the current fentanyl crisis, which added more than 67,000 to the death toll from 2013 to 2017. The transactional data kept by ARCOS is highly detailed. It includes the name, DEA registration number, address and business activity of every seller and buyer of a controlled substance in the United States. The database also includes drug codes, transaction dates, and total dosage units and grams of narcotics sold. The data tracks a dozen different opioids, including oxycodone and hydrocodone, which make up three-quarters of the total pill shipments to pharmacies.

Under federal law, drug manufacturers, distributors and pharmacies must report each transaction of a narcotic to the DEA, where it is logged into the ARCOS database. If company officials notice orders of drugs that appear to be suspicious because of their unusual size or frequency, they must report those sales to the DEA and hold back the shipments. As more and more towns and cities became inundated by pain pills, they fought back. They filed federal lawsuits against the drug industry, alleging that opioids from the companies were devastating their communities. They alleged the companies not only failed to report suspicious orders, but they also filled those orders to maximize profits. As the hundreds of lawsuits began to pile up, they were consolidated into the one centralized case in U.S. District Court in Cleveland. The opioid litigation is now larger in scope than the tobacco litigation of the 1980s, which resulted in a $246 billion settlement over 25 years.

Judge Polster is now overseeing the consolidated case of nearly 2,000 lawsuits. The case is among a wave of actions that includes other lawsuits filed by more than 40 state attorneys general and tribal nations. In May, Purdue settled with the Oklahoma attorney general for $270 million. In the Cleveland case, Polster has been pressing the drug companies and the plaintiffs to reach a global settlement so communities can start receiving financial assistance to mitigate the damage that has been done by the opioid epidemic.  To facilitate a settlement, Polster had permitted the drug companies and the towns and cities to review the ARCOS database under a protective order while barring public access to the material. He also permitted some court filings to be made under seal and excluded the public and press from a global settlement conference at the outset of the case. Last June, The Post and the Charleston Gazette-Mail asked Polster to lift the protective order covering the ARCOS database and the court filings. A month later, Polster denied the requests, even though he had said earlier that “the vast oversupply of opioid drugs in the United States has caused a plague on its citizens” and the ARCOS database reveals “how and where the virus grew.” He also said disclosure of the ARCOS data “is a reasonable step toward defeating the disease.”

 Lawyers for The Post and the Gazette-Mail appealed Polster’s ruling. They argued that the ­ARCOS material would not harm companies or investigations because the judge had already decided to allow the local government plaintiffs to collect information from 2006 through 2014, withholding the most recent years beginning with 2015 from the lawsuit. “Access to the ARCOS Data can only enhance the public’s confidence that the epidemic and the ensuing litigation are being handled appropriately now — even if they might not have been handled appropriately earlier,” The Post’s lawyer, Karen C. Lefton, wrote in her Jan. 17 appeal. The lawyers also noted the DEA did not object when the West Virginia attorney general’s office provided partial ARCOS data to the Gazette-Mail in 2016. That data showed that drug distribution companies shipped 780 million doses of oxycodone and hydrocodone into the state between 2007 and 2012.

On June 20, the 6th Circuit Court of Appeals in Ohio sided with the news organizations. A three-judge panel reversed Polster, ruling that the protective order sealing the ARCOS database be lifted with reasonable redactions and directed the judge to reconsider whether any of the records in the case should be sealed.  On Monday, Polster lifted the protective order on the database, ruling that all the data from 2006 through 2012 should be released to the public, withholding the 2013 and 2014 data.

‘Prescription tourists’  –  The pain pill epidemic began nearly three decades ago, shortly after Purdue Pharma introduced what it marketed as a less addictive form of opioid it called OxyContin. Purdue paid doctors and nonprofit groups advocating for patients in pain to help market the drug as a safe and effective way to treat pain. But the new drug was highly addictive. As more and more people were hooked, more and more companies entered the market, manufacturing, distributing and dispensing massive quantities of pain pills. Purdue ending up paying a $634 million fine to the Food and Drug Administration for claiming OxyContin was less addictive than other pain medications.

 

Annual opioid sales nationwide rose from $6.1 billion in 2006 to $8.5 billion in 2012, according to industry data gathered by IQVIA, a health care information and consulting company. Individual drug company revenues ranged in single years at the epidemic’s peak from $403 million for opioids sold by Endo to $3.1 billion in OxyContin sales by Purdue Pharma, according to a 2018 lawsuit against multiple defendants by San Juan County in New Mexico.

During the past two decades, Florida became ground zero for pill mills — pain management clinics that served as fronts for corrupt doctors and drug dealers. They became so brazen that some clinics set up storefronts along I-75 and I-95, advertising their products on billboards by interstate exit ramps. So many people traveled to Florida to stock up on oxycodone and hydrocodone, they were sometimes referred to as “prescription tourists.”  The route from Florida to Georgia, Kentucky, West Virginia and Ohio became known as the “Blue Highway.” It was named after the color of one of the most popular pills on the street — 30 mg oxycodone tablets made by Mallinckrodt, which shipped more than 500 million of the pills to Florida between 2008 and 2012.

 When state troopers began pulling over and arresting out-of-state drivers for transporting narcotics, drug dealers took to the air. One airline offered nonstop flights to Florida from Ohio and other Appalachian states, and the route became known as the Oxy Express.

A decade ago, the DEA began cracking down on the industry. In 2005 and 2006, the agency sent letters to drug distributors, warning them that they were required to report suspicious orders of painkillers and halt sales until the red flags could be resolved. The letter also went to drug manufacturers. Even just one distributor that fails to follow the law “can cause enormous harm,” the 2006 DEA letter said. DEA officials said the companies paid little attention to the warnings and kept shipping millions of pills in the face of suspicious circumstances.  As part of its crackdown, the DEA brought a series of civil enforcement cases against the largest distributors.

The corporations to date have paid nearly $500 million in fines to the Justice Department for failing to report and prevent suspicious drug orders, a number that is dwarfed by the revenue of the companies.

But the settlements of those cases revealed only limited details about the volume of pills that were being shipped.

In 2007, the DEA brought a case against McKesson. The DEA accused the company of shipping millions of doses of hydrocodone to Internet pharmacies after the agency had briefed the company about its obligations under the law to report suspicious orders. “By failing to report suspicious orders for controlled substances that it received from rogue Internet pharmacies, the McKesson Corporation fueled the explosive prescription drug abuse problem we have in this country,” the DEA’s administrator said at the time.  In 2008, McKesson agreed to pay a $13.25 million fine to settle the case and pledged to more closely monitor suspicious orders from its customers.

That same year, the DEA brought a case against Cardinal Health, accusing the nation’s ­second-largest drug distributor of shipping millions of doses of painkillers to online and retail pharmacies without notifying the DEA of signs that the drugs were being diverted to the black market. Cardinal settled the case by paying a $34 million fine and promising to improve its suspicious monitoring program.

Some companies were repeat offenders.  In 2012, the DEA began investigating McKesson again, this time for shipping suspiciously large orders of narcotics to pharmacies in Colorado. One store in Brighton, Colo., population 38,000, was ordering 2,000 pain pills per day. The DEA discovered that McKesson had filled 1.6 million orders from its Aurora, Colo., warehouse between 2008 and 2013 and reported just 16 as suspicious. None involved the Colorado store. DEA agents and investigators said they had amassed enough information to file criminal charges against McKesson and its officers but they were overruled by federal prosecutors. The company wound up paying a $150 million fine to settle, a record amount for a diversion case.

Also in 2012, Cardinal Health attracted renewed attention from the DEA when it discovered that the company was again shipping unusually large amounts of painkillers to its Florida customers. The company had sold 12 million oxycodone pills to four pharmacies over four years. In 2011, Cardinal shipped 2 million doses to a pharmacy in Fort Myers, Fla. Comparable pharmacies in Florida typically ordered 65,000 doses per year.  The DEA also noticed that Cardinal was shipping unusually large amounts of oxycodone to a pair of CVS stores near Sanford, Fla. Between 2008 and 2011, Cardinal sold 2.2 million pills to one of the stores. In 2010, that store purchased 885,900 doses — a 748 percent increase over the previous year. Cardinal did not report any of those sales as suspicious. Cardinal later paid a $34 million fine to settle the case. The DEA suspended the company from selling narcotics from its warehouse in Lakeland, Fla. CVS paid a $22 million fine.  As the companies paid fines and promised to do a better job of stopping suspicious orders, they continued to manufacture, ship and dispense large amounts of pills, according to the newly released data. “The depth and penetration of the opioid epidemic becomes readily apparent from the data,” said Peter J. Mougey, a lawyer for the plaintiffs from Pensacola, Fla. “This disclosure will serve as a wake up call to every community in the country. America should brace itself for the harsh reality of the scope of the opioid epidemic. Transparency will lead to accountability.”

Aaron Williams, Andrew Ba Tran, Jenn Abelson, Aaron C. Davis and Christopher Rowland contributed to this report.

Scott Higham is a Pulitzer-Prize winning investigative reporter at WAPO; has worked on Metro, National and Foreign projects since 2000.

Sari Horwitz is a Pulitzer-Prize winning reporter who covers DOJ, law enforcement &  criminal justice issues for WAPO, where she has been a reporter for 34 years.

Steven Rich is the database editor for investigations at WAPO; has worked on investigations involving the NSA,, police shootings, tax liens & civil forfeiture; reporter on two teams to win Pulitzer Prizes, for public service in 2014 and national reporting in 2016.

Source:   https://www.washingtonpost.com  Feb. 4th 2019

A pilot programme at Shanghai’s rehab centres taps the technology to measure addiction and determine how to treat it.

In a treatment room at a suburban Shanghai drug rehabilitation centre, “Victor Wu”, a recovering addict, sits in front of a computer screen, viewing assorted scenes through a virtual reality headset.

Wu (not his real name) takes in a lifelike image of a young man and a woman sitting on a sofa drinking a clear liquid through a straw from a small bottle. As he does so, clips attached to three of the fingers on his left hand pick up his physical reactions.

The data reveals to his observers – including police officers who can see on the computer screen what Wu sees – the degree to which this stimulus excites him.

As the woman in this VR-enhanced scene holds her straw out to Wu, enticing him to drink with her and the man, Wu remains captivated for at least 10 seconds – a detail the observers note with interest.

Although he can choose the scenes to view and their duration by using the switch he holds in his right hand, “Wu’s attention is stuck on this scene for a while before [he moves on] to look at other no-drug scenes”, an officer told the South China Morning Post.

“It means he is still a bit interested in having drugs.”

It is all part of a revolutionary effort to use VR technology to reveal the extent of drug users’ addiction – and the type of treatment they need – to help them to turn their lives around.

Clad in the centre’s official inmate uniform of green sleeveless T-shirt, shorts and sandals, Wu and his fellow addicts are part of a trial of VR technology that was expanded this summer to all five of Shanghai’s rehab facilities, from just two in October.

Although the Shanghai centres were not the first in China to begin using VR – some rehab institutes in the eastern province of Zhejiang had employed it last year – their application of the technology is nevertheless distinctive in its application of eyeball movement tracking science.

Being able to read how an inmate’s eyeballs move over certain images gives staff a clearer idea of whether the addict’s gaze is fixed squarely on the repulsive “educational” images of drug addicts he or she must watch.

Tracking eyeball movement also gives staff extra information they can use to gauge the accuracy of the self-evaluations that inmates are required to fill out; many have been known to lie about the degree of their drug dependency in an attempt to speed up their release from the programme.

“In the rehab centre we see those awful pictures of drug addicts through VR helmet several times a month, as part of our education here,” Wu told the Post. “I really abhor drugs now.”

While it is not known how many addicts in China ultimately are to be exposed to the VR programme, the number is expected to be considerable. The five centres in Shanghai and one at Qingdong alone treat 1,800 male addicts.

Xu Ding, a drug rehab veteran from Shanghai Drug Rehabilitation Management Bureau who spearheads the VR project, said the technology’s use has helped alleviate “a major frustration” encountered when trying to treat drug addicts by showing them revolting images of other addicts.

 “In the past, to depress the addicts’ desire for drugs, we let them watch TV or presented them horrible pictures of people whose health was seriously affected after long-term consumption of drugs,” Xu said. “But both TV or pictures on papers don’t look real enough.

“What’s more, we can’t tell if these people are really focusing on our education,” Xu said. “They would look at other places, or just close their eyes.”

In 2015, when the VR industry was beginning to get a lot of attention in China, Xu and his colleagues moved to incorporate it in treating addicts. “VR is a kind of embedded viewing experience and is so real,” Xu said.

The VR system that was first used in two of the city’s rehab centres in October was jointly developed by Shanghai Mental Health Centre, East China Normal University’s School of Psychology and Cognitive Science, eyeball movement tracking company Shanghai Qing Tech and the Shanghai drug rehabilitation authority.

In the system, an instrument to trace eyeball movement is installed in the VR headset along with devices to measure electrodermal activity (EDA) and pulse phase, to make observers aware when addicts refuse to look at what they are supposed to see.

EDA measures the change in the electrical characteristics of a person’s skin in response to sweat secretion.

 “Shanghai is the first in the world to introduce an eyeball-movement tracking machine to drug rehabilitation, according to the literature I can find on the internet,” Xu said.

Cao Lei, director of the psychotherapeutic department of Shanghai Qingdong Drug Rehab Centre, said the reports on addiction level based on inmates’ responses to watching VR scenes “are objective and people can’t fool the system since they can’t control their EDA and pulse speed”.

Previously, inmates could lie when filling out a questionnaire on their drug dependency to get released early, Cao said.

Under mainland law, people caught possessing drugs must spend two years undergoing treatment at a rehab centre. Inmates who “perform very well” in treatment can get out early.

So far, assessing the VR programme’s effectiveness is difficult, given the lack of concrete results.

Last year, however, the Ministry of Justice said many rehab centres across the country were using innovative methods to try to help people kick drug habits, including virtual reality technology, people.com.cn reported.

The measures, which also included Tibetan medicine, traditional Chinese medicine, massage and physical exercise, had achieved good results, according to the ministry.

Some 2.55 million people in China had possessed illegal drugs as of the end of last year, according to the 2017 China Drug Situation Report issued in June by the China National Narcotics Control Commission.

Among them, 321,000 were put in rehab centres across the country, about 2 per cent more than in the previous year. More than 60 per cent of addicts possessed synthetic drugs such as methamphetamine, a central nervous system stimulant known in the illicit drug trade as “ice”.

Wu, 28, said his drug habit began six years ago at a pub where a friend offered him ketamine – a synthetic drug that induces a trancelike state and is usually referred to on the street as “K powder”.

“I knew drugs are bad, but at that time I was confident that I could control myself [and would] not become addicted to drugs,” said Wu, a former sales representative with an insurance company.

But he failed to do that. Last year, police, tipped off by his friend that Wu had illegal drugs at home, raided Wu’s house and took him away.

“I think I will not touch drugs after I get out [of the rehab centre],” Wu said. “I don’t want to come back again. I hate losing my freedom.”

Source: How China is using virtual reality to help drug addicts turn their lives around | South China Morning Post (scmp.com) July 2018

After Lynley Graham’s custody photo was posted to a police force’s Facebook page, horrified users were quick to discuss the harmful effects of hard drugs

Deep lines etched across a woman’s face and cheeks sunken to the bone – this one shocking image illustrates the effects of substance abuse.

Lynley Graham’s custody picture has been released by Humberside Police after she was jailed for 18 months for drug offences.
Graham was found in possession of class A drugs, including heroin and cocaine, and was subsequently charged with possessing a class A drug with intent to supply, Grimsby Live reports.

After the photo was posted to Humberside Police’s Facebook page on Wednesday, users were quick to discuss the 53-year-old’s weathered appearance.

Before and after pictures show a striking physical transformation.

One said: “I’m 64, I look young compared to her. Is she a lesson, perhaps, in what substance abuse can do to your skin?”

Another added: “Let’s hope some young people look at her and see what a life of drugs does apart from ruining entire families.”

Drug addiction and misuse contributed to more than 2,500 UK deaths in 2017.

Inhalants can cause damage to the kidneys, liver and bone marrow, and persistent drug consumption can result in abscesses, tooth decay – known as ‘meth mouth’ in the United States.

Other symptoms include premature ageing of the skin, often adding decades to someone’s appearance.

Rehabs.com, a US-based charity, has also published startling images of drug users to demonstrate the long-term toll narcotics have on one’s appearance.

Drugs can damage almost every system in the body; bloodshot eyes, dilated pupils, puffy faces and discoloured skin are all noticeable signs.

Some users suffer a rapid physical deterioration – with facial appearances sometimes ruined in just a matter of years.

Self-inflicted wounds, common among consumers of methamphetamine, can be caused by users picking at their skin to relieve the sensation of irritation – sometimes described as like crawling insects.

And a skeletal appearance can be the result of appetite-suppression.

Cocaine can commonly lead to chronic skin ulcers, pus-filled skin and the development of Buerger’s disease – an inflammation in small and medium-sized blood vessels.

Heroin has been known to dry the skin, leaving addicts with itchy and aged skin.

In May, Sir Angus Deaton, a world-leading economist, warned that drug abuse and alcoholism claim more lives of those in middle-age than heart disease.

‘Economic isolation’ is cited as one of the biggest contributors.

In 2017, a poll of 1,600 adults found that almost nine in ten said that seeing the physical effects of hard drugs made them less likely to take them.

The publication of such images is a common tactic among anti-addiction campaigners.

Scotland is experiencing its own drug crisis, with a 27 per cent rise in drug-related deaths, according to official statistics.

It puts Scotland’s drug mortality rate three times higher than the UK as a whole, and higher than any other country in the European Union.

The NHS offer services for drug and alcohol recovery, as do outside agencies, such as Addaction

Source: https://www.mirror.co.uk/news/uk-news/shocking-image-illustrates-how-drugs-18790997 July 2019

A USA TODAY NETWORK-Wisconsin project

Heroin entered their lives so easily.

For 10 addicts, the hard part is staying clean.

They got the pills from their doctors, then kept using them until they couldn’t stop. They switched to heroin because it was cheaper, because a friend said it was an easier, better way to get high.

They went to parties as teens, took pills, snorted powders. They got bored with the drugs they were doing and then found heroin, the drug they loved the most.

They had faced abuse, poverty, tragedy. Their pain was deep, and psychological, and the drug was an escape.

The stories of 10 recovering heroin addicts from Wisconsin are the stories of millions of Americans who have been hooked on opiates and either died, or lived with the consequences. They’ve lost friends. They’ve been arrested. They’ve lost touch with their family and friends, lost custody of their children.

COUNTY BY COUNTY: Deaths and ODs in Wisconsin.

“It wasn’t what they always told us it was going to be,” said Moriah Rogowski, a 22-year-old recovering addict, about her first time using heroin. She didn’t develop an addiction right away. But somewhere, more gradually than she expected, she lost control.

Like the other nine recovering heroin users profiled in this special report from USA TODAY NETWORK-Wisconsin, Rogowski has taken back control of her life. She’s clean. She lives in a different city, imagines a different future for herself.

Recovery from opiate addiction is hard, filled with setbacks. But these 10 people from across Wisconsin have taken the first steps toward a life after heroin. In photos, in words and in their own voices, these are their stories about how they started on heroin and fought to get off the drug.

‘That was the only way I liked to get high’

Moriah Rogowski, Green Bay

Moriah Rogowski liked the feeling of downers: Percocet, Vicodin, Oxycontin. She and her friends, the summer before high school, would go out to parties and crush pills and snort them.

She and her three siblings lived in a rural home near Mosinee, where she was homeschooled until eighth grade. In high school, she found her place among the stoners. One night she found herself in a drug house in Marshfield with 33-year-olds. She was 15.

That was the day she first tried heroin. She was afraid of needles, so she let someone else shoot the drug into a vein in her arm.

“That was the only way I liked to get high after that,” she said.

Rogowski is now 22. She’s been in and out of programs in Minnesota and Green Bay as she tried to get clean. But she’d come home and hang out with the same friends; each time they led her back to the drug.

She sought treatment at the methadone clinic in Wausau, where she saw others abusing the methadone and still using heroin. She fell into the same pattern.

She mixed heroin, crack, Xanax. There is a week of her life she can’t remember. She took her brother’s car and got an OWI. Her license was suspended.

Then, from somewhere, she found the will to change. She called her mom to come get her because she wanted to get clean. She began to use the methadone program correctly, taking classes and attending therapy sessions.

Rogowski has lived in Green Bay for two years. She hopes to complete her GED. And she’s trying to help others by working toward becoming a recovery coach.

— Laura Schulte, leschulte@gannett.com

A soldier’s widow masks her pain

Sarah Bear, Wausau

Sarah Bear didn’t want to feel anymore.

Her husband, Jordan, was killed in Afghanistan in 2012 during an attack at his base in the Kandahar province. More than a year later, just when she started being able to grieve her husband’s death, her oldest son’s dad died.

Bear’s addiction started in the summer of 2014 with pills — Vicodin, Oxycontin, Percocet. They dampened the pain of her losses. A friend had been prodding her to try heroin: It was cheaper, he said, and she wouldn’t have to use as much. She swore she would never touch it.

One day, Bear couldn’t get any pills. The withdrawals hit. She got sick; she couldn’t take care of her children. Eventually, she called the friend, and within a half hour was snorting heroin for the first time in her Antigo apartment.

Then, she felt nothing, just like she wanted.

“I completely, seriously fell in love with that drug,” she said. “There was nothing that compared to it, honestly. Sadly.”

She did heroin every day, either snorting or smoking it, and eventually injecting it.



Beginning in January 2015, Bear was in and out of jail, and on and off heroin. She tried methadone treatment but it didn’t stick.

In October 2016, Bear’s four children were taken from her. Two went to stay with her mom, and two with her grandmother.

Almost a year later, Bear, 33, found herself in North Central Health Care’s Lakeside Recovery in Wausau, a 21-day medically monitored substance abuse treatment program. She believes she hit rock bottom.

She started the program in mid-September and could feel the change within her as her Oct. 6 graduation approached. She’s determined to get better.

“I remember a time when my life was good, and I know that I can be back there,” she said. “I know that I can have that again.”

— Haley BeMiller, hbemiller@gannett.com

He laughed at the idea he could be saved

Nathan Scheer, Fond du Lac

Nathan Scheer felt the bottom drop out the day before Christmas Eve 2016. His wife and kids watched the cops haul him away.

His probation officer had heard he would test dirty and showed up at his home unannounced.

“On the way to jail I was higher than I’d been in years, but I remember my probation officer telling me she was going to save my life,” he said. “I laughed and told her you can’t save someone who doesn’t want to be saved.”

He first used prescription opiates after a car crash. One day he didn’t have enough money for hydrocodone pills. In their place, he was offered “dog food” —  a street name for heroin.

A decade-long fling with heroin followed, and it turned the 35-year-old factory worker from a regular, middle-class guy into a liar and a thief.


“I once explained to my wife that it (heroin) felt like what I imagine looking into the eyes of God would feel like,” Scheer said. “It’s the most religious experience you could ever imagine.”

But since the day the probation officer showed up a little more than a year ago, Scheer got clean through counseling, group support and a local church. He learned to feed his addictive personality through the gratification that comes with community service.

Today, Scheer and his 4-year-old son, Bentley, have gained recognition in Fond du Lac by cleaning up parks and playgrounds. Giving back is his metaphor for recovery. Father and son call it #cleanstreetforkids.

“I call it my beautiful disaster, because the way everything happened, I was so lucky. I had people who stuck by me while I waged war on myself.”

— Sharon Roznik, sroznik@gannett.com

‘They just kept prescribing pain meds’

Rebecca Palmieri, Wisconsin Rapids

Rebecca Palmieri’s house is quiet now. In August, a court commissioner ordered her to give up her five children. It was the second time in two years that she lost them.

She’s lost everything since she started using heroin. She’s been homeless. She has a record.

Palmieri, 39, had medical complications when she had her fifth child. That was in 2013.

“They just kept prescribing pain meds for five months after I had my son. They did corrective surgery, but, by then, I was hooked.”

She used pills for about two years. In January 2015, a friend came to her Wisconsin Rapids apartment with heroin. He told her to hold out her arm. In the empty bedroom, with her children in another part of the house, he injected her.

Using wasn’t an everyday thing, she said, until it was. She would look around her apartment to see what she could sell or return for money to buy the drug.

The courts put her kids into foster care. She was homeless for about six months. The kids went to live with her husband; they came back to her when he went to prison. She got clean and found a house. But the courts sent the kids back to her husband when he got out.

Palmieri said she has been clean since November 2016. She goes to the YMCA every day to work out; she attends addiction support group meetings. She wants to get her kids back.

“It’s probably the hardest thing I ever had to do,” she said, “to get clean and stay clean.”

— Karen Madden, kmadden@gannett.com

Sacred fire lights a path to recovery

Joey Powless, Oneida

Joey Powless stood by the sacred fire burning under a tepee in the center of Oneida. He busied himself by keeping the fire steady and clean, moving ash and coals out of the flames.

Powless, 36, a member of the Oneida Nation, called it the Grandpa Fire, and without it, he said, he would not have been able to stay clean for the past five years or so.

The sacred fire represents the spirit of native people, a connection to the past and present, a source of strength, a place to pray, a gateway to understanding.

“Without fire, we couldn’t live,” Powless said. “This is what we cooked our food with. This is what gave us life. Gave us heat. So without it we could never live. This is our very first teaching right here.”

His mother abandoned him and his family when he was a kid, and he responded at a young age with anger, he said. He started drinking and smoking pot at age 13. By the time he was in his early 20s, he added opioid medications and cocaine to the mix.



Powless was 28 when he first tried heroin at a party. He was deep into drug culture, and selling drugs to pay for his own drugs. “Cocaine really wasn’t doing nothing for me no more,” he said. Snorting heroin seemed like a natural thing to do.

It made him sick at first, but as that feeling eased, he felt the high. “That’s when the magic happens,” he said. He continued to chase that high. He graduated from snorting heroin to shooting it into his veins.

He was about 31 when he was jailed, and put into solitary confinement. It was there that he decided he didn’t want to be an addict anymore. “Because I have children,” he said. (Powless is the father of two teenagers.) “I didn’t want to be out of their lives no more.”

— Keith Uhlig, kuhlig@gannett.com

Arrests pile up after friend overdoses

Jennifer Solis, Stevens Point

Jennifer Solis was out of pills and already felt sick.

In the bathroom of her friend’s house in Stevens Point, she crushed up a little heroin and snorted it. It was the first time she had tried the drug.

Her friend, close by, was injecting it. They didn’t talk.

Solis, who was in her mid-20s at the time, looked down on people who used needles. She told herself she wouldn’t cross that line. She would.

Solis, now 34, was born in Colorado but moved to Wisconsin as a teenager. She was already using drugs with her friends — first marijuana, then cocaine — by the time she was 16.

“I think I was always looking for the next best thing,” she said. “I didn’t see myself as an addict back then.”

Solis became addicted to pain pills after she suffered a serious back injury as a result of domestic abuse, she said. After her friend introduced her to heroin, she used it every day.

She called paramedics when a friend overdosed a few years ago, then watched as they used the counteracting drug naloxone to revive her. She was charged in that incident, and then arrests piled up quickly.

 

She joined Portage County’s drug court in May and stayed clean for her first three months. Then she relapsed by using heroin and methamphetamine. By October 2017, Solis had again been clean for three months.

Solis has five children but no contact with them. Her three oldest live with a relative and her two youngest were adopted as infants.

She wants to go back to school for interior design. But for now, Solis lives at the Salvation Army in Stevens Point, working to put her life back together.

— Chris Mueller, cmueller@gannett.com

‘I smoked pot with both my parents’

Kevin Williams, Wisconsin Rapids

Kevin Williams is 35 and lives in a Wisconsin Rapids assisted-care facility. His mother and father divorced when he was 8, and, he said, “I basically smoked pot with both my parents by the time I was 15.”
By the time Williams was an adult, he tried every drug he could.

Cocaine: “Why not? I was already stoned on weed.”

Meth: “I tell people I used meth once in my life for eight months.”

Opiates: A friend first gave him an oxycodone pill, “and I was like, ‘Why not?’ I crushed it up and snorted it. … It was like the absolute, most warmest hug I ever felt.”

He can’t remember when he first switched from prescription opiates to heroin. But shooting up the drug, he said, “was like stepping into the perfect temperature of bath water, and (the feeling) would go all the way up, and all the way down.”

Williams is disabled. He walks with a limp and his left arm hangs at his side.



“I went to prison a couple years back. I found out I had a brain tumor. They went in to take it out, and they cut a blood vessel … gave me a stroke.”

One day, two years ago, he ran out of money and got clean. He can’t explain why.

“These days … I feel better about my life than I ever have before. Which sounds pretty crazy, doesn’t it? I only got half a freakin’ body right now. … But I get by. I still joke and love and make it to the Dollar Tree. All my essentials are taken care of.”

— Keith Uhlig, kuhlig@gannett.com

Addiction becomes a legacy of abuse

Jodi Chamberlain, Stevens Point

Jodi Chamberlain couldn’t get pills. They cost too much.

She got heroin from a friend instead. She was alone in her bedroom the first time she snorted the drug.

She didn’t have to think or feel. She didn’t have to deal with anything. But, Chamberlain said, “when it ends, you just crave more.”

She used heroin again within a week.

Chamberlain was living in Stevens Point at the time. She was barely in her 20s, but was already a regular drug user — mostly pain pills, but also cocaine and other stimulants. Her addictions grew out of a turbulent childhood, which, she said, included incidents of sexual abuse by a relative.

“I was taught to lie and to not have feelings,” she said. “I’ve never felt feelings.”

Now 41, Chamberlain has been clean for about eight months. She moved back to Stevens Point late last year after living in Eau Claire. Sometimes she slept in a truck.

Chamberlain was arrested again and again. She was sentenced in May on felony drug charges, but instead of going to prison, a judge allowed her to participate in Portage County’s drug court. She’s never made it through treatment without going back to heroin. If she fails in drug court, she faces a prison sentence.

Chamberlain regrets how many people she hurt with her drug use, particularly her two children, who watched their mother struggle with addiction.

She wants to stay clean, but even she can’t say whether she will make it.

“I can’t make that promise to anyone, not even myself,” she said. “But I choose to have people in my life now who can help me when I am going through rough times.”

— Chris Mueller, cmueller@gannett.com

‘A very functional addict’ awaits prison

Kyle Keding, Wisconsin Rapids

Kyle Keding was 26 years old and had been a heavy user of drugs for years before he tried heroin.

He had been drinking and smoking marijuana for about half his life. He had been dependent on opiate painkillers such as Percodan and Oxycontin for about five years. The pills helped him get through long days as a welder and they helped him forget about the crap life handed him.

Keding was sexually molested when he was about 5 years old, first by a babysitter, then by a relative, he said. Those memories never left him, unless he was high. So he got high. A lot. For him, that was just part of life, in addition to work, being a parent and a husband.

 

“I was what you call ‘a very functional’ addict,” he said.

The heroin was a practical choice. Opiate painkiller manufacturers had changed the formula of their pills, making them more difficult to use to get high, and also created a huge opiate shortage.

“So I couldn’t find what I wanted. I called up my friend, and he was like, ‘Well, I’ve got some ‘ron (heroin). … (I was) kind of skeptical,” Keding said. “I had not done it before.”

He did not feel as if he had stepped over any kind of line. He had already liquefied prescription opiates and shot those up intravenously.

Shooting up, both synthetic opiates and heroin, gave him a stronger high. He chose the needle because his friend and dealer did not have enough pills to get Keding as high as he wanted.

“I can remember the words that came out of my mouth once I released the strap off my arm,” he said. “‘Oh, my God. This is amazing.’ And I knew right there, this is it. I was like, there was no turning back now. But there was.”

He used heroin for five years, until Dec. 2, 2014. That night he was with friends, getting high, and one of the people he was with died. He was charged with first-degree reckless homicide/deliver drugs. He accepted a plea deal on that charge on Dec. 1, 2017. He awaits sentencing in February and could face years in prison.

— Keith Uhlig, kuhlig@gannett.com

‘This is a lifelong battle’

Tommy Casper, Neenah

Tommy Casper said one of the main reasons he has stayed clean for more than seven months is because of his nephew Owen, who has only ever known him sober. Casper sees his sister Carly Fritsch, who overcame her own struggle with addiction, and Owen most days of the week after work. Casper plays on a recreational volleyball team with other recovering addicts and attends Narcotics Anonymous meeting three times a week.

Tommy Casper was alone in the basement of the two-story home where he grew up.

He sat on his bed and opened a small bag of heroin that had been on top of a dresser beside him. He hadn’t used the drug before, but at about $120 a bag, it was cheaper than the pills he used. He snorted it.

He found himself asking one thing as the feeling went away: “What do I need to do in order to feel that way again?” He used heroin again three hours later.

Casper was 21 years old and living in Muskego, a community of fewer than 25,000 people on the outskirts of Milwaukee. His mother had died about six months earlier and he struggled with the loss. His sporadic use of pain pills became an addiction.

“The first time I used (as a way) to cope — rather than using to have fun or go out — was at her funeral,” he said.

After he turned to heroin, Casper told himself he wouldn’t use a needle because “then I wasn’t as bad as other people.” He used a needle for the first time a year later.

After his mother died, Casper moved around — to a house in West Allis, then an apartment in Neenah. He began to steal to support his addiction, but got caught shoplifting at a Walmart in Fond du Lac. He was charged and went to treatment a few days later.

Casper hardly slept or ate for two weeks as he fought through the physical withdrawal from the drug.

 

Casper, now 29, has relapsed twice since going to treatment. He hasn’t used for about the last seven months and attends Narcotics Anonymous meetings three times a week. He has a full-time job at a call center in Appleton and hopes to use his story to help others.

“This is a lifelong battle that we’re going to be in,” he said.

— Chris Mueller, cmueller@gannett.com

About this project

Wisconsin has a heroin problem directly linked to its opioid epidemic. Every corner of the state has been affected, every taxpayer, every school district, every police department, every social service agency, every hospital.

But why do an estimated 6,600 Wisconsin residents regularly snort, inject or smoke heroin? And how do we get our state off this deadly drug?

A team of journalists from USA TODAY NETWORK-Wisconsin went to 10 people who know firsthand how heroin enters a person’s life, and how best to get away from its grip. Their stories are part of a project the news organization will continue in 2018 to investigate Wisconsin’s response to the opioid crisis and the most successful paths to recovery.

All photos and videos by Alexandra Wimley/USA TODAY NETWORK-Wisconsin

Send feedback to Robert Mentzer, project editor: rmentzer@gannett.com

How to get help

For people who want to get help with heroin addiction:

Emergency: In a life-threatening emergency, call 911.

United Way 2-1-1: If it’s not an emergency but you want information over the phone at any hour about local options, call 211.

Narcotics Anonymous: Local meetings can be found online at wisconsinna.org or by calling 1-866-590-2651.

Wisconsin Department of Health Services: Guide to treatment resources statewide, online at dhs.wisconsin.gov/opioids/.

Source: http://www.wisinfo.com/usat/heroin_addiction/?for-guid=7ba874c6-08dd-e611-b81c-90b11c341ce0#start

 

 

The authors of this ‘Before and After’ library (American Addiction Centers) have obviously spent a great deal of time in merging several still photographs which have produced a strikingly progressive presentation for each user, as time progresses.

 

Millions of Americans are trapped in a cycle of drug abuse and addiction: In 2013, over 24 million reported that they had abused illicit drugs or prescription medication in just the past month. More than 1.7 million were admitted to treatment programs for substance abuse in 2012. The pursuit of a drug habit can cost these people everything – their friends and family, their home and livelihood. And nowhere is that impact more evident than in the faces of addicts themselves.

Here, the catastrophic health effects of drug abuse are plain to see, ranging from skin scabs to decayed and missing teeth. While meth is often seen as one of the most visibly destructive drugs, leading to facial wasting and open sores,various other illicit drugs, and even prescription medications can cause equally severe symptoms when continuously abused. The use of opioids like OxyContin or heroin can cause flushing and a rash of red bumps all over the skin, while cocaine abuse can result in a significant drop in appetite and dangerous malnutrition and weight loss. Ecstasy may cause grinding of teeth, and smoking cannabis releases carcinogens and other chemicals that can diminish skin collagen and produce an appearance of premature aging. Even alcohol abuse can lead to wrinkles, redness, and loss of skin elasticity.

Beyond the direct effects of substance abuse, perhaps its most damaging result is addiction itself. The compulsion of addiction makes drug use the most important purpose in an addict’s life, leading them to pursue it at any cost and treat anything else as secondary. Self-neglect becomes normal – an accepted cost of continuing to use drugs. And the consequences of addiction can remain etched in their very skin for years.

Click here for an animated infographic

Disclaimer

The individuals in these before and after drug addiction photos were arrested on drug charges or related charges. There may be errors in arrest record reporting. All persons are considered innocent of these charges until proven guilty. These photos do not necessarily just show people after drugs and addiction; rather, they depict the physical deterioration of individuals who have been involved in repeated arrests, indicative of a life of crime and/or substance abuse.

Source: https://www.rehabs.com/explore/faces-of-addiction/

++++++++++++++++++++++++++++++

ADDITIONAL INFORMATION ON PROGRESSIVE EFFECTS OF DRUG ABUSE

Thanks must go to the Daily Telegraph (London) for this second format.

This presents still photographs, in contrast with the animated presentation above.

https://www.telegraph.co.uk/news/health/pictures/8345461/From-Drugs-to-Mugs-Shocking-before-and-after-images-show-the-cost-of-drug-addiction.html?image=31255

 

Waiheke Island lawyer and meth researcher Chloe Barker is thrilled to see Jacinda Ardern, who acted on her findings, become Prime Minister.

For her Master’s thesis, Barker carried out heart-breaking research on the impacts on children of growing up in methamphetamine laboratories in New Zealand.

She found that through contact with contaminated environments, children sometimes had levels of meth in their hair, blood and urine that were higher that that of addicts.

Although the impacts on children are devastating, the laws are “toothless” and often fail to protect them, Barker said.

After her research findings were published in a police magazine in 2012, Jacinda Ardern contacted her and suggested meeting over coffee.

“She was amazingly passionate and obviously really cared about the issue,” Barker said.

A Labour list MP at the time, Ardern arranged for broader publication of Barker’s research, helping to raise awareness of the issue.

Ardern cited Barker’s research in parliament to support law changes to make it a crime for people to manufacture meth when a child is present.

However, the Sentencing (Protection of Children from Criminal Offending) Amendment Bill never made it into law.

Police can prosecute meth manufacturers under general child abuse laws, but the rates of conviction are low, because it is hard to prove children have been intentionally harmed by P [methamphetamine] manufacture, Barker said.

Ardern campaigned for a protocol to be introduced assigning responsibilities to the police and Child, Youth and Family (CYF) when children are found in P labs. New protocols have since been developed.

“I was really impressed that she had a million things on her plate, but she cared enough to be proactive and make practical changes that have assisted the police.

“I’m absolutely stoked about Jacinda becoming the Prime Minister.

“I think she’s going to give a voice to a lot of people who don’t have a voice currently,” Barker said.

Examining police files, Barker found that from 2006 to 2010, 191 children were living in the presence of methamphetamine laboratories that were shut down by police.

In 2002, children were living in 34 percent of the houses where laboratories were discovered.

The dangers of growing up in P laboratories include exposure to toxic chemicals, risks of explosions and fires, and a higher likelihood of having weapons in the house.

Children in meth laboratories also face higher risks of physical, sexual and emotional abuse, she said. 

“Given everybody can clearly see the dangers to children, there should be a specific law that says if you cook meth in the presence of a child, you’re committing a crime,” Barker said.

The 39-year-old has returned to her full time job as a commercial lawyer after completing her Master of Forensic Science degree at the University of Auckland.

Barker said Ardern won’t provide a “magic answer” for all life’s ills, but she is hopeful children might yet get the legal protection from meth exposure that they deserve.

“There is obviously a problem with P on Waiheke and I’m sure there are lots of communities around New Zealand that are exactly the same,” she said. 

Source: https://www.stuff.co.nz/national/politics/98147222/meth-researcher-thrilled-with-new-prime-minister October 2017

Research on children living in homes used as methamphetamine labs confirms police concerns over the risks. Ellen Brook reports.

The worrying trend of young children living in meth labs and being exposed to toxic chemicals has been highlighted in a research project with support from the Police National Clan Lab Response team in Auckland.

Auckland lawyer Chloe Barker, who analysed Police and ESR (Environmental Science and Research) data related to children and clandestine (clan) labs as part of a master’s degree thesis last year, has raised the red flag on the risks for young children. Her conclusions not only back up anecdotal evidence from police officers, but go on to say that existing child abuse laws are inadequate for prosecuting offenders.

Ms Barker’s research, based on Police data from 2006 to 2010, showed that dozens of children, with an average age of six years, were exposed to clan lab activity each year. On average, children were living or present in 25 per cent of New Zealand meth labs, rising to 34 per cent in 2010.

Latest figures show that of the 94 clan labs located in 2012, children were in 27 of them; 45 children were identified and 25 were present at the time police found the labs.

Other findings included:

  1. About a quarter of the labs where children were present were either “A” or “B” grade, ie, “up and bubbling” or ready to use.
  2. Weapons were found in about 36 per cent of the labs in which children were present.
  3. There was a higher proportion of gang affiliation for labs in which children were present than in total meth labs (51% compared with 43%).
  4. Fires and explosions occurred in 16 labs between 2006 and 2010, two of which had children present.
  5. The percentage of labs in which children were living or present and in which one or more referrals were made to Child, Youth and Family increased from about 5 per cent in 2006 to 93 per cent in 2010.

A more detailed audit of police files from 2008-2009 gave an even more disturbing picture of the dangers children were exposed to.

  1. In 21 per cent of labs there was evidence that children were present during the manufacturing process.
  2. In 45 of 53 labs reviewed there was evidence of chemicals within reach of children.
  3. In 36 of 53 labs, chemicals were stored in food or drink containers. In one case, a child’s school drink bottle, complete with a name and school room number, was found to contain highly acidic chemicals.

Source: https://www.policeassn.org.nz/newsroom/publications/featured-articles/meth-kids March 2013 

Once you drop, you can’t stop – sometimes for up to 15 hours. Images revealing how LSD interacts with receptors in the brain could explain why a trip lasts so long, while another study involving a similar receptor unpicks how the drug makes these experiences feel meaningful.

LSD acts on with a number of different receptors in the brain, including ones for the chemicals serotonin and dopamine, but it’s not known exactly which receptors are responsible for its various effects. Daniel Wacker and his colleagues at the University of North Carolina, Chapel Hill, used crystallography to look at the structure of LSD when it binds to a receptor in the brain that normally detects serotonin. They discovered that part of this serotonin 2B receptor acts as a lid, closing around the LSD molecule and trapping it.

This could explain the extended trips the drug produces. “It takes LSD very long to get into the receptor, and once it’s stuck it doesn’t go away,” says Wacker.

However, there is conflicting evidence. Other studies have shown that LSD hangs around in the blood for a long time. “No prolonged action at the receptor is needed to explain the duration of action,” says Matthias Liechti at the University of Basel, Switzerland.

But if Wacker is right, the fact that LSD seems to get stuck inside the receptor might mean it can have effects at very low doses. In recent years, there have been reports of some people taking LSD in amounts too small to cause hallucinations, in an attempt to boost creativity or general well-being.

There’s little hard evidence about whether this microdosing works, but Wacker says psychoactive effects at low doses are plausible. “Our study suggests even very low amounts of LSD may be enough to cause psychoactive effects.” Scientific interest in LSD’s clinical use has revived in recent years – notably to relieve severe psychiatric conditions such as PTSD and anxiety. There are also signs that LSD has helpful non-psychoactive effects on other ailments, such as cluster headaches.

Suppressing bliss

A second study finds evidence that LSD affect the brain by binding to serotonin receptors, and hints at possible ways to harness some of its effects therapeutically. Katrin Preller and her colleagues at the University of Zurich, Switzerland, gave 22 volunteers 100 micrograms of LSD each to determine the role of the serotonin 2A receptor, which is similar to the one studied by Wacker’s team.

In some of the tests, subjects were also given ketanserin, a drug that blocks the serotonin 2A receptor. In those tests, the trippy effects of LSD – including hallucinations, feeling separate from the body, and feelings of bliss – were completely blocked, showing that this receptor must be responsible for them.

The researchers also played songs to the participants. Some of the songs were ones the volunteers had chosen as meaningful beforehand, while others were not. While on LSD, they rated what had been non-meaningful songs as highly meaningful – an effect that, once again, ketanserin blocked.

Preller thinks these findings suggest that the serotonin 2A receptor is important for how we decide which things are relevant to us. “This is something that’s incredibly important for our everyday life,” she says. “We do it constantly, for example if you see a familiar face.”

Some psychiatric conditions, such as schizophrenia and phobias, are associated with paying too much attention to unimportant stimuli. Preller speculates that LSD might help people refocus their attention in a different direction.

“If you have a depressed patient ruminating about negative thoughts, LSD might facilitate a process where you attribute meaning to other things,” says Preller.

Alternatively, people with these conditions might benefit from drugs that reduce the action of the serotonin 2A receptor, like ketanserin.

Source: Journal reference: Current Biology, DOI: 10.1016/j.cub.2016.12.030 Journal reference: Cell, DOI: 10.1016/j.cell.2016.12.033

Fentanyl is a painkiller that is 50 times stronger than heroin. It has already killed thousands, including Prince. Chris McGreal reveals why so many are playing Russian roulette with this lethal drug Natasha Butler had never heard of fentanyl until a doctor told her that a single pill had pushed her eldest son to the brink of death – and he wasn’t coming back. “The doctor said fentanyl is 100 times more potent than morphine and 50 times more potent than heroin. I know morphine is really, really powerful. I’m trying to understand. All that in one pill? How did Jerome get that pill?” she asked, her voice dropping to a whisper as the tears came. “Jerome was on a respirator and he was pretty much unresponsive. The doctor told me all his organs had shut down. His brain was swelling, putting pressure on to the spine. They said if he makes it he’ll be a vegetable.”

Painkiller addiction claims more lives in the US than guns, cutting across class, race and region

The last picture of Jerome shows him propped immobile in a hospital bed, eyes closed, sustained only by a clutch of tubes and wires. Natasha took the near impossible decision to let him die.  “I had to remove him from life support. That’s the hardest thing to ever do. I had him at 15 so we grew together. He was 28 when he died,” she said. “I had to let him die but after that I needed some answers. What is fentanyl and how did he get it?” That was a question asked across Sacramento after Jerome and 52 other people in and around California’s capital overdosed on the extremely powerful synthetic opioid, usually only used by hospitals to treat patients in the later stages of cancer, over a few days in late March and early April 2016. Twelve died.

Less than a month later, this mysterious drug – largely unheard of by most Americans – killed the musician Prince and burst on to the national consciousness. Fentanyl, it turned out, was the latest and most disturbing twist in the epidemic of opioid addiction that has crept across the United States over the past two decades, claiming close to 200,000 lives. But Prince, like almost all fentanyl’s victims, probably never even knew he was taking the drug.

“The number of people overdosing is staggering,” said Lieutenant Tracy Morris, commander of special investigations who manages the narcotics task force in Orange County, which has seen a flood of the drug across the Mexican border. “It is truly scary. They don’t even know what they’re taking.” The epidemic of addiction to prescription opioid painkillers, a largely American crisis, sprung from the power of big pharmaceutical companies to influence medical policy. Two decades ago, a small family-owned drug manufacturer, Purdue Pharma, unleashed the most powerful prescription painkiller yet sold over the pharmacist’s counter. Even though it was several times stronger than anything else on the market, and bore a close relation to heroin, Purdue claimed that OxyContin was not addictive and was safe to treat even relatively minor pain. That turned out not to be true.

It spawned an epidemic that in the US claims more lives than guns, cutting across class, race and geographic lines as it ravages communities from white rural Appalachia and Mormon Utah to black and Latino neighbourhoods of southern California. The prescription of OxyContin and other painkillers with the same active drug, oxycodone, became so widespread that entire families were hooked. Labourers who wrenched a back at work, teenagers with a sports injury, just about anyone who said they were in pain

was put on oxycodone. The famous names who ended up as addicts show how indiscriminate the drug’s reach was; everyone from politician John McCain’s wife Cindy to Eminem became addicted.

Clinics staffed by unscrupulous doctors, known as “pill mills”, sprung up churning out prescriptions for cash payments. They made millions of dollars a year. By the time the epidemic finally started to get public and political attention, more than two million Americans were addicted to opioid painkillers. Those who finally managed to shake off the drug often did so only at the cost of jobs, relationships and homes.

After the government finally began to curb painkiller prescriptions, making it more difficult for addicts to find the pills and forcing up black market prices, Mexican drug cartels stepped in to flood the US with the real thing – heroin – in quantities not seen since the 1970s. But, as profitable as the resurgence of heroin is to the cartels, it is labour intensive and time-consuming to grow and harvest poppies. Then there are the risks of smuggling bulky quantities of the drug into the US.

The ingredients for fentanyl, on the other hand, are openly available in China and easily imported ready for manufacture. The drug was originally concocted in Belgium in 1960, developed as an anaesthetic. It is so much more powerful than heroin that only small quantities are needed to reach the same high. That has meant easy profits for the cartels. The Drug Enforcement Administration (DEA) has said that 1kg of heroin earns a return of around $50,000. A kilo of fentanyl brings in $1m.

At first the cartels laced the fentanyl into heroin to increase the potency of low-quality supplies. But prescription opioid painkillers command a premium because they are trusted and have become increasingly difficult to find on the black market. So cartels moved into pressing counterfeit tablets.  But making pills with a drug like fentanyl is a fairly exact science. A few grammes too much can kill. “It’s very lethal in very small doses,” said Morris. “Even as little as 0.25mg can be fatal. One of our labs had a dime next to 0.25mg and you could barely see it. It’s about the size of the head of a pin. Potentially that could kill you.”

The authorities liken buying black market pills to playing Russian roulette. “These pills sold on the street, nobody knows what’s in them and nobody knows how strong they are,” said Barbara Carreno of the DEA.

After Prince died, investigators found pills labelled as prescription hydrocodone, but made of fentanyl, in his home, suggesting he bought them on the black market. The police concluded he died from a fatal mix of the opioid and benzodiazepine pills, a particularly dangerous combination. It is likely Prince did not even know he was taking fentanyl.  Others knowingly take the risk. In his long battle with addiction, Michael Jackson, used a prescription patch releasing fentanyl into his skin among the arsenal of drugs he was fed by compliant doctors. Although it was two non-opioids that killed him, adding fentanyl into the mix was hazardous.

Jerome Butler, a former driver for Budweiser beer who was training to be a security guard, thought he was taking a prescription pill called Norco. His mother’s voice breaks as she recounts what she knows of her son’s last hours. Natasha said she was aware he used cannabis, but had no idea he was hooked on opioid painkillers. She said her son at one time had a legitimate prescription and may have become addicted that way. She has since discovered he was paying a doctor, well known for freely prescribing opioids, to provide pills.  “I didn’t even know,” she said. “You find stuff out after. It’s killing me because they’re saying, ‘Well, yeah, Jerome was taking them pills all the time.’ And I’m like, ‘He was doing what?’”

Jerome may have had a prescription, but like many addicts he will have needed more and more. The pill that killed him was stamped M367, a marking used on Norco pills made of an opioid, hydrocodone. It was a fake with a high dosage of fentanyl.   This is fentanyl. The first time you take it you’re not coming back. You’re gone

“If Jerome had known it was fentanyl he would never have took that,” said Natasha. “This ain’t like crack or a recreational drug that people been doing for so many years and survived it but at 60 or 70 die from a drug overdose because their heart can’t take it no more. This is fentanyl. The first time you take it you’re not coming back. You’re gone.”

That wasn’t strictly true of the batch that hit Sacramento. It claimed 11 other lives. The youngest victim was 18-year-old George Berry from El Dorado Hills, a mostly white upscale neighbourhood. The eldest was 59. But others survived. Some were saved by quick reactions; doctors were able to hit them with an antidote before lasting damage was done. Others swallowed only enough fentanyl to leave them seriously ill but short of death.

It was a matter of luck. When investigators sent counterfeit pills seized after the Sacramento poisonings for testing at the University of California, they found a wide disparity in the amount of fentanyl each contained. Some pills had as little as 0.6mg. Others were stuffed with 6.9mg of the drug, which would almost certainly be fatal. The DEA thinks the difference was probably the result of failing to mix the ingredients properly with other powders, which resulted in the fentanyl being distributed unevenly within a single batch of counterfeit pills.

That probably explains the unpredictable mass overdosing popping up in cities across the US. In August, 174 people overdosed on heroin in six days in Cincinnati, which has one of the fastest-growing economies in the Midwest. Investigators suspect fentanyl because the victims needed several doses of an antidote, Naloxone, where one or two will usually suffice with heroin. The same month, 26 people overdosed on fentanyl-laced heroin in a four-hour period in Huntington, a mostly white city in one of the poorest areas of West Virginia. In September seven people died from fentanyl or heroin overdoses in a single day in Cuyahoga County, Ohio.

The US authorities don’t know for sure how many people fentanyl kills because of the frequency with which it is mixed with heroin, which is then registered as the cause of death. The DEA reported 700 fatalities from fentanyl in 2014 but said it is an underestimate, and rising. In 2012, the agency’s laboratory carried out 644 tests confirming the presence of fentanyl in drug seizures. By 2015, the number of positive tests escalated to 13,002.

The police did not have to look far for the source of the drug that killed Jerome. He and his girlfriend were staying at the house of her aunt, Mildred Dossman, while they waited for their own place to live. Jerome was smoking cannabis and drinking beer with Dossman’s son, William. Shortly before 1am, William went to his mother’s bedroom and came back with the fake Norco pill. Jerome took it and said he was going to bed.  Jerome’s girlfriend was in jail after being arrested for an unpaid traffic fine and so he was alone with their 18 month-old daughter, Success, lying next to him.

“The doctors explained to me that within a matter of minutes he went into cardiac arrest,” said his mother. “Then as he lay there that’s when time progressed for the organs to be poisoned by fentanyl. He was dying with his daughter next to him.” Natasha said other people in the house heard her son in distress, complaining his heart was hurting. But they did nothing because they were afraid that calling an ambulance would also bring the police.

It was not until 10 hours later that the Dossmans finally sought help from a neighbour who knew Jerome. He tried CPR and then called the medics. The police came, too, and in time Mildred Dossman, 50, was charged with distributing fentanyl and black market opioid painkillers. She was the local dealer.

The DEA is tightlipped about the investigation into the Sacramento deaths as its agents work on persuading Dossman to lead them to her suppliers. But it is likely she was getting the pills from Mexican cartels using ingredients from labs in China where production of fentanyl’s ingredients is legal.  Carreno said some Mexican cartels have long relationships with legitimate Chinese firms which for years supplied precursor chemicals to make meth amphetamine.

Packages of fentanyl are often moved between multiple freight handlers so their origins are hard to trace. Larger shipments are smuggled in shipping containers. Last year, six Chinese customs officials fell ill, one of them into a coma, after seizing 72kg of various types of fentanyl from a container destined for Mexico. American police officers have faced similar dangers. In June, the DEA put out a video warning law enforcement officers across the US that fentanyl was different to anything they have previously encountered and they should refrain from carting seizures back to the office.   “A very small amount ingested, or absorbed through the skin, can kill you,” it said.   A New Jersey detective appears in the video after accidentally inhaling “just a little bit of fentanyl puffed into the air” during an arrest: “It felt like my body was shutting down… I thought that was it. I thought I was dying.”

Along with the Mexican connection, a home-grown manufacturing industry has sprung up in the US. Weeks after Jerome died, agents arrested a married couple pressing fentanyl tablets in their San Francisco flat.

Candelaria Vazquez and Kia Zolfaghari made the drug to look like oxycodone pills. They sold them across the country via the darknet using Bitcoin for payment – on one occasion Zolfaghari cashed in $230,000. The couple shipped the drugs through the local post office. Customers traced by the DEA thought they were buying real painkiller pills. The couple ran the pill press in their kitchen. According to a DEA warrant, a dealer said Zolfaghari made large numbers of tablets: “He could press 100 out fast as fuck.”

The pair made so much money that agents searching their flat found luxury watches worth $70,000, more than $44,000 in cash and hundreds of “customer order slips” which included names, amounts and tracking numbers. The flat was stuffed with designer goods. The seizure warrant described Vazquez’s shoe collection as “stacked virtually from floor to ceiling”. Some still had the $1,000 price tags on them. Zolfaghari was arrested carrying a 9mm semi-automatic gun and about 500 pills he was preparing to post. The dealers made so much money that their flat was stuffed with luxury goods and cash.

Even as Americans are getting their heads around fentanyl, it is being eclipsed. In September, the DEA issued a warning about the rise of a fentanyl variant that is 100 times more powerful – carfentanil, a drug used to tranquilise elephants.

“Carfentanil is surfacing in more and more communities,” said the DEA’s acting administrator, Chuck Rosenberg. “We see it on the streets, often disguised as heroin. It is crazy dangerous.”

The drug has already been linked to 19 deaths in Michigan. Investigators say that with its use spreading, it is almost certainly claiming other lives. Dealers are also getting it from China, where carfentanil is not a controlled drug and can be sold to anyone.

Natasha Butler is still trying to understand the drug that killed her son. She wants to know why it is that it took Jerome’s death for her to even hear of it. She accuses the authorities of failing to warn people of the danger, and politicians of shirking their responsibilities.   A bill working its way through California’s legislature stiffening sentences for fentanyl dealing died in the face of opposition from the state’s governor, Jerry Brown, because it would put pressure on the already badly crowded prisons.

“I’m so dumbfounded. How does that happen?” says Natasha. Her tears come frequently as she sits at a tiny black table barely big enough to seat three people. She talks about Jerome and the tragedy for his three children, including Success, who she is now raising.

But some of the tears are to mourn the devastating impact on her own life. “Look where I’m at. I was in Louisiana. I had a house. I had a job. I had a car. I had a life. I worked every day. I was a manager for a major company. I came here, I became homeless. I had to move into this apartment to help out my granddaughter,” she said. “You see me. This is what my kitchen table is. My son is dead. He had three kids and those two mothers of those kids are depending on me to be strong. I want answers and help. I say, you got the little fish. Where did they get it from? How did they get it here? You are my government. You are supposed to protect us.”

Source:  https://www.theguardian.com/global/2016/dec/11/pills-that-kill-why-are-thousands-dying-from-fentanyl-abuse–

There’s a new drug in town.

It’s called Shatter and it looks like dark-amber toffee. It’s THC, the chemical that causes the high in marijuana, extracted from the plant and has highly addictive qualities, said Stratford police Insp. Sam Theocharis.

It’s been around for a while but it’s new to Stratford, Theocharis said.  Police have started to see the drug a bit more frequently and wanted to get the message out to the public.

“When you look at it, it just looks like goo but it’s a new form of marijuana drug,” he said.

Shatter is clear, smooth and solid. It can consist of more than 80% THC, according to the High Times website.

Police seized some Tuesday along with methamphetamine, cocaine, marijuana and prescription drugs after an investigation by the Street Crime Unit.  Two men in their 40s were arrested and face several charges including possession for the purpose of trafficking. The drugs seized are valued at more than $1,500. Cell phones, scales and baggies were also seized, police said.

Shatter sells for about $100 a gram on the streets. It’s dangerous and often leads to overdose, police said.  Whether it will overshadow crystal meth and oxycodone in popularity has yet to be seen.

“I can’t predict but anything that gives you a better high is going to be sought after,” Theocharis said.

Source: http://www.stratfordbeaconherald.com/

 

President Obama this week told an audience in Jamaica that U.S. efforts against illegal drugs were “counterproductive” because they relied too much on incarceration—particularly for “young people who did not engage in violence.”

In what the president termed “an experiment … to legalize marijuana” in Colorado and Washington state, he said he believed they must “show that they are not suddenly a magnet for additional crime, that they have a strong enough public health infrastructure to push against the potential of increased addiction.”

In regard to Jamaica and the entire Caribbean and Central American region, he said, “a lot of folks think … if we just legalize marijuana, then it’ll reduce the money flowing into the transnational drug trade, there are more revenues and jobs created.”

To some of us, Jamaica hardly seems an auspicious location for encouraging “experimentation” with drugs, in particular because of the challenges already faced by their deficient institutions of public health and criminal justice. The U.S. Department of State 2015 International Narcotics Control Strategy Report(INCSR) states:

Jamaica remains the largest Caribbean supplier of marijuana to the United States and local Caribbean islands. Although cocaine and synthetic drugs are not produced locally, Jamaica is a transit point for drugs trafficked from South America to North America and other international markets. In 2014, drug production and trafficking were enabled and accompanied by organized crime, domestic and international gang activity, and police and government corruption. Illicit drugs are also a means of exchange for illegally-trafficked firearms entering the country, exacerbating Jamaica’s security situation.

Drugs flow from and through Jamaica by maritime conveyance, air freight, human couriers, and to a limited degree by private aircraft. Marijuana and cocaine are trafficked from and through Jamaica into the United States, Canada, the United Kingdom, Belgium, Germany, the Netherlands, and other Caribbean nations. Jamaica is emerging as a transit point for cocaine leaving Central America and destined for the United States, and some drug trafficking organizations exchange Jamaican marijuana for cocaine. . . .

The conviction rate for murder was approximately five percent, and the courts continued to be plagued with a culture of trial postponements and delay. This lack of efficacy within the criminal courts contributed to impunity for many of the worst criminal offenders and gangs, an abnormally high rate of violent crimes, lack of cooperation by witnesses and potential jurors, frustration among police officers and the public, a significant social cost and drain on the economy, and a disincentive for tourism and international investment.

This does not seem like a place where “legal” marijuana would contribute to “reduced money flow” to the transnational drug trade, or “create jobs.”  The president apparently thinks Jamaica should consider allowing more drugs, based on a faulty understanding of what is actually happening in Jamaica and in the U.S.

His charge of high incarceration rates for non-violent offenders is not factual. For instance, data show that only a fraction of one percent of state prison inmates are low-level marijuana possession offenders, while arrests for marijuana and cocaine/heroin possession and use were no more than 7 percent of all arrests,nationwide, in 2013.

Though critics of drug laws claim that hundreds or even thousands of prisoners are low-level non-violent offenders unjustly sentenced, the reality was shown recently by the President’s inability to find more than a  of incarcerated drug offenders who would be eligible for  of their sentence because they fit the mythological portrait of excessive or unjust drug sentences.

Further, since 2007, the US is currently experiencing a surge in daily marijuana use, an epidemic of heroin overdose deaths (with minorities hardest hit), while the southwest border is flooded with heroin and methamphetamine flow, as shown by skyrocketing border seizures.

Importantly, Colorado, following marijuana “legalization,” has become a black-market magnet, and is currently supplying marijuana, including ultra-high-potency “shatter” to the rest of the U.S., leading to law suits by adjacent states. Legalization 

As for Central America, Obama’s policies have shown stunning neglect. Actual aid for counter-drug activities, and for resources for interdicting smugglers have all diminished, while the countries of Central America have become battlegrounds for Mexican cartels, with meth precursors piling up at the docks, the cocaine transiting Venezuela to Honduras is surging, and violence is at an all-time high, with families fleeing north in unprecedented numbers. The Caribbean/Central American region has become deeply threatened, as noted by the State Department report above—torn apart by drug crime.

In this context the president encourages governments in the region to make drugs more acceptable and more accessible in their communities, and with even greater legal impunity?

Moreover, these developments have been accompanied by a steady drumbeat of medical science  increasingly showing the serious dangers of marijuana use, especially for youth.   Yet President Obama speaks in a manner increasingly disconnected from the domestic and international reality of the drug problem.

Source:  David W. Murray and John P. Walters  WEEKLY STANDARD  April 11, 2015

I K Lyoo, S Yoon, T S Kim, S M Lim, Y Choi, J E Kim, J Hwang, H S Jeong, H B Cho, Y A Chung and P F Renshaw

Abstract

Adolescence is a period of heightened vulnerability both to addictive behaviors and drug-induced brain damage. Yet, only limited information exists on the brain mechanisms underlying these adolescent-specific characteristics. Moreover, distinctions in brain correlates between predisposition to drug use and effects of drugs in adolescents are unclear.

Using cortical thickness and diffusion tensor image analyses, we found greater and more widespread gray and white matter alterations, particularly affecting the frontostriatal system, in adolescent methamphetamine (MA) users compared with adult users.

Among adolescent-specific gray matter alterations related to MA use, smaller cortical thickness in the orbitofrontal cortex was associated with family history of drug use. Our findings highlight that the adolescent brain, which undergoes active myelination and maturation, is more vulnerable to MA-related alterations than the adult brain.

Furthermore, MA-use-related executive dysfunction was greater in adolescent MA users than in adult users. These findings may provide explanation for the severe behavioral complications and relapses that are common in adolescent-onset drug addiction. Additionally, these results may provide insights into distinguishing the neural mechanisms that underlie the predisposition to drug addiction from effects of drugs in adolescents.

Source:  Molecular Psychiatry , (10 February 2015) | doi:10.1038/mp.2014.191

It’s not often that Sherwood, Oregon – a small, quiet suburb located southwest of Portland – makes the front page news – especially for stories related to drugs.  But it did the first weekend of February 2014, when two teenage girls ended up in the hospital after using a dangerous and relatively new designer drug.  The drug – officially known as 25i-NBOMe – is most commonly referred to as simply “25I” or “N-Bomb”.  “Smiles” is another nickname for N-Bomb and other closely related substances.

Fortunately for the Oregon teens, an off-duty deputy sheriff spotted them on the roadside as one of the girls was having a seizure.  He stopped and called an ambulance, only to have the other girl soon start seizing as well.  These girls survived, but several other teens experimenting with the deadly LSD-like drug haven’t been as lucky.  It’s been estimated that at least 19 deaths in the past couple of years are linked to the drug, including:

* June 2012 – The death of North Dakota teen Christian Bjerk, who was found lying dead on the ground after a fatal reaction to 25I [1].

 

* June 2012 – The death of 17-year-old Elijah Stai, who stopped breathing and ended up on life support after ingesting 25I mixed with chocolate.  The Minnesota teen died 3 days later, when his parents made the gut-wrenching decision to take him off life support [1].

* October 2012 – The death of a 21-year-old Arkansas male, who reportedly used N-Bomb intranasally.

* January 2013 – The death of Noah Carrasco, an 18-year-old Scottsdale, Arizona high school student.  He quickly lost consciousness after taking the deadly drug via nose drops that he thought contained LSD [2].

* April 2013 – The death of an 18-year-old student attending Arizona State University, believed to be caused by the designer drug N-Bomb [3].

* June 2013 – The death of 17-year-old Henry Kwan of Sydney, Australia, who threw himself out of a window and fell to his death after taking N-Bomb [4]

* September 2013 – The death of a 17-year-old high school student in Pennsylvania.  An overdose of the drug caused him to stop breathing, reportedly resulting in his death [5].

* February 2014 – The death of Jake Harris, a 21-year-old U.K. lifeguard and father-to-be.  Harris reportedly stabbed himself in the neck multiple times with broken glass after taking the drug [6]

 

Needless to say, the drug has the authorities – as well as many parents – very concerned.  One of the biggest problems is that the drug is often sold as LSD.  Although it’s similar to LSD in many ways, its effects can be significantly more dangerous.

 

Legal Issues Unfortunately, designer drugs often slip through the cracks in terms of drug enforcement, making them legal until deemed otherwise by the authorities.  With regards to N-Bomb, which had previously been legal, the fatalities linked to its use resulted in the Drug Enforcement Administration classifying it as a Schedule I controlled substance in October 2013.  The authorities have not been lenient with those individuals who either sold or supplied the drug to those who have suffered or died from its effects.

In the case of the two girls from Oregon, an adolescent boy was taken into custody for allegedly supplying them with the drug.  A total of 15 individuals have been charged in connection to the deaths of Elijah Stai and Christian Bjerk, a law-enforcement endeavor that’s been aptly dubbed “Operation Stolen Youth”.  Adam Budge, the 18 year-old friend who gave the drug to Stai, is facing murder charges for his death.  Charles Carlton, a 29-year-old man from Katy, Texas, pleaded guilty to numerous charges related to the two teens’ deaths, including possession with intent to distribute.  He had sold the deadly drugs via his online business, Motion Resources [7].

Potent Hallucinogen

N-Bomb is a hallucinogenic designer drug that is often likened to LSD, although some say that it’s up to 25 times more potent.  Designer drugs are synthetically produced by altering the chemical structure of existing drugs, like cocaine or marijuana.  They are meant to be used recreationally, and mimic the effects of the other drugs.  N-Bomb is actually derived from phenethylamine, commonly known as mescaline.  Mescaline is a natural substance found in the peyote cactus.  Mescaline’s use as a recreational drug became illegal in the U.S. in 1970, due to its psychedelic properties.

N-Bomb and other hallucinogens are known for causing powerfully altered perceptions, including brightly colored and widely distorted visual images.  Some users of the drug have described its effects as “Nirvana” and “ecstasy”, reporting “trips” very similar to those experienced with LSD.  As is typically the case with psychedelics, the unpredictable effects of N-Bomb have varied widely from one individual to the next.

Pleasurable effects of N-Bomb may include:

* Euphoria

* Bright moving colors and other vivid visual hallucinations

* Spiritual “awakening”

* A sense of profoundness

* Positive mood

* Enhanced awareness

* Enhanced creativity

* Loving feelings

* Sexual sensations and enhanced desire

Side effects of N-Bomb may include:

* Psychosis

* Altered state of consciousness

* Agitation

* Erratic behavior

* Chills, flushing

* Severe double vision

* Teeth grinding, jaw clenching

* Dilated pupils

* Depressed mood

* Confusion

* Nausea

* Intense negative emotions

* Paranoia

* Intense anxiety

* Muscle spasms and contractions

* Insomnia

* Impaired communication

* Vasoconstriction

* Swelling of feet, hands, face

* Kidney damage / failure

* Seizures

* Heart failure

* Coma

* Asphyxiation

How N-Bomb Is Used

N-Bomb or 25I is often sold on strips of blotter paper, which is one of the reasons users often erroneously assume it’s LSD.  The strip of paper is placed under the tongue, which allows the drug to enter the bloodstream sublingually. N-Bomb is also available as a powder.  Users can snort the powder like cocaine, smoke it, or mix it with a liquid and inject it like heroin.   Some users combine it with water in a nasal spray bottle to administer via the nose.  Vaporizing and then inhaling the drug is another method of administration used by some, but it makes controlling the dose very precarious.

When the drug is taken orally or sublingually, the effects generally last between 6 and 10 hours.  Those who inhale or snort the drug will generally experience its effects for a shorter period, ranging from 4 to 6 hours.  This can vary though, depending on the amount used.  When the substance is vaporized and then inhaled, the effects may kick in much more quickly but not last as long.

Dosing N-Bomb

A typical dose of N-Bomb is somewhere between 600 and 1200 micrograms.  Because the doses are so tiny (1 gram is the equivalent of 1,000,000 micrograms), it’s often very difficult to measure a dose accurately.  This is why users have a high risk of accidentally overdosing on the drug [8].

Multiple Concerns Arise About N-Bomb

Like so many designer drugs – particularly newer ones – N-Bomb isn’t fully understood.  It’s been on the street for less than 5 years, and it was discovered in a lab just 11 years ago.  So the full and long-term effects are not yet known.  What little information we do have is primarily from those who have had a bad reaction to the drug or died from it. Also, like other designer drugs and street drugs in general, there’s no way of knowing exactly what you’re getting.  It’s not at all uncommon for these substances to have other substances added in – making them even more dangerous than ever for users who don’t know what they’re getting.   Dealers often sell them under false names, like LSD.  After all, it’s a hallucinogenic drug with similar effects used in a similar manner.  No big deal…to them.

Information For Parents

If you’re the parent of a teen, it’s important to be aware of drugs in general, but especially designer drugs like N-Bomb.  First, these drugs are more readily available than you might realize.  Since new designer drugs are being created and coming available practically daily, they

slip through the cracks legally (at least for a while) so they’re much easier for teens to obtain.  Many are sold online or by friends or acquaintances.

Second, they’re appealing to many teens because they’re “exciting” and “cool”. They may rationalize that since it’s not a “real” drug, like cocaine or methamphetamine, it’s safe (or at least safer) to try.  And of course, their peers will often try to convince them that these drugs are harmless fun.  On top of that, teens tend to be reckless.  They tend to still perceive themselves as invincible, and often don’t consider the potential long-term consequences of their behavior.  Even when the risks are presented, teens often ignore them – much the same way they roll their eyes when reminded ad nauseam that drinking and driving is very dangerous or that wearing seatbelts saves lives.

Still, it’s vital to talk to your teen about N-Bomb and other designer drugs.  Strive to maintain good communication with him or her, and make sure your teen knows (both by your words AND your actions) that you genuinely care and that your door is always open, so to speak. If you do think your teen is using N-Bomb or any other drugs – including illegitimate prescription drugs, designer drugs, and regular street drugs – have a conversation as soon as possible.  Don’t ignore it.  Don’t minimize it.  Don’t assume that experimenting with drugs is just a normal part of adolescence.  Take it very seriously.  Consider setting up an appointment for an evaluation with an addiction specialist to determine if drug rehab is necessary.  Your teen may resent you, but a dead teen will never have the opportunity to appreciate how much you really do care.

Source:  addictiontreatmentmagazine.com  21st April 2014

Resources:

[1] http://www.houstonpress.com/2013-03-14/news/motion-research-charles-carlton/

[2] http://www.usatoday.com/story/news/nation/2013/05/04/n-bomb-drug-stirs-fear/2135407/

[3] http://www.azcentral.com/news/arizona/articles/20130503phoenix-area-n-bomb-drug-stirs-fear.html

[4] http://www.theaustralian.com.au/news/features/high-alert-why-synthetic-drugs-are-so-hard-to-police/story-e6frg8h6-1226673596866

[5] http://www.abc27.com/story/23605144/deadly-drug-n-bomb-claims-teens-life

[6] http://www.dailymail.co.uk/news/article-2552893/Lifeguard-stabbed-neck-taking-former-legal-high-N-bomb-hallucinating-tried-stop-effect-drug.html

[7] http://www.chron.com/neighborhood/katy/crime-courts/article/Katy-man-pleads-guilty-in-multi-state-drug-ring-5305077.php

[8] healthandwelfare.idaho.gov

Youngsters exposed to methamphetamine before birth had increased cognitive problems at age 7.5 years, highlighting the need for early intervention to improve academic outcomes and reduce the potential for negative behaviors. The researchers studied 151 children exposed to methamphetamine before birth and 147 who were not exposed to the drug. They found the children with prenatal methamphetamine exposure were 2.8 times more likely to have cognitive problem scores than children who were not exposed to the drug.

In the only long-term, National Institutes of Health-funded study of prenatal methamphetamine exposure and child outcome, researchers found youngsters exposed to the potent illegal drug before birth had increased cognitive problems at age 7.5 years, highlighting the need for early intervention to improve academic outcomes and reduce the potential for negative behaviors, according to the study published online by The Journal of Paediatrics.

The researchers studied 151 children exposed to methamphetamine before birth and 147 who were not exposed to the drug. They found the children with prenatal methamphetamine exposure were 2.8 times more likely to have cognitive problem scores than children who were not exposed to the drug in a test often used for measuring cognitive skills, the Connors’ Parents Rating Scale.

“These problems include learning slower than their classmates, having difficulty organizing their work and completing tasks and struggling to stay focused on their work,” said Lynne M. Smith, MD, a lead researcher at the Los Angeles Biomedical Research Institute (LA BioMed) and corresponding author of the study. “All of these difficulties can lead to educational deficits for these children and potentially negative behavior as they find they cannot keep up with their classmates.”

Methamphetamine use among women of reproductive age is a continuing concern, with 5% of pregnant women aged 15-44 reporting current illicit drug use. Methamphetamine usage during pregnancy can cause a restriction of nutrients and oxygen to the developing fetus, as well as potential long-term problems because the drug can cross the placenta and enter the fetus’s bloodstream.

Previous research in Sweden found evidence of lower IQ scores, decreased school performance and aggressive behavior among children with prenatal methamphetamine exposure. The study tracked the children through age 15, but it didn’t compare them to children who had no prenatal methamphetamine exposure.

Researchers at LA BioMed and in Iowa, Oklahoma and Hawaii — all places where methamphetamine usage is prevalent — have been tracking children who were not exposed to the drug and children with prenatal methamphetamine exposure since 2002, as part of the Infant Development, Environment and Lifestyle (IDEAL) Study. This study, which is the only prospective, longitudinal National Institutes of Health study of prenatal methamphetamine exposure and child outcome, was conducted under the auspices of Principal Investigator Barry M. Lester, PhD, at Women & Infants Hospital of Rhode Island.

“By identifying deficits early in the child’s life, we can intervene sooner and help them overcome these deficits to help them have greater success in school and in life,” said Dr. Smith. “Through the IDEAL Study, we are able to track these children and better understand the long-term effects of prenatal methamphetamine exposure.”

Source: Effects of Prenatal Methamphetamine Exposure on Behavioral and Cognitive Findings at 7.5 Years of Age.  The Journal of Pediatrics,    March  2014 

Purdue Pharma L.P. will present a poster describing the changes in abuse of OxyContin® and immediate-release oxycodone in rural Kentucky following the August 2010 introduction of reformulated OxyContin. This data is composed of follow-up interviews with a cohort of individuals in Kentucky who self-identified as original OxyContin abusers and will be presented at the College on Problems of Drug Dependence (CPDD) 75th Annual Meeting June 15 to 20 in San Diego.

Details of the scheduled poster presentation follows:

* Monday, June17, 8:00-10:00 a.m. PDT,  Poster No. 73

* “Abuse of OxyContin and immediate-release (IR) oxycodone in a rural Kentucky county following introduction of reformulated OxyContin – results from 6-month follow-up interviews” A. DeVeaugh-Geiss, C. Leukefeld, J. Havens, H. Kale, P. Coplan, H. Chilcoat

Study participants (individuals that reported abuse of original OxyContin prior to the reformulation) were initially interviewed about their drug use before and after the introduction of reformulated OxyContin, followed by six-month follow-up interviews.

Among the 164 participants who completed the 6-month follow-up interviews, 76 percent selected original OxyContin as their preferred drug prior to the reformulation.  In contrast, 66 percent of this population selected immediate-release oxycodone as their preferred drug after the reformulation; only one participant selected reformulated OxyContin as his or her preferred drug.

In follow-up interviews, 23 percent of participants reported attempting to manipulate the reformulated OxyContin for purposes of abuse.

From the initial interviews following the reformulation to the 6-month follow-up, the overall prevalence of original OxyContin abuse declined from 60 percent to 11 percent, and the overall frequency of abuse among those who abused declined from 11.3 days per month to 3.3 days per month.

During the same time period, prevalence of reformulated OxyContin abuse declined from 33 percent to 18 percent, while frequency among those who abused remained stable at 5.9 days per month vs. 5.7 days per month.

A decline in the prevalence of immediate-release oxycodone abuse, from 96 percent to 85 percent, also was observed during this time, while the frequency of abuse remained relatively constant.

Some abuse of OxyContin continued, and further research is necessary to determine whether similar effects are observed in other populations that abuse or misuse OxyContin.

The research was funded by Purdue Pharma L.P.

Source:  www.new.gnom.es   San Diego 17th June 2013

Drug traffickers in the central city of Da Nang have switched their focus on methamphetamine and heroin from opium and marijuana over the last two years, a senior police officer told a press conference on drug prevention on Friday.

Lieutenant colonel Nguyen Xuan Cuong, Deputy Head of Counter Narcotics Office under the city’s Public Security Department, said the number of traffickers caught with methamphetamine in 2012 was seven times more than the amount in 2011.

Cuong added the city’s narcotics police force last year arrested a total of 128 drug offenders with 921.4 grams of methamphetamine, 54 grams of heroin and 133.6 grams of marijuana extracts.

A report at the conference shows there are an estimated 1,500 addicts and drug users at rehabilitation centers across the city.

Source: www.tuoitrenews.vn   16th June 2013

 

Not many of us are chemists. Yet by removing one oxygen atom average people here in Missouri regularly are turning common decongestants like Sudafed and Claritin-D into the illicit drug methamphetamine. Nationwide those explosive mom and pop meth labs were estimated by a Rand study to cost taxpayers more than $23 billion a year in health care costs, child endangerment and clean-up. But as St. Louis Public Radio’s Maria Altman reports a local pharmaceutical company may have the answer.

In a non-descript office building in suburban St. Louis a little company was busy developing big technology; a binding agent to make a tamper-resistant drug. They weren’t yet sure exactly what drug Westport Pharmaceuticals they would tackle. Paul Hemings is the General Manager and Vice President of the Highland Pharmaceuticals subsidiary. He says looking back, it was staring them in the face.

“It started with our patent attorney who also has a chemistry background and lives out in Pacific where this meth problem is huge and one day she just mentioned ‘have you thought about this?” That is how to prevent pseudoephedrine, a common ingredient in nasal decongestants, from being turned into methamphetamine. Zephrex-D was the result.

How It Works

Hemings points out the pills’ waxy white coating. He says the new drug works just as well as other pseudoephedrine products, but meth cooks can’t extract the key ingredient. That means they can’t make meth. “We can end meth labs in the U.S. starting right here in our backyard where the problem is the biggest,” Hemings said. Last year alone law enforcement seized more than 1,800 clandestine labs in Missouri, the most of any state in the country. Detective Sgt. Jason Grellner is with the Franklin County Narcotics Enforcement Unit and is considered the expert on Missouri’s meth lab epidemic.Grellner says he was skeptical of Zephrex-D after years of being told by large pharmaceutical companies that a tamper-resistant drug couldn’t be made.

Now he says he’s a believer. “I’ve seen the testing by independent laboratories; I’ve personally tested the product in a one-pot meth lab setting; and I know of other testing that has been done,” he said. “They have manufactured a product that is meth lab resistant.”

Requiring A Prescription?

Grellner doesn’t expect “big pharma,” as he calls it, to change their pseudoephedrine products, at least not yet. He says for now the best way to keep the pills that still can be converted into meth away from criminals is to require prescriptions. “They have manufactured a product that is meth lab resistant.” – Detective Sgt. Jason Grellner

That faces strong opposition, including from the St. Louis Chapter of the Asthma and Allergy Foundation. “We do know that meth is a terrible problem in Missouri, we just disagree on how to take care of this,” said Joy Krieger, the foundation’s executive director and a registered nurse. Krieger says they support a proposed law to further limit the amount of pseudoephedrine people can buy each month, but she says getting a prescription is an expensive hassle. “Pseudoephedrine is safe for those purchasing it for proper reasons, so penalizing

residents and citizens who have done nothing wrong we think is not a fair way to look for a solution,” she said.

The Legal Perspective

State Representative Jeff Roorda has sponsored legislation for the state-wide prescription law every year since 2005. The Democrat from Jefferson County, the heart of Missouri’s meth country, says with Zephrex-D, there is a good alternative available for cold and allergy sufferers, so there can be no more excuses. “Now we have a pseudoephedrine that’s incapable of being converted into methamphetamine, I mean arguments against this just hold absolutely no water anymore,” Roorda said. The impact of Zephrex-D remains to be seen.

Westport Pharmaceuticals officials say they’re open to selling their binding technology to other drug-makers. Right now Zephrex-D is only available in Missouri and the Metro East. Officials say they plan a national roll-out this summer.


Source: http://www.news.stlpublicradio.org 13th March

 

 

The two pals are believed to have taken deadly GBL, a solvent found in paint strippers and chillingly known on the club scene as “coma in a bottle”

A heartbroken mum yesterday warned that Britain faces a new epidemic after banned party drug GBL was blamed for killing two friends within hours.

Carl Fearon, 24, was found dead at his flat at about 1pm on Saturday afternoon.

Just eight hours later, mum-of-one Lynette Nock, 28, died at a memorial wake held by his friends.

The two pals are believed to have taken deadly GBL, a solvent found in paint strippers and chillingly known on the club scene as “coma in a bottle”.

The tragedy comes exactly three years after medical student Hester Stewart, 21, was found dead at a house in Brighton after a party.

Police found a bottle of GBL next to her body.

Hester’s mum Maryon Stewart, who went on to launch drug awareness charity the Angelus Foundation, said yesterday: “They are not drugs, they are chemicals and when you take them you’re playing Russian Roulette with your life.

But you can’t control something like paint stripper because it has legitimate uses. When you ban one of these things probably a dozen others pop up to replace it.

“Last year 49 new substances appeared and no one really knows what’s in them. This is a major epidemic.

 “The Home Office should be taking responsibility to protect young people and raise awareness. There were directives from Europe 18 months before Hester died but nothing was done.’

 “Sadly, the message has still not filtered through and the same thing has happened and I’m deeply saddened.”

Electrical engineer Carl was found dead at his flat in Birmingham . Friends said he collapsed after taking GBL the previous night.

When word of his death spread, pals hosted a wake at a house in the city on Saturday night at which accountant Lynette collapsed.

Neighbour Emma Heath, 24, said: “I heard they put it in a Fanta bottle and several of them ended up being taken to hospital.” Lynette’s heartbroken father Dave, 69, yesterday paid tribute to his daughter and called for something to be done about GBL, describing it as “a lethal drug, a killer”. He says he fears Lynette’s drink may have been spiked, adding: “If Lynette had GBL in her system, did she and the others at that party ingest it without knowing what they were taking? Was it that their drink was spiked? From what I’ve read, this GBL has no taste and no smell.”

Det Insp Andy Hawkins said: “We believe the controlled substance Gamma-Butyrolactone, or GBL, may have been used as a drug at the gathering.” A spokesman for drugs charity FRANK said: “GBL is a dangerous drug with sedative and anaesthetic effects that can produce feelings of euphoria and can cause drowsiness. “It can kill.”

“It can do almost anything”: Analysis by drugs policy expert Dr Jonathan Cave

THE body converts GBL to date rape drug GHB, and because of how it is converted, GBL takes effect more quickly. It’s often advertised as a nutritional supplement but is harmful. GBL is unpredictable because it can do almost anything. It can have a mild effect, give people a headache or in some cases do a lot worse. It’s not directly toxic but the people to whom it is toxic won’t know until they take it. Some get addicted and take it 24 hours a day.

GBL, or Gamma-Butyrolactone, is known as “coma in a bottle”. It is used as paint stripper and was banned for consumption in 2009.

GBL is odourless and tasteless when diluted and is sold online for as little as 50p a shot.

The effect is similar to ecstasy but there is a high risk of overdosing.  Some users say it feels as if their muscles are being torn apart.  Medics say it kills six a year, damages organs and leads to psychosis.  It is related to banned date rape drug GHB.

Source:  www.Mirror.co.uk  2 May 2012

 

 


 

TORONTO, Nov. 2 — Methamphetamine can be detected in the hair of newborns whose mothers used the drug during pregnancy, researchers here have found.

Action Points

Note that this study shows that methamphetamine used during pregnancy can be found in the hair of neonates, suggesting it crosses the placental barrier with effects that are not completely understood.

Advise patients who ask that drug abuse during pregnancy can be detrimental to the fetus, with a range of physical and intellectual sequelae, as well as hazardous to the mother.

It represents the first direct evidence in humans that crystal meth, which is a growing drug-abuse problem in North America, can cross the placenta and affect the growing fetus, according to Facundo Garcia-Bournissen, M.D., of the Motherisk program at the Hospital for Sick Children.
Researchers at the program have been testing hair samples from parents and adults across Canada for several years, usually when there is clinical suspicion of drug abuse on the part of parents, Dr. Garcia-Bournissen and colleagues reported in the online issue of Archives of Disease in Childhood.
From June 1997 through December 2005, the database accumulated results of 34,278 tests for drugs in hair, representing 8,270 people. Nearly 60% (or 4,926) of these people were positive for at least one drug of abuse, the researchers said.
In a retrospective analysis, Dr. Garcia-Bournissen and colleagues examined the incidence of methamphetamine in hair samples:
• The first methamphetamine was found in hair in 2003, when six samples tested positive, with a slight increase in 2004, with eight cases.
• There were 372 cases in 2005 and the researchers said preliminary data for 2006 indicates that the surge has not stopped.
• The study identified 11 mother-neonate pairs in which each was positive for methamphetamine.
• Also, one newborn was negative, although the mother was positive.
The median methamphetamine values in the mother-baby pairs were 1.75 ng/mg for the mothers and 1.63 ng/mg for the newborns. Dr. Garcia-Bournissen and colleagues said.
The median concentrations were not significantly different, “suggesting that the transplacental transfer of methamphetamine is extensive,” the researchers said. On an individual level, maternal and neonatal drug levels correlated significantly (at P=0.003, using Spearman’s rho test, with r=0.8).
Interestingly, among the 171 subjects who were positive for methamphetamine and whose hair was tested for other drugs, 83.5% were positive for at least one other drug, usually cocaine, Dr. Garcia-Bournissen and colleagues found.
In contrast, among the 1,053 subjects negative for methamphetamine but positive for some other drug, only 38% were positive for more than one drug, they said.
“Positive exposure to methamphetamine strongly suggests that the person is a polydrug user, which may have important implications for fetal safety,” the researchers said.
The effects of the drug on the exposed child remain unclear, Dr. Garcia-Bournissen and colleagues noted, although there is some evidence that “children exposed in utero to methamphetamine are at risk of developmental problems, because of either the effect of direct exposure to the drug during pregnancy or growing in the environment associated with parental methamphetamine misuse, or probably both.”
Because the study was retrospective and anonymous, clinical information on the exposed infants is not available, the researchers said.

Source: www.medpage.today.com 2nd Nov. 2006

Canadian scientists also confirm previous research showing possible link between cannabis dependence and schizophrenia

In the first worldwide study of its kind, scientists from Toronto’s Centre for Addiction and Mental Health (CAMH) found evidence that heavy methamphetamine users might have a higher risk of developing schizophrenia. This finding was based on a large study comparing the risk among methamphetamine users not only to a group that did not use drugs, but also to heavy users of other drugs.

The report will be published online on Nov. 8, 2011, at AJP in Advance, the advance edition of the American Journal of Psychiatry, the official journal of the American Psychiatric Association.

Methamphetamine and other amphetamine-type stimulants are the second most common type of illicit drug used worldwide.

“We found that people hospitalized for methamphetamine dependence who did not have a diagnosis of schizophrenia or psychotic symptoms at the start of our study period had an approximately 1.5 to 3.0-fold risk of subsequently being diagnosed with schizophrenia, compared with groups of patients who used cocaine, alcohol or opioid drugs,” says Dr. Russ Callaghan, the CAMH scientist who led the study. Dr. Callaghan also found that the increased risk of schizophrenia in methamphetamine users was similar to that of heavy users of cannabis.

To establish this association, the researchers examined California hospital records of patients admitted between 1990 and 2000 with diagnosis of dependence or abuse for several major abused drugs: methamphetamine, cannabis, alcohol, cocaine or opioids. They also included a control group of patients with appendicitis and no drug use. The methamphetamine group had 42,412 cases, while cannabis had 23,335.

Records were excluded if patients were dependent on more than one drug or had a diagnosis of schizophrenia or drug-induced psychosis during their initial hospitalization. Readmission records within California hospitals were analyzed for up to 10 years after the initial admission. The researchers then identified patients who were readmitted with a schizophrenia diagnosis in each drug group.

There has been a longstanding debate as to whether there is a connection between methamphetamine use and schizophrenia. Many Japanese clinicians have long believed that methamphetamine might cause a schizophrenia-like illness, based on their observations of high rates of psychosis among methamphetamine users admitted to psychiatric hospitals. However, they lacked long-term follow-up studies of methamphetamine users initially free of psychosis. In North America, this link has mostly been discounted, as psychiatrists believed that the psychosis was already present and undiagnosed in these methamphetamine users.

“We really do not understand how these drugs might increase schizophrenia risk,” says Dr. Stephen Kish, senior scientist and head of CAMH’s Human Brain Laboratory. “Perhaps repeated use of methamphetamine and cannabis in some susceptible individuals can trigger latent schizophrenia by sensitizing the brain to dopamine, a brain chemical thought to be associated with psychosis.” Dr. Kish also cautions that the findings do not apply to patients who take much lower and controlled doses of amphetamines or cannabis for medical purposes.

Since this is the first such study showing this potential link, the researchers emphasize that the results need to be confirmed in additional research involving long-term follow-up studies of methamphetamine users.

“We hope that understanding the nature of the drug addiction-schizophrenia relationship will help in developing better therapies for both conditions,” says Dr. Callaghan.

In an earlier study using California hospital records, the researchers found evidence for a possible association between heavy methamphetamine use and Parkinson’s disease.

Source:www.eurekalert.org.  8th Nov. 2011  

TORONTO, Nov. 2 — Methamphetamine can be detected in the hair of newborns whose mothers used the drug during pregnancy, researchers here have found.
Action Points

  • Note that this study shows that methamphetamine used during pregnancy can be found in the hair of neonates, suggesting it crosses the placental barrier with effects that are not completely understood.
  • Advise patients who ask that drug abuse during pregnancy can be detrimental to the fetus, with a range of physical and intellectual sequelae, as well as hazardous to the mother.

It represents the first direct evidence in humans that crystal meth, which is a growing drug-abuse problem in North America, can cross the placenta and affect the growing fetus, according to Facundo Garcia-Bournissen, M.D., of the Motherisk program at the Hospital for Sick Children.
Researchers at the program have been testing hair samples from parents and adults across Canada for several years, usually when there is clinical suspicion of drug abuse on the part of parents, Dr. Garcia-Bournissen and colleagues reported in the online issue of Archives of Disease in Childhood.
From June 1997 through December 2005, the database accumulated results of 34,278 tests for drugs in hair, representing 8,270 people. Nearly 60% (or 4,926) of these people were positive for at least one drug of abuse, the researchers said.
In a retrospective analysis, Dr. Garcia-Bournissen and colleagues examined the incidence of methamphetamine in hair samples:

  • The first methamphetamine was found in hair in 2003, when six samples tested positive, with a slight increase in 2004, with eight cases.
  • There were 372 cases in 2005 and the researchers said preliminary data for 2006 indicates that the surge has not stopped.
  • The study identified 11 mother-neonate pairs in which each was positive for methamphetamine.
  • Also, one newborn was negative, although the mother was positive.

The median methamphetamine values in the mother-baby pairs were 1.75 ng/mg for the mothers and 1.63 ng/mg for the newborns. Dr. Garcia-Bournissen and colleagues said. The median concentrations were not significantly different, “suggesting that the transplacental transfer of methamphetamine is extensive,” the researchers said. On an individual level, maternal and neonatal drug levels correlated significantly (at P=0.003, using Spearman’s rho test, with r=0.8).
Interestingly, among the 171 subjects who were positive for methamphetamine and whose hair was tested for other drugs, 83.5% were positive for at least one other drug, usually cocaine, Dr. Garcia-Bournissen and colleagues found.
In contrast, among the 1,053 subjects negative for methamphetamine but positive for some other drug, only 38% were positive for more than one drug, they said.
“Positive exposure to methamphetamine strongly suggests that the person is a polydrug user, which may have important implications for fetal safety,” the researchers said. The effects of the drug on the exposed child remain unclear, Dr. Garcia-Bournissen and colleagues noted, although there is some evidence that “children exposed in utero to methamphetamine are at risk of developmental problems, because of either the effect of direct exposure to the drug during pregnancy or growing in the environment associated with parental methamphetamine misuse, or probably both.”

Because the study was retrospective and anonymous, clinical information on the exposed infants is not available, the researchers said.

Source: www.medpage.today.com 2nd Nov. 2006

People who abused methamphetamine or other amphetamine-like stimulants were more likely to develop Parkinson’s disease than those who did not, in a new study from the Centre for Addiction and Mental Health (CAMH).
The researchers examined almost 300,000 hospital records from California covering 16 years. Patients admitted to hospital for methamphetamine or amphetamine-use disorders had a 76 per cent higher risk of developing Parkinson’s disease compared to those with no diagnosis. Globally, methamphetamine and similar stimulants are the second most commonly used class of illicit drugs.
“This study provides evidence of this association for the first time, even though it has been suspected for 30 years,” said lead researcher Dr. Russell Callaghan, a scientist with CAMH. Parkinson’s disease is caused by a deficiency in the brain’s ability to produce a chemical called dopamine. Because animal studies have shown that methamphetamine damages dopamine-producing areas in the brain, scientists have worried that the same might happen in humans.
It has been a challenge to establish this link, because Parkinson’s disease develops in middle and old age, and it is necessary to track a large number of people with methamphetamine addiction over a long time span. The CAMH team took an innovative approach by examining hospital records from California – a state in which methamphetamine use is prevalent – from 1990 up to 2005. In total, 40,472 people, at least 30 years of age, had been hospitalized due to a methamphetamine- or amphetamine-use disorder during this period.
These patients were compared to two groups: 207,831 people admitted for appendicitis with no diagnosis of any type of addiction, and 35,335 diagnosed with cocaine use disorders. A diagnosis of Parkinson’s disease was identified from hospital records or death certificates. Only the methamphetamine group had an increased risk of developing Parkinson’s disease.
While the appendicitis group served as a comparison to the general population, the cocaine group was selected for two reasons. Because cocaine is another type of stimulant that affects dopamine, this group could be used to determine whether the risk was specific to methamphetamine stimulants. Cocaine users also served as a control group to account for the health effects or lifestyle factors associated with dependence on an illicit drug.
“It is important for the public to know that our findings do not apply to patients who take amphetamines for medical purposes, such as attention deficit hyperactivity disorder (ADHD), since these patients use much lower doses of amphetamines than those taken by patients in our study,” said Dr. Stephen Kish, a CAMH scientist and co-author.
To put the study findings into numbers, if 10,000 people with methamphetamine dependence were followed over 10 years, 21 would develop Parkinson’s, compared with 12 people out of 10,000 from the general population. “It is also possible that our findings may underestimate the risk because in California, methamphetamine users may have had less access to health-care insurance and consequently to medical care,” said Dr. Callaghan.
The current project is significant because it is one of the few studies examining the long-term association between methamphetamine use and the development of a major brain disorder. “Given that methamphetamine and other amphetamine stimulants are the second most widely used illicit drugs in the world, the current study will help us anticipate the full long-term medical consequences of such problematic drug use,” said Dr. Callaghan.
Media Contact: Michael Torres, Media Relations, CAMH; 416-595-6015

Source: www.camh.net 26th July 2011

Background

Methamphetamine (METH), an abused illicit drug, disrupts many cellular processes, including energy metabolism, spermatogenesis, and maintenance of oxidative status. However, many components of the molecular underpinnings of METH toxicity have yet to be established. Network analyses of integrated proteomic, transcriptomic and metabolomic data are particularly well suited for identifying cellular responses to toxins, such as METH, which might otherwise be obscured by the numerous and dynamic changes that are induced.

Methodology/Results

We used network analyses of proteomic and transcriptomic data to evaluate pathways in Drosophila melanogaster that are affected by acute METH toxicity. METH exposure caused changes in the expression of genes involved with energy metabolism, suggesting a Warburg-like effect (aerobic glycolysis), which is normally associated with cancerous cells. Therefore, we tested the hypothesis that carbohydrate metabolism plays an important role in METH toxicity. In agreement with our hypothesis, we observed that increased dietary sugars partially alleviated the toxic effects of METH. Our systems analysis also showed that METH impacted genes and proteins known to be associated with muscular homeostasis/contraction, maintenance of oxidative status, oxidative phosphorylation, spermatogenesis, iron and calcium homeostasis. Our results also provide numerous candidate genes for the METH-induced dysfunction of spermatogenesis, which have not been previously characterized at the molecular level.

Conclusion

Our results support our overall hypothesis that METH causes a toxic syndrome that is characterized by the altered carbohydrate metabolism, dysregulation of calcium and iron homeostasis, increased oxidative stress, and disruption of mitochondrial functions.

Source: . PLoS ONE 6(4): e18215. doi:10.1371/journal.pone.0018215. (2011)
Sun L, Li H-M, Seufferheld MJ, Walters KR Jr, Margam VM, et al. Sun L, Li H-M, Seufferheld MJ, Walters KR Jr, Margam VM, et al.

A new study suggests that the brain damage suffered by children whose mothers used metamphetamine during pregnancy may be even worse than the effects that alcohol has on a fetus.

Researchers at the University of California, Los Angeles, found that some of the brain regions of meth-exposed children were even smaller than in alcohol-exposed children. One such region is the caudate nucleus, which plays a role in learning, memory, motor control, and motivation.

“Our findings stress the importance of drug abuse treatment for pregnant women,” said research team leader Elizabeth Sowell.

According to Sowell and her colleagues, being able to identify which brain structures are affected in meth-exposed children may help predict the specific types of leaning and behavioral problems that will afflict these children.

 Source:  The Journal of Neuroscience. March 17 2011

The State Government figures show that out of 4619 drivers pulled over, one in 73 tested positive to either cannabis or methamphetamines. This compared to an average of one in 250 drivers testing positive for alcohol. The results surprised police.

The results come just two days after research by the National Drug and Alcohol Research Centre showed 57 per cent of clubbers admitted driving under the influence of alcohol and 52 per cent under the influence of cannabis. The VicRoads-commissioned study reported that just under half of those surveyed admitted driving soon after taking other drugs.

43% said they had taken ecstasy and 42 % speed.

Source: Minister for Police & Emergency Services. Victoria. Australia. April 15 2005

The number of people admitted into hospital because of GHB poisoning has quadrupled in the period 2004-2009. In total, 1200 persons were admitted in the ER’s of hospitals who had swallowed the party drug (23 persons per week). This was reported by the Consumer and Safety Foundation last Sunday.
Almost sixty percent of the treatments took place in the weekend. It mainly concerns males (69 percent). Something more than half of the victims was in the age of 20 to 29 years, one in five in the age of 30 to 39 (22 percent) and fourteen percent between 15 and 19.

Many of the patients not only used GHB, but also alcohol (34%) or other drugs like XTC (10%), cocaine (7%) or speed (1%). Almost all victims at the ER’s suffer from GHB poisoning, 40 percent need to be admitted into hospital, half of which even at the IC department.

Going ‘out’ because of GHB is regarded as something normal. The Consumer and Safety Foundation wants there to be more education and information on GHB. According to the foundation the party drug now has a too positive image: “It’s cheap, simply to get, people break loose and become jolly and do not suffer a hangover. That image has to change for reality. GHB is addictive and can even be life threatening. And the long term damage to health is not yet known.”

(Source: http://www.veiligheid.nl/csi/veilighe id.nsf/wwwVwContent/M_7CC86ED715F24DE9C125778500330C70) Aug 2010

Children whose mothers abused methamphetamine (meth) during pregnancy show brain abnormalities that may be more severe than that of children exposed to alcohol prenatally, according to a study in the March 17 issue of The Journal of Neuroscience. While researchers have long known that drug abuse during pregnancy can alter fetal brain development, this finding shows the potential impact of meth. Identifying vulnerable brain structures may help predict particular learning and behavioral problems in meth-exposed children.
________________________________________
“We know that alcohol exposure is toxic to the developing fetus and can result in lifelong brain, cognitive, and behavioral problems,” said Elizabeth Sowell, PhD, of the University of California, Los Angeles, who led the research team. “In this study, we show that the effects of prenatal meth exposure, or the combination of meth and alcohol exposure, may actually be worse. Our findings stress the importance of drug abuse treatment for pregnant women,” Sowell said. A structure called the caudate nucleus, which is important for learning and memory, motor control, and motivation, was one of the regions more reduced by meth than alcohol exposure.
Of the more than 16 million Americans over the age of 12 who have used meth, about 19,000 are pregnant women, according to data from the National Surveys on Drug Use and Health. About half of women who say they used meth during pregnancy also used alcohol, so isolating the effects of meth on the developing brain is difficult.
Sowell’s team evaluated the specific effects of prenatal meth-exposure by comparing brain scans of 61 children: 21 with prenatal meth and alcohol exposure, 13 with heavy alcohol exposure only, and 27 unexposed. Structural magnetic resonance imaging (MRI) showed that the sizes and shapes of certain brain structures varied depending on prenatal drug exposure.
Previous studies have shown that certain brain structures are smaller in alcohol-exposed children. In this study, the authors found these brain regions in meth-exposed children were similar to the alcohol-exposed children, and in some areas were smaller still. Some brain regions were larger than normal. An abnormal volume increase was noted in meth-exposed children in a region called the cingulate cortex, which is associated with control and conflict resolution.
The researchers were also able to predict a child’s past exposure to drugs based on brain images and IQ information. Detailed data about vulnerable brain structures may eventually be used to diagnose children with cognitive or behavioral problems but without well-documented histories of drug exposure. Christian Beaulieu, PhD, of the University of Alberta in Canada, who was unaffiliated with the study, said this finding will help researchers understand which brain areas are most sensitive to injury during development.
“Ultimately, the goal would be to come up with strategies to first, minimize brain damage in the womb, and second, to improve the child’s cognitive performance,” Beaulieu said.
.

Source: Society for Neuroscience, March 17 2010


According to experimental scientists a common antipsychotic drug used in emergency rooms to treat methamphetamine overdose can damage nerve cells in an area of the brain known to regulate movement.
Investigators from the Boston University School of Medicine used a rat model to determine that only the combination of the medication, haloperidol, and methamphetamine causes the destructive effects, not either one alone.
Senior author Bryan Yamamoto, PhD, and his team suspect the damage results from the exaggerated stimulation of cells by the amino acid glutamate, which proves toxic to cells producing the neurotransmitter gamma-aminobutyric acid (GABA).
Their results are published in the May 30 issue of The Journal of Neuroscience.
“This work in laboratory animals raises immediate concerns that a standard treatment for methamphetamine overdose in humans might worsen drug abuse-related brain injuries,” says William Carlezon, PhD, at Harvard’s McLean Hospital, who was not affiliated with the study.
“A crucial next step is to determine how atypical antipsychotic medications would affect methamphetamine toxicity in the same model.”
The rats in the experiment were injected with either methamphetamine or a saline solution over a period of eight hours. When the rats were given haloperidol before and nearly halfway through the eight-hour period, Yamamoto and his colleagues noted more than a fivefold rise in base levels of glutamate in the substantia nigra, a part of the brain known to play a role in movement disorders such as Huntington’s disease.
After examining the long-term effects of the combination, they found that glutamate concentrations in the substantia nigra were twice as high in methamphetamine-treated rats as in saline-treated ones two days after injections.
Yamamoto and his colleagues were able to link this rise in glutamate to the death of GABA-containing cells in one part of the substantia nigra. This may predispose some people who have been treated for a methamphetamine overdose to seizures and the development of movement disorders, they say, although the study did not measure movement specifically.
In addition to future studies of other antipsychotic medications, says Yamamoto, “we hope to examine if the loss of cells results in abnormal involuntary movements resembling Tourette’s syndrome and Huntington’s disease.”

Source: Society for Neuroscience May 30th 2007

There were 897 deaths involving heroin or morphine in 2008, an 8 per cent rise compared with 2007 and the highest number since 2001. The number of deaths involving methadone rose throughout 2004 to 2008, to 378 in the latest year, an increase of 16 per cent compared with 2007 (and 73 per cent higher than in 2004). There were 235 deaths involving cocaine in 2008, continuing the long-term upward trend.

 

There were 99 deaths involving amphetamines in 2008, with nearly half of these being accounted for by deaths mentioning ecstasy. Cannabis was mentioned in 19 deaths in 2008, while the number of deaths mentioning GHB rose to 20 in 2008 from 9 in 2007. The number of deaths that mentioned benzodiazepines rose to 230 in 2008, an increase of 11.

 

Source: Office for National Statistics  26 August 2009

What do suffering a traumatic brain injury and using club drugs have in common? University of Florida researchers say both may trigger a similar chemical chain reaction in the brain, leading to cell death, memory loss and potentially
irreversible brain damage.

A series of studies at UF over the past five years has shown using the
popular club drug Ecstasy, also called MDMA, and other forms of
methamphetamine lead to the same type of brain changes, cell loss and
protein fluctuations in the brain that occur after a person endures a
sharp blow to the head, according to recent findings.

“Using methamphetamine is like inflicting a traumatic brain injury on
yourself,” said Firas Kobeissy, a postdoctoral associate in the College
of Medicine department of psychiatry. “We found that a lot of brain
cells are being injured by these drugs. That’s alarming to society now.
People don’t seem to take club drugs as seriously as drugs such as
heroin or cocaine.”

Working with UF researchers Dr. Mark Gold, chief of the division of
addiction medicine at UF’s McKnight Brain Institute and one of the
country’s leading experts on addiction medicine, and Kevin Wang,
director of the UF Center for Neuroproteomics and Biomarkers Research,
Kobeissy compared what happened in the brains of rats given large doses
of methamphetamine with what happened to those that had suffered a
traumatic brain injury.

The group’s research has already shown how traumatic brain injury
affects brain cells in rats. They found similar damage in the rats
exposed to methamphetamine. In the brain, club drugs set off a chain of
events that injures brain cells. The drugs seem to damage certain
proteins in the brain, which causes protein levels to fluctuate. When
proteins are damaged, brain cells could die. In addition, as some
proteins change under the influence of methamphetamine, they also begin
to cause inflammation in the brain, which can be deadly, Kobeissy said.

Kobeissy and other researchers in Gold’s lab are using novel protein
analysis methods to understand how drug abuse alters the brain. Looking
specifically at proteins in the rat cortex, UF researchers discovered
that about 12 percent of the proteins in this region of the brain showed
the same kinds of changes after either methamphetamine use or traumatic
brain injury. There are about 30,000 proteins in the brain so such a
significant parallel indicates that a similar mechanism is at work after
both traumatic brain injury and methamphetamine abuse, Kobeissy said.

“Sometimes people go to the clubs and take three tablets of Ecstasy or
speed,” Kobeissy said. “That may be a toxic dose for them. Toxic effects
can be seen for methamphetamine, Ecstasy and traumatic injury in
different areas of the brain.”

About 1.3 million people over the age of 12 reported using
methamphetamine in the previous month, according to the 2006 National
Survey on Drug Use and Health. In 2004, more than 12 million Americans
reported having tried the drug, the survey’s findings show.

People often think the effects of drugs of abuse wear off in the body
the same way common medications do, but that may not be the case, Gold
said.

“These data and the previous four years of data suggest some drugs,
especially methamphetamine, cause changes that are not readily
reversible,” Gold said. “Future research is necessary for us to
determine when or if methamphetamine-related brain changes reverse
themselves.”

Gold and Dennis Steindler, director of UF’s McKnight Brain Institute and
an expert on stem cells, are planning studies to find out if stem cells
can be applied to repair drug-related brain damage.

UF researchers are also trying to uncover all the various ways drugs
damage and kill brain cells. During their protein analysis, researchers
discovered that oxidation was damaging some proteins, throwing the
molecules chemically off balance.

“When proteins are oxidized they are not functional,” Kobeissy said.
“When proteins are not working, the cell cannot function.”

Neurologist Dr. Jean Lud Cadet, chief of the molecular neuropsychiatry
branch of the National Institute on Drug Abuse, said analyzing proteins
is important to understanding how drugs such as methamphetamine affect
the brain.

“I think saying the results of methamphetamine abuse are comparable to
the results of a traumatic brain injury is a new idea,” Cadet said. “I
agree with (the findings). Our own work shows that methamphetamine is
pretty toxic to the brains of animals. In humans, imaging studies of
patients who use methamphetamine chronically show abnormalities in the
brain.

“Abuse of methamphetamine is very dangerous.”

This research was presented at a Society for Neuroscience conference
held recently in San Diego.

Source: Science Daily (Nov. 29, 2007)

Children and adolescents who abuse alcohol or are sexually active are more likely to take methamphetamines (MA), also known as ‘meth’ or ‘speed’. New research reveals the risk factors associated with MA use, in both low-risk children (those who don’t take drugs) and high-risk children (those who have taken other drugs or who have ever attended juvenile detention centres).

MA is a stimulant, usually smoked, snorted or injected. It produces sensations of euphoria, lowered inhibitions, feelings of invincibility, increased wakefulness, heightened sexual experiences, and hyperactivity resulting from increased energy for extended periods of time. According to the lead author of this study, Terry P. Klassen of the University of Alberta, Canada, “MA is produced, or ‘cooked’, quickly, reasonably simply, and cheaply by using legal and readily available ingredients with recipes that can be found on the internet”.
Because of the low cost, ready availability and legal status of the drug, long-term use can be a serious problem. In order to assess the risk factors that are associated with people using MA, Klassen and his team carried out an analysis of twelve different medical studies, combining their results to get a bigger picture of the MA problem. They said, “Within the low-risk group, there were some clear patterns of risk factors associated with MA use. A history of engaging in behaviors such as sexual activity, alcohol consumption and smoking was significantly associated with MA use among low-risk youth. Engaging in these kinds of behaviors may be a gateway for MA use or vice versa. A homosexual or bisexual lifestyle is also a risk factor.”
Amongst high-risk youth, the risk factors the authors identified were, “growing up in an unstable family environment (e.g., family history of crime, alcohol use and drug use) and having received treatment for psychiatric conditions. Among high-risk youth, being female was also a risk factor”.

Source: BMC Pediatrics (2008, October 29). Methamphetamine Abuse Linked To Underage Sex, Smoking And Drinking. ScienceDaily. Retrieved November 12, 2009, from http://www.sciencedaily.com

University of Washington researchers say that animal studies show that methamphetamine use causes lasting changes in the brain’s dopamine system, making it especially difficult for users to stop using the drug.
HealthDay News reported April 9 that researcher Nigel Bamford and colleagues found that long-term methamphetamine use depressed the synaptic dopamine-release system in the corticostriatal area of the brain — a condition that gets temporarily reversed when a dose of methamphetamine is administered.
Researchers said that methamphetamine appears to cause long-term changes in certain dopamine receptors and with the neurotransmitter acetylcholine. The findings “might provide a synaptic basis that underlies addiction and habit learning and their long-term maintenance,” Bamford and colleagues wrote.
Source: April 10, 2008 issue of the journal Neuron.

Research Summary
Animal studies show that amphetamines are converted into free radicals in the brain, which in turn can cause brain damage, HealthDay News reported April 13.
University of Toronto researchers said the mouse studies could explain how methamphetamine causes brain damage, even after the drug has been metabolized out of the body. The study authors said the enzyme prostaglandin H synthase (PHS) appears to play a role in converting amphetamines into free radicals, which can cause neurodegenerative diseases like Parkinson’s and Alzheimer’s.
Source: April 2006 issue of the FASEB (Federation of American Societies for Experimental Biology) Journal.

Methamphetamine Abuse Linked To Underage Sex, Smoking And Drinking

Children and adolescents who abuse alcohol or are sexually active are more likely to take methamphetamines (MA), also known as ‘meth’ or ‘speed’. New research reveals the risk factors associated with MA use, in both low-risk children (those who don’t take drugs) and high-risk children (those who have taken other drugs or who have ever attended juvenile detention centres).

MA is a stimulant, usually smoked, snorted or injected. It produces sensations of euphoria, lowered inhibitions, feelings of invincibility, increased wakefulness, heightened sexual experiences, and hyperactivity resulting from increased energy for extended periods of time. According to the lead author of this study, Terry P. Klassen of the University of Alberta, Canada, “MA is produced, or ‘cooked’, quickly, reasonably simply, and cheaply by using legal and readily available ingredients with recipes that can be found on the internet”.
Because of the low cost, ready availability and legal status of the drug, long-term use can be a serious problem. In order to assess the risk factors that are associated with people using MA, Klassen and his team carried out an analysis of twelve different medical studies, combining their results to get a bigger picture of the MA problem. They said, “Within the low-risk group, there were some clear patterns of risk factors associated with MA use. A history of engaging in behaviors such as sexual activity, alcohol consumption and smoking was significantly associated with MA use among low-risk youth. Engaging in these kinds of behaviors may be a gateway for MA use or vice versa. A homosexual or bisexual lifestyle is also a risk factor.”
Amongst high-risk youth, the risk factors the authors identified were, “growing up in an unstable family environment (e.g., family history of crime, alcohol use and drug use) and having received treatment for psychiatric conditions. Among high-risk youth, being female was also a risk factor”.

Source: BMC Pediatrics (2008, October 29). Methamphetamine Abuse Linked To Underage Sex, Smoking And Drinking. ScienceDaily. Retrieved November 12, 2009, from http://www.sciencedaily.com

DALLAS — June 3, 2008 — Young adults who abuse amphetamines may be at greater risk of suffering a heart attack, UT Southwestern Medical Center researchers have found.In the study, available online in the journal Drug and Alcohol Dependence, researchers examined data from more than 3 million people between 18 and 44 years old hospitalized from 2000 through 2003 in Texas and found a relationship between a diagnosis of amphetamine abuse and heart attack.

Individual case reports have suggested a link between heart attack and amphetamine abuse, but this is believed to be the first epidemiological study of a large group of people on the issue, said Dr. Arthur Westover, assistant professor of psychiatry at
UT Southwestern and the study’s lead author.
  
“Most people aren’t surprised that methamphetamines and amphetamines are bad for your health,” Dr. Westover said. “But we are concerned because heart attacks in the young are rare and can be very debilitating or deadly.”

Amphetamines are stimulants that can be used to treat medical conditions such as attention-deficient disorder. They are illegally abused as recreational drugs or performance enhancers.

The researchers note that abuse of methamphetamine, a type of amphetamine often sold illegally, is increasing in most major U.S. cities.

In Texas, the researchers found greater amphetamine abuse in the north and Panhandle regions.

“This paper sounds a warning to amphetamine abusers, alerts emergency department personnel to look for amphetamine abuse in young heart attack patients, and it allows us to focus preventive efforts in geographical areas where the problems are greatest,” said Dr. Robert W. Haley, chief of epidemiology at UT Southwestern and senior author of the study. Dr. Haley holds the U.S. Armed Forces Veterans Distinguished Chair for Medical Research, Honoring America’s Gulf War Veterans.
“We’re also concerned that the number of amphetamine-related heart attacks could be increasing,” Dr. Westover said. “We’d rather raise the warning flag now than later. Hopefully, we can decrease the number of people who suffer heart attacks as the result of amphetamine abuse.”
Amphetamines may contribute to heart attacks by increasing heart rate and blood pressure and by causing inflammation and artery spasms that limit blood to the heart muscle. More research is needed to determine the exact mechanism of how amphetamines work on the heart, he said.
The current research could help doctors determine the cause of heart attacks in young adults, as well as treatment. Doctors recognizing an amphetamine-caused heart attack might choose not to administer a beta-blocker medication, a common treatment for heart attack, because it could interact with methamphetamine to make the heart attack worse.

The results could have broad implications in the general population, Dr. Westover said. Texas ranks 27th among all states in use of methamphetamine among 18- to 25-year-old adults, according to a 2006 government report.

“We’re talking about a state that is near the middle of prevalence of methamphetamine use in the United States, so it’s possible that the number of heart attacks in young adults in other states with a much higher prevalence of amphetamine abuse may be higher as well,” said Dr. Westover, who is a National Institutes of Health Multidisciplinary Clinical Research Scholar at UT Southwestern.
Dr. Paul Nakonezny, assistant professor of clinical sciences and psychiatry at
UT Southwestern, was also involved in the study.

The work was supported by a North and Central Texas Clinical and Translational Science Initiative grant from the National Center for Research Resources, a component of the National Institutes of Health.

Source: www.utsouthwestern.edu June 3rd 2008

 

A drug used to tranquillize horses, called ketamine, is gaining popularity within the dance scene in a number of countries throughout the world. That´s according to a recent report by the United Nations Office of Drugs and Crime, which warned that long-term use of ketamine use can have serious effects on the brain, the kidneys and internal organs.

Now the most abused drug by so called “clubbers” in Hong Kong, ketamine is gaining popularity across southern China. Its use is spreading throughout East Asia as well as Australia, Europe and North America. But because ketamine is a legal substance – and therefore not controlled – the true extent of its use is unclear and probably underestimated.

Nicknamed ‘Special K’, ketamine can be taken in powder, liquid or tablet form but is often mixed with other drugs or alcohol. Sometimes ketamine is laced with synthetic drugs such as methamphetamine and then sold as ecstasy because it commands a higher price than straight ketamine.

“It is a new candy for the youth “, explains UNODC expert Jeremy Douglas, who cautioned that people can be easily fooled. “Sometimes they know they’re using ketamine, sometimes they don’t”. Uncertainty about the content of tablets sold as “ecstasy” is of concern and poses particular risk.

The effect of the drug depends on the dose. With low doses, party-goers may feel euphoric, have psychedelic experiences and high levels of energy, but high doses might plunge the user into an out-of-body or near-death experience known as the “K-hole.” “It’s an anaesthetic so it can put someone in a catatonic state, a different state of being. Perception of the body, time and reality is severely altered,” Douglas said.

Long-term use may impair the memory and cognitive functions, and damage the kidneys and internal organs.

The emergence of ketamine on the synthetic drug scene has gone unnoticed in many parts of the world. Unlike illicit drugs, the trade in ketamine is not internationally controlled. This makes it hard to get a clear picture of how the drug is being diverted for illicit purposes. “We’re seeing the use of ketamine taking off, but it’s up to Member States and national governments to control it. Anyway, it seems that the use is growing both in developing countries and in the west”, Douglas says.

Source: CADCA Coalitions Online 13th Nov.2008

Research Summary
Children exposed to methamphetamine during pregnancy may suffer from altered brain development, Reuters reported April 15.
Researchers at the University of Hawaii, Honolulu assessed the brain structure of children who were exposed to methamphetamine during pregnancy and found that they had up to 4 percent less diffusion of molecules in brain white matter than those who were not exposed.
While it is unclear how methamphetamine exposure leads to lower brain diffusion, author Linda Chang said the condition usually indicates that nerve fibers are compacted.
“Methamphetamine use is an increasing problem among women of childbearing age, leading to an increasing number of children with prenatal meth exposure,” Chang said. “But until now, the effects of prenatal meth exposure on the developing brain of a child were little known.”
Source: Neurology. April 15, 2009

In a study published online by the Journal of Substance Abuse Treatment, UC Davis researchers report that it takes at least a year for former methamphetamine users to regain impulse control. The results tell recovering substance abusers, their families and drug-treatment specialists that it can take an extended period of time for the brain functions critical to recovery to improve.

“Recovery from meth abuse does not happen overnight,” said Ruth Salo, lead author of the study and a UC Davis assistant professor of psychiatry and behavioral sciences. “It may take a year – or even longer – for cognitive processes such as impulse control and attentional focus to improve. Treatment programs need to consider this when monitoring recovering addicts’ progress during their early periods of abstinence.”

Salo specializes in the behavioral, neuropsychiatric and cognitive outcomes of methamphetamine addiction – a particularly difficult condition to treat, primarily due to prolonged, intense cravings for the drug. During her career, she has worked with hundreds of methamphetamine addicts.

“All of them want to know if there is hope,” Salo said. “We used to think most, if not all, effects of meth addiction were permanent. This study adds to the growing evidence that this assumption is not true. I can confidently tell patients that the longer they stay in a structured rehabilitation program and remain drug free, the more likely it is that they will recover some important brain functions.”

For the current study, Salo used the widely-validated, computer-based Stroop attention test to measure the abilities of 65 recovering methamphetamine abusers to use cognitive control – or direct their attention to specific tasks while ignoring distractors. Study participants had been abstinent for a minimum of three weeks and a maximum of 10 years, and they had previously used the drug for periods ranging from 24 months to 28 years. The data for the 65 individuals were compared to Stroop attention test data from 33 participants who had never used methamphetamine.

“The test taps into something people do in everyday life: make choices in the face of conflicting impulses that can promote a strong but detrimental tendency,” Salo explained. “For meth users, impairments in this decision-making ability might make them more likely to spend a paycheck on the immediate satisfaction of getting high rather than on the longer-term satisfaction gained by paying rent or buying groceries.”

The study analyzed cognitive control in terms of the amount of time since methamphetamine was last used as well as total time spent using the drug. The researchers found that those who were recently abstinent (three weeks to six months) performed significantly worse on the Stroop test than those who had been abstinent one year or longer. In addition, there was no statistical difference between test results for those abstinent at least one year and non-drug using controls. Longer-term methamphetamine use was associated with worse test scores. Similarly, longer-term abstinence was connected to improved test performance.

According to Salo, the new study mirrors previous magnetic resonance imaging (MRI) studies she and her colleagues published in 2005 showing a partial normalization of chemicals in selected brain regions after one year of methamphetamine abstinence.

“Together, the studies provide strong evidence that, eventually, meth abusers in recovery may be able to make better decisions and regain the impulse control that was lost during their drug use period,” she said.

Salo said that more research is needed to determine just how the brain recovers from methamphetamine addiction and if behavioral treatments can hasten that recovery. She plans to continue neuroimaging studies to further define the brain functions affected by the drug. Her ultimate goal is to provide information essential to refining treatment programs for this population of drug users.

“Meth use worldwide is pandemic,” she said, referring to the estimated 35 million people who have used the neurotoxic stimulant or similar drugs. “Recovery is difficult, but possible. The point of my research is to better understand the neural and behavioral consequences of this toxic drug along with the brain and behavior changes that are possible with long-term abstinence.”
Source: Journal of Substance Abuse Treatment, Ruth Salo et al 1st July 2009

An Alabama doctor who lost a brother to methamphetamine addiction has formed a support group called “After he died, I started looking into it as a physician, as a scientist”, said Dr. Mary Holley, an obstetrician in Albertville. “What is this drug that destroyed his life in just two years?”

Holley formed the group last year and there now are chapters in Tennessee, Georgia, Oklahoma, Missouri, and Ohio.

The group works with churches to form addiction-support groups. In addition, the MAMa website offers information that explains the dangers of meth.

“People don’t realize what this drug is doing,” Holley said. “One look at the brain scan in my pamphlets will change that attitude.”

Holley, a Christian, said a religious approach to treating drug addiction is more effective than law enforcement. “Law enforcement is helpless. They can’t possibly bust every lab. They can’t keep them in jail long enough for them to heal,” Holley said. “Education is helpless. They lack the resources and the moral authority to change the situation.”

Holley said that when speaking with young people, she found that, “20 percent of meth users are basically healthy kids who made a bad decision. About 75 percent are broken, hurting people, abused and battered as kids.

Source: Associated Press reported Aug. 28. 2004

This publication summarizes current knowledge about rates of use, methods of action, effects, and acute and long-term dangers of two important classes of drugs of abuse. Hallucinogenic drugs, which include LSD and mescaline, act on the serotonin system to produce profound distortions of the user’s sense of reality. The dissociative drugs include the anesthetic agents PCP and ketamine and the cough suppressant dextromethorphan, all of which cause feelings of separation from the body. Ketamine use has increased thiwt in recent years; in addition to its conscious abuse, it has also been given to unsuspecting victims to incapacitate them for sexual assaults.

Source: National Institute of Drug Abuse(NIDA), NIH Publication. March 2001.

Drug  trafficking groups are using the Internet to distribute the “date rape” drug, GHB, and its derivative drugs, GBL and 1, 4 Butanediol 1,4 BD.) GHB, GBL and 1,4 BD are abused to produce euphoria, intoxication and hallucinogenic states, and for their alleged role as a muscle growth hormone. These substances are also used as “date rape” drugs, acting as central nervous system depressants, which cause drowsiness, dizziness, nausea, loss of inhibition, memory loss and visual disturbances. Higher doses of these substances will cause unconsciousness, seizures, severe respiratory depression, coma and even death. DEA has documented 72 deaths relating to GHB and its derivatives.

Source: DEA Media Advisory. Sept 2002.

A new brain-imaging study at the U.S. Department of Energy’s Brookhaven National Laboratory indicates that some of the damage  caused by methamphetamine, a drug abused by ever-increasing numbers of Americans, can be reversed by prolonged abstinence from the drug. The results appear in the December 1, 2001 issue of The Journal of Neuroscience.

“Methamphetamine is a particularly problematic, highly addictive drug,” said Nora Volkow, who led the study with Linda Chang. Their team had previously shown that methamphetamine abusers have significantly depleted levels of dopamine transporters. These proteins, found on the terminals of some brain cells, recycle dopamine, a brain chemical associated with pleasure and reward and also essential for movement. The study also found that meth abusers had impaired cognitive and motor function. “These changes could mean that meth abusers would be predisposed to such neurodegenerative disorders as Parkinson’s disease, which is also characterized by problem with dopamine and motor function,” Volkow said. “It depends in part on whether the damage is reversible.” To help answer this question, Volkow and her team used positron emission tomography, or PET scanning, to measure the level of dopamine transporters in methamphetamine abusers after varying periods of abstinence. One group of 12 methamphetamine abusers was scanned within 6 months of taking the drug, and, for 5 of these subjects who managed to stay drug-free, the scan was repeated after 9 months of abstinence. Another group of 5 methamphetamine abusers was studied only after 9 months of abstinence. All subjects were compared with normal controls.

For each scan, each study volunteer was given an injection carrying a radiotracer, a radioactive chemical “tag” designed to bind to dopamine transporters in the brain. The researchers then scanned the subjects’ brains using a PET camera, which picks up the radioactive signal of the tracer bound to the transporters. The strength of the signal indicates the number of transporters. The scientists also looked for improvements in cognitive and motor function after abstinence by administering a battery of neuropsychological tests. These included tests of fine and gross motor function and tests of attention and memory. The main finding was that, in methamphetamine abusers who were able to stay drug-free for at least 9 months, dopamine transporter levels showed significant improvement, approaching the level observed in control subjects. In abusers studied within 6 and after 9 months, the longer the period between the first and second evaluation, the larger the increase in dopamine transporter levels. Cognitive and motor function showed a trend toward improvement on some tests, but these changes were not statistically significant.

“The increase in dopamine transporter levels with prolonged abstinence indicates that the terminals of dopamine secreting cells, which are thought to be damaged by methamphetamine abuse, are able to regenerate,” Volkow said. Another possibility is that other,  undamaged terminals are able to branch out and make up for the loss. “These findings have implications for the treatment of methamphetamine abusers because they suggest that protracted abstinence and proper rehabilitation may reverse some of the meth  induced alterations in dopamine cells,” Volkow said. “Unfortunately, we did not see a parallel improvement in function.” The recovery of dopamine transporters may not have been sufficient to completely make up for the damage to the dopamine terminals, she suggested. Additionally, other systems necessary for neuropsychological function might also be damaged by the drug   and less able to recover. Also, Volkow noted, the sample sizes were small. “Further study in larger samples is required to assess whether recovery of dopamine transporters with protracted abstinence is associated with recovery of neuropsychological function,” she said.

Source: Author NoraVolkow and Linda Chang, U.S. Department of Energy’s Brookhaven National Laboratory. Dec 2001.

New research suggests that individuals who stop using methamphetamine may experience brain abnormalities similar to those seen in people with depression and anxiety disorders, according to a Jan. 5 press release from the National Institute on Drug Abuse (NIDA).

For the study, Dr. Edythe London and colleagues at the University of California at Los Angeles, the University of  California Irvine, and NIDA’s Intramural Research Program used positron emission tomography (PET) to image brain activity in methamphetamine users. .The researchers compared the glucose metabolism in the brains of 18 people who did not use the drug to the brain activity of 17 individuals addicted to methamphetamine for an average of 10 years, but who had stopped using the drug for four to seven days before the test. After reviewing the PET scans, the researchers found that in methamphetamine users, the glucose metabolism was lower in brain regions linked to depressive disorders, depressed mood and sadness, but higher in brain regions linked to anxiety and drug cravings.

In addition, questionnaires given to all participants showed that methamphetamine users had higher ratings of depression and anxiety than non users. Based on the study’s results, the researchers recommended that practitioners provide therapy for depression and anxiety in order to improve the success rate for methamphetamine users receiving addiction treatment. The study’s findings are published in the January 2004 issue of the Archives of  General Psychiatry.

Source: London, E., et at (2004) Mood Disturbances and Regional Cerebral Metabolic Abnormalities in Recently Abstinent Methamphetamine Abusers. Archives of General Psychiatry, 61W: 73-84.

The methamphetamine problem may have grown so huge in Cowlitz County that an average of more than a baby a day born at St. John Medical Center might have the drug in their systems.

As local doctors and mental health experts try to get a handle on the growing problem — including a Friday appeal to U.S. Rep. Brian Baird, D-Vancouver, for help — a new study could point to an even graver need to attack the problem.

Already, doctors have identified between 10 percent and 20 percent of babies born at St. John with meth in their systems. Many of those babies start their lives going through drug withdrawal.

But if Dr. Aidan deRenne’s suspicions are correct, twice that many — perhaps between 30 percent and 40 percent — of the 1,200 babies born at St. John Medical Center each year are exposed to meth during their final six months in the womb.

DeRenne and Dr. Shawn Aaron, a PeaceHealth doctor who heads the local association of family physicians, will collect samples of the first bowel movements of all babies born at St. John during a six-month period. Unlike blood or urine, those early stools retain measurable traces of any drugs the mother used during the final six months of the pregnancy, deRenne said.

“I think (the number of drug babies) is just going to blow us away,” said deRenne, a pediatrician at Child and Adolescent Clinic and head of the local pediatrician association. “We’ve got a bigger problem than we really know right now.”

He based his estimate on his own experience with patients, discussions with other doctors, maternity nurses and drug-prevention experts, and the results of similar tests conducted elsewhere.

“I hope I’m wrong, let me put it that way,” he said. “Both Shawn and I were so tired of seeing drug-addicted babies up in our NICU (neonatal intensive care unit).”

The way the study is designed, it can’t tie the positive drug tests in the babies to individual women, deRenne said. Instead, the lab simply will test one sample per baby born at the hospital to determine how many had drugs in their system when they left the womb. Because the tests are anonymous and don’t require a medical procedure, new mothers won’t have to consent to the testing.

The results could help attract grant money or other funding to help the community’s pregnant women get off drugs and to treat children harmed by their mothers’ drug use, said deRenne and Dr. Phyllis Cavens, a partner at Child and Adolescent.

The study should begin in about a month and collect roughly 600 samples. The cost of lab tests will make up most of the study’s cost, pegged at up to $30,000. Kaiser Permanente is paying for the lab work and PeaceHealth is contributing staff time, deRenne said.

Cavens and other medical and mental health officials invited Baird, who already has pushed for funding to fight meth, to the Friday discussion for several health-related issues, including soliciting his help in finding ways to halt the epidemic of meth-addicted babies. “Meth is our number-one community issue,” said Eric Yakovich, chief executive officer for Lower Columbia Mental Health Center in Longview. “It just dominates the use of our resources here in this county.”

Baird pledged more work on the problem and talked about the idea of finding more money to help children harmed by the meth epidemic, which he called “social corrosion.”

He said he speaks to students about the drug’s perils every chance he gets, but many teens roll their eyes. Still, he warns them, “It’s a decision basically to end your life, if you start (using) methamphetamines.”

Source: By Eric Apalategui www.tdn.com Sep 19, 2004

PHILADELPHIA (Reuters) – Gay men who combine the drugs crystal meth and Viagra run a greater chance of getting sexually transmitted diseases than nonusers, according to a study released on Wednesday.

Figures show men who have sex with other men and use both crystal methamphetamines and the erectile dysfunction drug Viagra were six times more likely to contract syphilis than those who do not use either, a researcher said at a national conference on sexually transmitted disease prevention.

The findings published in Philadelphia come as the use of the two drugs are on the rise among gay men. The use of crystal meth has been highlighted by gay advocates as endemic at bath houses, which have seen a resurgence in recent years after drug cocktails have helped people live with HIV (news – web sites).

With the national incidence of syphillis increasing over the past three years, the San Francisco Department of Public Health (news – web sites) study found gay men were at the highest risk of contracting STDs. The gay community has been the focus of prevention efforts by U.S. health care authorities including the Centers for Disease Control and Prevention (news – web sites).

“The increased threat of syphillis and other STDs among gay and bisexual men is being driven in part by a troubling combination of drug use and complacency,” said Dr. Ronald Valdiserri, deputy director of HIV, STD and tuberculosis prevention programs at the federal center.

“The CDC is very concerned about this data,” he added. “We have a real challenge here dealing with the American public that is clearly uncomfortable talking about sexually transmitted infections.”

Crystal meth use also makes men more likely to have unprotected sex with other men, according to the CDC. The research found 16% of 388 gay men took the drug the last time they had anal sex, and that users were twice as likely to have unprotected sex as nonusers .

CDC data shows the national incidence of primary and secondary syphilis rose last year to 7,082 from 6,862 in 2002. Since a national upturn began in 2000, the overall infection rate has jumped 18%, with a 65% rise among men but a 50% decline among women.

Among gay men, the incidence of syphilis multiplied 12 times between 1999 and 2003, the CDC found.
Source www.dpna.org online 15.03.04

Injured methamphetamine users are more likely to be admitted to the hospital, stay longer, and have higher hospital costs, says a study in the August issue of the Archives of Surgery.

Researchers at The Queen’s Medical Center in Honolulu examined the records of 212 patients, aged 18 to 55, admitted to the hospital’s trauma center in 2002. Of those 212 patients, 57 tested positive for amphetamine or methamphetamine use. Those who tested positive were more likely to have an intentional self-inflicted injury or intentional assault-related injury than those who tested negative (37% vs. 22%).

The patients who tested positive were more likely to be older (average age 33.6 years vs. 29.9 years), and more likely to be admitted to the hospital (91% vs. 70%). Those who tested positive also were more likely to have longer hospital stays (2.7 days vs. 1.7 days) and much higher average hospital costs ($15,617 vs. $11,600).

“Our study demonstrated an increased use of hospital resources, measured by hospital LOS (length of stay) and charges, in the minimally injured adult trauma patients who tested positive for methamphetatmine. This can be explained by the physiological and psychological effects of the drug,” the study authors wrote.

Hawaii has one of the highest rates of methamphetamine use in the United States. The study said that 40% of people arrested in Honolulu test positive for methamphetamine, which can cause aggressive and erratic behavior. After a high, which can last six to 12 hours or more, methamphetamine users can suffer severe exhaustion.
Source: TUESDAY, Aug. 10 2004 (Health Day News)

Researchers say that the onset, pattern, and duration of the “highs” produced by cocaine and methamphetamine differ significantly — findings that could have implications for development of anti-addiction medications.

The authors from the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA found that cocaine-using research subjects reported a quicker peak and decline of their “high” than methamphetamine users. The body’s cardiovascular system responds quickly to both drugs, but physical responses to cocaine also decline more quickly than with meth use.

“These differences help explain patterns of use by addicts. Methamphetamine users, for instance, report using the drug daily throughout each day, while cocaine users typically engage in binges that occur most often in the evening,” said lead study author Thomas F. Newton. “In addition, the study results may impact development of medication treatments for addiction to these two very different stimulants.”

Source: Momstell News online Aug. 2005

OCALA – Methamphetamine abuse continues to spread, despite new laws and public education campaigns aimed at stamping it out. Now, medical researchers are warning that meth is not only addictive, it literally causes brain damage – all the more so when mixed with an HIV infection.

Both methamphetamine abuse and HIV infection distort different parts of the brain, diminishing thought processes such as memory, problem-solving and attention span, researchers at the HIV Neurobehavioral Research Center of the University of California-San Diego report in this month’s American Journal of Psychiatry.

Dr. Jay Rubin, a neurologist in Ocala, said the findings agree with what doctors already know about drugs and other stresses on the brain.

“Things like cocaine abuse can cause strokes,” Rubin said. “There may be some certain areas of the brain that are probably more susceptible to damage. It’s known, for instance, that suffocation or near-suffocation causes damage in the parts of the brain like the hippocampus.”

Ocala Police Maj. Guy K. Howie, who commands Marion County’s multi-agency drug enforcement team, said the findings likewise bear out with his own observations of the growing numbers of local meth abusers.

“It doesn’t surprise me at all,” he said. “When you talk to somebody that’s on meth, you know. You watch the way they talk, the way they twitch. And I’ve known some to be up for two to three days at a time. All of the toxic chemicals used to make it has got to do something to both the body and the brain.”

The researchers in San Diego analyzed brain scans of 103 adults divided into four groups: meth abusers, HIV-positive, HIV-positive meth abusers and a control group with neither problem. They also tested each group on their attention span and memory, the speed at which they mentally process information, their ability to learn, verbal skills, motor skills and other brain functions.

Methamphetamine abuse, they found, is related to swelling of the parietal cortex, which helps people understand and pay attention to their surroundings, as well as the basal ganglia, which is linked to motor skills and motivation.

HIV, on the other hand, appears to shrink three parts of the brain: the cerebral cortex, which plays a role in higher thinking, reasoning and memory; the hippocampus, involved in learning and memory; and the basal ganglia.

Both meth abuse and HIV appear to damage the brain separately, and cause the most damage when paired together.

“In HIV-infected people, the . . . impairments are associated with decreased employment and vocational abilities, difficulties with medication management, impaired driving performance and problems with general activities of daily living, such as managing money,” Terry Jernigan, leader of the research team, explained in a released statement.

While the impact of meth is less understood, “abusers of the drug have impaired decision-making abilities,” he said. “These could potentially affect treatment and relapse prevention efforts, as well as things like money management and driving performance.”

The findings are especially significant given the risky sexual behavior and contaminated needles that tend to link meth abuse with HIV infection, according to Nora D. Volkow, director of the National Institute on Drug Abuse (NIDA).

They are also significant given the rate at which meth use is gaining. A recent survey by the National Association of Counties revealed that the white crystalline drug poses a bigger problem for law enforcement agencies across 45 states than cocaine, heroine or marijuana.

In Marion County, Howie said, police have identified 21 meth labs compared to three at this time in 2004. They have also confiscated 1,584 grams of the drug, compared to 475 grams at this time last year. The 12 cases of meth possession in 2005 – not including the labs – represents an increase as well.

“It’s starting to get popular among teenagers, but it’s more popular with the 20- to 30-year-old crowd,” Howie said. “There are a lot of people in their 40s using it, too.”

Relatively cheap, highly addictive and too-often mistaken as harmless, meth cuts across most economic classes but has been more popular with whites than blacks, Howie said. Abusers of the white, crystalline drug usually develop pock marks on the skin, and scabs that result from scratching.

Lately, meth trafficking has been up locally while production has dropped slightly – but only slightly, Howie said. “That’s because we put several of the people cooking it in jail.”

Beating the epidemic is going to require continued, aggressive education about the drug’s effects and addictiveness, he said – otherwise, “This is going to just take over like crack did in the 1980s.”

Source: American Journal of Psychiatry, August 2005
Methamphetamine is currently the number-one drug problem in many parts of the United States, according to a report issued today by the National Association of Counties (NACo). The drug, which stimulates the central nervous system, modifies the behavior of users and after lengthy use can change the way the brain functions. Psychological effects can include anger, panic, paranoia, hallucinations, repetitive behavior, confusion, jerky or flailing movements, irritability, insomnia, aggression, incessant talking, convulsions, aggressive acts, and suicide. “Now add a child to this mixture,” the NACo report suggests, and there is a risk of child abuse and neglect, a fact that’s being reflected in increasing numbers of children grossly neglected by addicted parents or exposed to the harmful effects of small-scale in-home labs that produce the drug. A survey of counties in 13 states showed marked increases in methamphetamine-caused out-of-home placements of children over the past three years, with many of the children removed from their homes already sick and in need of intensive medical and social services. County officials also reported that it is much harder to reunify meth-related families, with recidivism so great with meth users that reunification often does not last. “Children who are the victims of the methamphetamine epidemic are presenting many challenges to social service workers, foster parents, counselors, and adoption workers,” the report concludes. Copies of the NACo methamphetamine survey are available at jratner@naco.org.
Source: Center for Health & Healthcare in Schools, www.healthinschools.org. July 5 2005

The San Francisco Health Department is offering cash rewards to methamphetamine users who quit using the drug and stay clean, the reported.

Payments of up to $40 per week have been given to meth users who quit. Program participants are required to visit a clinic three times weekly for a drug test; clean urines are rewarded with a check, and participants are not even required to go to counselling as part of the deal, even if they fail a drug test.

“Here I am getting clean, I feel better and I’m getting something for it,” said said former meth addict Robert Bowers. “That means something.”

Experts say that many addicts respond very well to rewards, even small ones, that acknowledge their progress toward sobriety. “You’re using the exact same technique that parents use with their children every day,” said Nancy Petry of the University of Connecticut School of Medicine. “It’s behaviour modification and behaviour shaping.”

The 12-week San Francisco program has had 159 participants since November 2004; backers see it as an effective and inexpensive alternative for those who can’t get into treatment or are on waiting lists.

A recent UCLA study found that a cash voucher program for meth addicts was actually more effective in producing clean urine tests than a therapy program lacking a reward component. “Clearly, it wasn’t the money,” said UCLA researcher Steven Shoptaw. “It was the fact that somebody recognized them.”

Source: Los Angeles Times Dec. 28 2005

Every week in Great Falls, Montana, a baby is born who tests positive for methamphetamine. Meth babies spend their first weeks asleep, some barely waking to feed. Within four to six weeks, they begin crying uncontrollably, irritated by normal sounds and lights. But just like their babies, addicted parents have plenty of problems to overcome even after kicking the habit. Meth’s pull is like no other drug. Because it permanently alters the brain’s chemistry, treatment takes two years, not 12 weeks. Addicts don’t feed themselves, let alone their kids. They go days without sleeping and then crash. Breastfeeding babies share meth with their moms. If someone is cooking meth in the house, babies are exposed to hazardous and explosive chemicals.

Source Great Falls Tribune, March 13, 2006.

Researchers at the University at Buffalo have presented the first evidence that the addictive drug methamphetamine, or meth, also commonly known as “speed” or “crystal,” increases production of a docking protein that promotes the spread of the HIV-1 virus in infected users.

The investigators found that meth increases expression of a receptor called DC-SIGN, a “virus-attachment factor,” allowing more of the virus to invade the immune system.

“This finding shows that using meth is doubly dangerous,” said Madhavan P.N. Nair, Ph.D., first author on the study, published in the online version of the Journal of Neuroimmune Pharmacology. The study will appear in print in the September issue of the journal.

“Meth reduces inhibitions, thus increasing the likelihood of risky sexual behavior and the potential to introduce the virus into the body, and at the same time allows more virus to get into the cell,” said Nair, professor of medicine and a specialist in immunology in the UB School of Medicine and Biomedical Sciences.

His research centers on dendritic cells, which serve as the first line of defense again pathogens, and two receptors on these cells — HIV binding/attachment receptors (DC-SIGN) and the meth-specific dopamine receptor. Dendritic cells overloaded with virus due to the action of methamphetamine can overwhelm the T cells, the major target of HIV, and disrupt the immune response, promoting HIV infection.

“Now that we have identified the target receptor, we can develop ways to block that receptor and decrease the viral spread,” said Nair. “We have to approach this disease from as many different perspectives as possible.

“If we could prevent the upregulation of the meth-specific dopamine receptor by blocking it, we may be able to prevent the interaction of meth with its specific receptors, thereby inhibiting the virus attachment receptor,” said Nair.

“Right now, we don’t know how the virus-attachment receptor and meth-specific receptors interact with each other, leading to the progression of HIV disease in meth-using HIV-infected subjects. That is the next question we want to answer.

“Since meth mediates its effects through interacting with dopamine receptors present on the cells, and meth increases DC-SIGN, which are the HIV attachment receptors, use of dopamine receptor blockers during HIV infection in meth users could be beneficial therapeutically to reduce HIV infection in these high-risk populations,” Nair said.

Additional researchers on the publication, all from the UB Department of Medicine, are Supriya Mahajan, Ph.D., research assistant professor; Donald Sykes, Ph.D., research associate professor; Meghana V. Bapardekar, Ph.D., postdoctoral associate, and Jessica L. Reynolds, Ph.D., research assistant professor.

Source: www. Medical News Today Aug.17th 2006

Anja C Huizink, assistant professor1, Robert F Ferdinand, psychiatrist1, Jan van der Ende, assistant professor1, Frank C Verhulst, professor1

1 Department of Child and Adolescent Psychiatry, Erasmus Medical Center Rotterdam/Sophia Children’s Hospital, PO Box 2060, 3000 CB Rotterdam, Netherlands

Correspondence to: A C Huizink a.c.huizink@erasmusmc.nl

Abstract

Objective To investigate whether using ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is preceded by symptoms of behavioural and emotional problems in childhood and early adolescence.

Design Prospective, longitudinal, population based study

Setting:The Dutch province of Zuid-Holland. Participants: A sample of 1580 individuals, followed up across a 14 year period, from childhood into adulthood.

Main outcome measures The first assessment took place in 1983 before MDMA appeared as a recreational drug in the Netherlands and included the child behaviour checklist to obtain standardised parents’ reports of their children’s behavioural and emotional problems. Use of the drug was assessed with the composite international diagnostic interview 14 years later.

Results Eight syndrome scales of childhood behaviour were examined. Scores in the deviant range for the scales designated as anxious or depressed in childhood were significantly related to use of MDMA in adolescents and adults, resulting in an increased risk (hazard ratio 2.22, 95% confidence interval 1.20 to 4.11, P = 0.01).

Conclusions Individuals with childhood symptoms of anxiety and depression may have an increased tendency to use MDMA in adolescence or young adulthood. Its effects are supposed to include enhanced feelings of bonding with other people, euphoria, or relaxation

Source:BMJ 2006;332:825-828 (8 April), doi:10.1136/bmj.38743.539398.3A (published 24 February 2006)

A new health education campaign launching in the Phoenix area seeks to respond to data from the Partnership for a Drug-Free America (PDFA) that finds usage rates of methamphetamine and Ecstasy among Phoenix-area teens are above national averages. The campaign unveiled today by the Partnership – with support from the Partnership for a Drug-Free Arizona, the Arizona Chapter of the American Academy of Pediatrics (AzAAP) and Consumer Healthcare Products Association (CHPA) – is dedicated to reducing methamphetamine and Ecstasy use among teens in the Phoenix area. The campaign consists of a pediatrician-driven media outreach effort designed to educate parents and teens about the dangerous health consequences of these drugs, and includes an intensive public service advertising campaign in the Phoenix market. Phoenix is one of two U.S. cities where the campaign is being introduced.

“The disturbing number of teens in the Phoenix area who already are experimenting with these drugs makes this a health problem that must be addressed,’ said Dr. Peggy Stemmler, president of the AzAAP, a key partner in the new health education campaign. “Paediatricians are in a unique position to help close the gap between perception and reality about the real consequences of these drugs.”

In the Phoenix area, 14 paediatricians will serve as primary spokespeople for the media communications effort. Campaign coordinators believe the voice of the medical community will resonate with parents in particular in order to motivate them to take an active role in persuading their teens not to use these drugs. HMA Public Relations, a local public relations agency, will coordinate media efforts for paediatricians participating locally.

“More than one of every three teens in the Phoenix area has been offered Ecstasy or ‘meth,’ and teen use of both drugs is above national averages,” said Steve Pasierb, president and CEO of the Partnership, the national non profit organization best known for its media-based drug education campaigns. “Phoenix needs the facts about the real risks of using these drugs if we’re going to turn those numbers around.” The Partnership is providing the local effort with hard-hitting public service ads for television, radio, print and Internet, as well as with research to measure the impact of the effort.

Top-line findings of the Partnership for a Drug-Free America’s study include:

* 13 percent of Phoenix-area teenagers report having used methamphetamine (meth), compared to nine percent of all teens nationwide; 13 percent report having used Ecstasy, compared to 11 percent of all teens nationwide;
* 33 percent of teens report having been offered methamphetamine, and 35 percent report being offered Ecstasy;
* 61 percent of teens report knowing someone who uses Ecstasy, and half (50 percent) report knowing someone who uses methamphetamine; and
* Just one to two percent of Phoenix-area parents surveyed (one percent for Ecstasy, two percent for meth) agree that it’s possible their kids may have tried these drugs.

“Survey data also show parents and teens underestimate the specific health risks of these drugs,’ said Pasierb. “Risk-related attitudes correlate strongly with trends in drug use; for example, when teenagers see greater risks associated with a particular drug, use of that drug declines, Unfortunately, the opposite holds true as well, so the time is right for a concerted intervention to reverse the trends were seeing in Phoenix.”

Methamphetamine is an addictive stimulant. Often called ‘speed’ or ‘crystal’, meth is a crystal-like, powdered substance that sometimes comes in large rock-like chunks. Meth is usually white or slightly yellow, depending on the purity. The drug can be taken orally, injected, snorted or smoked. Once a threat largely in the American southwest, production and use of the drug, which is cheaper and longer lasting than cocaine, has moved steadily eastward in recent years, finding willing users in a generation unlikely to remember the phrase, ‘speed kills’. Long-term use and/or high doses of methamphetamine can bring on full-blown toxic psychosis, often exhibited as violent, aggressive behaviour. Ecstasy–chemically known as 3-4 methylenedioxymethamphetamine, or MDMA – is a psychoactive drug with amphetamine-like and hallucinogenic properties. It can be extremely dangerous, especially in high doses. Usually taken orally in pill form, the drug accelerates the release of serotonin in the brain and provides users with an intense high, characterized by feelings of love and acceptance, as well as a general sense of well being, decreased anxiety and enhanced sensitivity to touch. Ecstasy can cause dramatic increases in body temperature, muscle breakdown, and kidney and cardiovascular system failure, as reported in some fatalities.
Source: Press release, Partnership For Drug Free America June 200

Ads warning about the dangers of smoking pot or taking Ecstasy can persuade young people stay away from drugs, according to a study released by an advocacy group.A survey of teens conducted for the Partnership for a Drug Free America found kids who see or hear anti drug ads at least once a day are less likely to do drugs than youngsters who don’t see or hear ads frequently. Teens who got a daily dose of the anti drug message were nearly 40 percent less likely to try methamphetamine and about 30 percent less likely to use Ecstasy, the study found. When asked about marijuana, kids who said they saw the ads regularly were nearly 15 percent less likely to smoke pot.

The partnership produces most of the anti drug messages for the White House. Among them: one featuring a young man visiting the site where his brother was killed by a driver under the influence of marijuana. The difficulty is getting kids to see the ads and pay attention to them. A University of Pennsylvania study released last year found the ads are largely ignored by teens.

A spokesman for the government’s drug policy office, Tom Riley said the partnership changed the tone of the ads in the last year to make them harder hitting and punchier. The ads also play up the negative consequences of drugs more, he said.
“These ads have taught millions of teens the truth that marijuana is a harmful drug,” said Riley.

Barry McCaffrey drug czar during the Clinton administration said the anti drug ads are having a profound impact in a fundamental way, affecting not just adolescents but adults” as well including parents, pediatricians and teachers. The drop in drug use proves the ads are a key part in the battle, he said.
Source: Sunday Partnership for Drug free America 2003

UK DRUG DEATHS SOAR

LONDON: British deaths from ecstasy, cocaine and amphetamines have rocketed 47 per cent in the past year.The toll topped 1500 for the first time, fuelled by a rise in so-called “recreational hard drugs taken by weekend users.
Ecstasy, cocaine and speed are increasingly used by young people who take cocktails of drugs every weekend.The findings emerged in a study of coroners reports which suggested stronger tablets, easier availability, falling prices and the growing popularity of drug cocktails were behind the rising death toll.
Dr Fabrizio Schifano, who led the research at the European Centre for Addiction Studies at St George’s Hospital Medical School in South London, said recreational users did not see themselves as addicts or considered they were at risk of dying’  Schifana said.
Many weekend users took a cocktail of drugs and alcohol in sessions of up to 12  hours.In dozens of fatal cases, the victims also smoked cannabis.Cocaine was involved in 147 deaths lost year, a 47 per cent rise on 2001, Amphetamines were linked to 53 deaths, a 60 per cent rise. There were 64 ecstasy-related deaths, up 34 per cent.
Dr Schifono so that even a small amount of a drug could kill a hardened user who had built up a tolerance over months or years. In a process called “reverse tolerance”, the user suddenly become acutely sensitive and died.The first death in Britain from a new synthetic form of morphine called Oxycontin was recorded ast year.Called “hillbilly heroin” it has killed hundreds in the US.Overal drug-related deaths rose by about 6 per cent on 2001 last year – from 1495 to 1583, About 45 per cent were due to heroin, morphine and other drugs.The greatest increase in drug-related deaths were in West London. Brcdgend and Glamorgan Volleys, West Yorkshire, Nottinghamshire, North Northumberland and East Lancashire.

Source:Sunday Times(Australia) Oct 2003

Inbred strains of rats differ in how aggressively they seek cocaine after a few weeks of use, researchers say.

The finding, posted online Jan. 18 by Psychopharmacology, is another piece of evidence that genetics plays a role in the relapse of drug-seeking behavior in humans, says Dr. Paul J. Kruzich, behavioural neuroscientist at the Medical College of Georgia and lead study author.

It also fingers glutamate, a neurotransmitter involved in learning and memory, as an accomplice in stirring the cravings and uncontrollable urges that drive some drug users to use again, he says.

“Given the right environmental stimuli, all persons addicted to psychostimulants can relapse, but potentially some people are a little more susceptible than others … it’s all about gene-environment interaction,” says Dr. Kruzich.

He took two strains of inbred rats – Fischer 344 and Lewis – with known genetic differences, enabled each to self-adminster cocaine for 14 days, then took the drug away for a week but not the levers the animals used to access it.

During that hiatus, he adminstered a drug that stimulates glutamate receptors, possible targets for drugs of abuse.

He found that the F344 strain worked harder to get cocaine than the Lewis rats following treatment with the glutamate drug, suggesting they were more susceptible to relapse.

“Maybe 12-step programs and faith-based programs will be enough to keep some people from relapsing,” says Dr. Kruzich. “For others we may have to come up with medical treatments we can use on top of those to keep them from taking drugs again.”

He says there are many different versions of the hundreds of genes that may play a role in increasing the risk of relapse.

It’s known that some people become addicted more quickly than others, some literally with their first use, he says. The hardest part is not getting people to stop taking drugs: that happens when they are checked in a clinic or put in jail. The real work is keeping them from relapsing when they are out of such restricted environs, he says.

“Something happens, either they see an old colleague they have used with, they go into an old environment, they have a huge stressor in life and they start to want the drug. They have drug hunger, what we call drug craving,” says Dr. Kruzich. “When it gets bad enough, they engage in drug-seeking behavior.”

His lab is working to identify the relapse trigger to use as a target for developing ways to curb craving and subsequent relapse.

His studies focus on an area of the brain called the nucleus accumbens core, a target for drugs of abuse long considered a pleasure center, Dr. Kruzich says. Drugs such as cocaine and methamphetamine stimulate release of dopamine in the nucleus accumbens. Dopamine is a neurotransmitter believed responsible for the euphoria that come with drug use. In fact, animals given dopamine blockers won’t self-adminster drugs of abuse, and dopamine has long been a focus of drug-abuse studies.

“These drugs impinge upon the reward centers of the brain that normally food, sex, survival and adaptation impinge upon,” says Dr. Kruzich. “When you are having that great piece of cheesecake and thinking, ‘Oh man,’ that is the kind of response these drugs of abuse are evoking but much more so than that cheesecake could ever do.”

Glutamate, also released in the nucleus accumbens core, may play an equally important role in drug relapse, he says. Drugs such as cocaine appear to alter glutamate neurotransmission in the core, which may contribute to the rewiring of the brain that occurs with drug use. “It’s not that these drugs just damage neurons, which they can, but they rewire the circuitry of the brain so no longer is your spouse or your job or other things in your life important to you. Your brain is tricked into thinking that drugs are the most important thing for your survival,” Dr. Kruzich says.

Unfortunately, drugs that restore glutamate function also produce seizures, so scientists are looking for an indirect approach to restore the misdirected rewiring.
Source: Psychopharmacology, posted online Jan. 18 2006. Toni Baker Medical College of Georgia http://www.mcg.edu

On June 22, 1998, ‘Wired for Addiction’ was presented as part of NIDA’s Frontiers in Neuroscience seminar series. The theme of these presentations centered on the neuronal remodeling that emerges after repeated substance use and withdrawal, with particular emphasis on the possibility of altered cognitive function as a consequence of the neural remodeling. Presentations were made by Drs. Ann Graybiel, Tony Grace, John Marshall, Janet
Neisewander, and Regina Carelli, and a summary and discussion was presented by Dr. Steve Grant of NIDA. Brief summaries of two presentations follow.

Chronic exposure to psychomotor stimulants may rewire your brain
Exposure to amphetamine and cocaine induces gene expression in cortico-basal ganglia circuits. Chronic intermittent exposure to the same drugs down-regulates some of the inducible change. After a course of chronic intermittent treatment and withdrawal of the drug, a subsequent challenge with the drug induces new patterns of gene expression in cortico-basal ganglia circuits. The repeated administration and withdrawal of cocaine induces both immediate early gene (lEG) expression after drug challenge in neurons that are not activated acutely, and an increase in the size of the area in which this response in observed. These findings raise the possibility that prolonged exposure to psychomotor stimulants produces enduring changes in brain wiring.

Ann Graybiel, Ph.D., Massachusetts Institute of Technology:

Neuronal interactions within the limbic system of rats: Alteration during amphetamine sensitization
Amphetamine exerts differential actions on neurons in the nucleus accumbens when given acutely versus repeatedly. The studies show that repeated amphetamine administration causes an increase in electrical coupling among nucleus accumbens neurons, which appears to be driven by an increase in prefrontal corticoaccumbens afferent activation. It is proposed that such a condition would lead to alteration of information flow within this system, resulting in a perseverance of behavioral action that may contribute to drug-seeking behavior in humans.

Anthony Grace, Ph.D., University of Pittsburgh

Recreational use of 3,4 methylenedioxyethylamphetamine (MDMA), more commonly known as “ecstasy” (and a variety of other names including “XTC”, “Adam” or “E”), is now well established. In Britain upwards of 500,000 people are said to use the drug each week (Harris Poll (1992) for “Reportage”, BBC2, 22 Jan 1993).

MDMA is a ring-substituted amphetamine with psychoactive properties. First synthesised in 1914 from methylenedioxyamphetamine (MDA), itself a drug of misuse (known as the “love drug”), it has been used in psychotherapy and was originally used as an appetite suppressant. The drug has ceased to be used medicinally and is now an established part of the illegal drug scene. It is banned in most countries. In the UK it is a class A drug as defined in Schedule 2 of the Misuse of Drugs Act 1971. It has no medicinal use in the UK and cannot be prescribed.

As well as MDA and MDMA, another variant, methylenedioxyethylamphetamine (MDEA, known as “eve”), which is similarly proscribed, is commonly encountered. All have similar pharmacological effects.
In the UK, MDMA is often taken by young people at discos and rave parties. Both involve dancing, but especially at the latter there is vigorous repetitive dancing in crowded rooms with a hot and humid atmosphere. The dangers of this activity are recognised to a certain extent as rooms to “chill out” are often available for people to rest in after periods of exertion. Toxic effects and the occasional death following ring substituted amphetamine misuse have been reported but postmortem data are lacking. In this paper we report on deaths associated with ring substituted amphetamine misuse and detail the postmortem findings.

Seven deaths have been investigated by the University of Sheffield Department of Forensic Pathology in the past three years, which were associated with ring substituted amphetamine misuse. All of the subjects were white men, between 20 and 25 years of age. Three of the victims collapsed at a rave or disco, two were found in bed, one in a collapsed state and one dead, one collapsed in the street, and one was admitted to hospital with progressive jaundice.

Abstract
Aims – To study the postmortem pathology associated with ring substituted amphetamine (amphetamine derivatives) misuse.

Methods
The postmortem findings in deaths associated with the ring substituted amphetamines 3,4-methylenedioxymethyl-amphetamine (MDMA, ecstasy) and 3,4-methylenedioxyethylamphetamine (MDEA, eve) were studied in seven young white men aged between 20 and 25 years.

Results
Striking changes were identified in the liver, which varied from foci of individual cell necrosis to centrilobular necrosis. In one case there was massive hepatic necrosis. Changes consistent with catecholamine induced myocardial damage were seen in five cases. In the brain perivascular haemorrhagic and hypoxic changes were identified in four cases. Overall, the changes in four cases were the same as those reported in heat stroke, although only two cases had a documented history of hyperthermia. Of these four cases, all had changes in their liver, three had changes in their brains, and three in their heart. Of the other three cases, one man died of fulminant liver failure, one of water intoxication and one probably from a cardiac arrhythmia associated with myocardial fibrosis.

Conclusions
These data suggest that there is more than one mechanism of damage in ring substituted amphetamine misuse, injury being caused by hyperthermia in some cases, but with ring substituted amphetamines also possibly having a toxic effect on the liver and other organs in the absence of hyperthermia.

C M Milroy J C Clark A R W Forrest Department of Clinical Chemistry, Royal Hallamshire Hospital, Sheffield – Department of Forensic Pathology, University of Sheffield
Source: (J Clin Pathol 1996;49:149-.153)

Back to top of page

Powered by WordPress